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Chapter 1 9
InTroDuCTIon
Tumor Heterogeneity
Cancer presents with dynamic intratumoral and interlesional heterogeneity [1,2]. This 
process is driven by the genomic instability and rapid proliferation of cancer cells. Over 
time, cancer cell populations become even more diverse, known as temporal heterogene-
ity [3]. Tumor heterogeneity follows Darwinian evolutionary principles, where cancer cell 
subpopulations with optimal phenotypes including distinct surface marker expression, 
metabolism, proliferation, apoptosis, invasion, angiogenesis, drug sensitivity, and antigen 
presentation survive in a given tumor [4,5]. Tumor heterogeneity that enables malignant 
progression and metastatic spread by evolutionary selection is also the major cause of 
emergent resistance during cancer treatment. Yet, we rely on few standard diagnostic tumor 
biopsies for the characterization of a given cancer. These biopsies will provide only a partial 
characterization of the overall makeup of the dynamic systemic disease.
Circulating biomarkers
Tissue biopsies are invasive, expensive and represent a single snapshot in time of an evolv-
ing disease. The capturing and analysis of blood-based biomarkers is an alternative method 
to gain insight into the molecular makeup of cancer in a given patient. The major strength 
of circulating biomarkers is the possibility to compare serial samples from the same patient 
and thus generate a molecular readout of disease progression and therapy resistance in real 
time. Technologies have been rapidly developed over the past decade enabling the assess-
ment of cell free nucleic acids. Extracellular nucleic acids, such as DNA and microRNAs 
(miRs), are found in almost all human bodily fluids and the circulation provides an at-
tractive alternative to tumor tissue biopsies (Figure 1). The term “circulating” refers to the 
portion of extracellular molecules that are transported in the cell-free blood compartment. 
Identification of patient specific cancer markers is crucial for the improvement of control-
ling this disease. It is conceivable that blood samples can reflect the molecular profile of a 
primary tumor as well as residual cancer cells that are not accessible physically or below 
detection on radio graphical imaging. Liquid biopsies can be taken repeatedly to follow evo-
lution of the disease. Circulating DNA and miRs are relatively stable in plasma and serum 
samples, and easy to quantitate by PCR or sequencing methods. Still, the interpretation of 
circulating nucleic acids remains challenging. Extensive validation and protocol standard-
ization is required before circulating nucleic acid analysis can be used as clinically approved 
markers. Circulating miRs represent the tumor and the host response to malignant lesions. 
In contrast, circulating tumor-specific DNA harbors the molecular characteristics from the 
cancer cells such as mutations.
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Figure 1. Release of cell free DNA and miR into the circulation. Healthy organs e.g. brain, lung, heart, 
kidney, liver, bone marrow shed wild type DNA and microRNAs into the bloodstream as indicated by 
the dotted arrows. The cancer lesions contain cancer cells (colored) and stromal cells (grey). Tumor-
derived mutated DNA originates from the heterogeneous cancer cell populations and is shed into the 
circulation as cell-free (cf) DNA. MicroRNAs derived from blood cells, normal and tumor tissues refl ect 
the composite of signaling in cancer cells, stroma and normal tissues. Double helices in the plasma 
compartment indicate cfDNA, short, single-stranded nucleic acids in diff erent colors indicate miRNAs.
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Circulating DnA
Cell-free DNA
All human cells can release DNA into their extracellular environment. Extracellular DNA 
has been detected in saliva, mucus, pancreatic juice, lymph, breast milk, cerebrospinal fluid, 
urine, amniotic fluid, and blood. Necrosing or apoptosing cells are thought to be the major 
source of cell-free DNA, however active DNA release via extracellular vesicles or protein 
complexes has been observed in cells such as lymphocytes and cancer cells[6,7]. DNA in 
the cell-free compartment of the blood, i.e., the plasma or serum, is called ccfDNA. In order 
to study ccfDNA, blood samples collected with standard collection tubes must be rapidly 
processed, to allow for reproducible assessments of ccfDNA levels. If plasma or serum are 
not separated from the cells within short order (~2 hours), dying cells can shed their DNA 
as well as DNA degrading enzymes and thus bias the levels of ccfDNA. Some collection 
tubes that capture and fixate the blood components appear to mitigate this problem and 
allow for shipping and later (within 72 hours) separation by centrifugation [8]. CcfDNA can 
be encapsulated in lipid membrane microvesicles, trapped by leukocytes, bound to nucleo-
somes, serum- and/or lipoproteins. Studies on the half-life of ccfDNA have described times 
ranging from minutes to 13 hours. This discrepancy is not surprising, given the multitude 
of possible ccfDNA carriers and factors involved in ccfDNA clearance. When ccfDNA is 
bound to protein complexes, or inside membrane vesicles, the DNA is less vulnerable to 
degradation. Phagocytes clean up dead cells and nucleases in the blood and rapidly de-
grade ccfDNA, whereas the liver and kidneys metabolize it. These events occur at different 
rates, depending on (patho)physiological conditions of the individual at that time. As the 
knowledge on ccfDNA has dramatically increased over the past decade, it became clear that 
levels of DNA in the blood are a comprehensive indication of the present physiological and 
pathological processes throughout the body. CcfDNA can impact the immune system and 
signals through Toll-like receptors on dendritic cells and macrophages. Both ccfDNA from 
the host and from microbial invaders can elicit inflammatory responses [9-11]. In the case 
of the autoimmune disease systemic lupus erythematosus (SLE), DNA-specific antibodies 
bind to the abundant extracellular, double stranded ccfDNA and form immune complexes 
that elicit inflammation. Moreover, patients with DNAse deficiency have increased suscep-
tibility to autoimmune diseases such as SLE [12], due to the increased levels of ccfDNA. In 
the blood of healthy individuals, the vast majority of ccfDNA originates from erythrocytes, 
leukocytes, and endothelial cells [13,14]. In addition, ccfDNA is shed from cells of organs 
that incurred damage by hypoxia, trauma, inflammation, etc. [15,16]. CcfDNA levels are 
elevated after physical exercise [17-19], surgery [20], myocardial infarction [21], and many 
other disorders. Especially in patients with cancer, ccfDNA levels rise dramatically [22-24]. 
Ever since this observation was made in the late 1970s, ccfDNA has become a major player 
in the field of cancer biomarkers.
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Circulating DNA levels in patients with cancer
The levels of ccfDNA in patients with cancer can be increased due to higher rates of cel-
lular turnover and cell death in tumor tissues. Tumor-derived ccfDNA is termed circulating 
cell-free tumor DNA, in short ‘ctDNA’. Cancer cells are not the only cells in tumors that 
contribute to the high levels of ctDNA: activated tumor-associated fibroblasts, endothelial 
cells, and immune cells also shed DNA. It is well established that ctDNA does not originate 
from intact circulating tumor cells: cell-free ctDNA levels are 100-1000 times more abun-
dant than the intracellular DNA content of circulating tumor cells and the typical number of 
circulating tumor cells per mL of blood (<10), cannot account for the numerous micrograms 
of ctDNA per mL of blood observed in cancer patients [25,26]. CtDNA is smaller in size 
than ccfDNA from healthy individuals [27,28]. The sizes of ctDNA fragments range from 
120-180 base pairs (bp) and peak below 150 bp [27,29,30]. The packaging of extracellular 
DNA is different for cancer cells from different origin and also depends on the extent of 
phagocytosis by immune cells. A small portion of ctDNA is packaged into exosomes and 
can measure 100-2500 bp; even larger DNA strands can bind to the outer membrane of 
exosomes [31]. Aside from the release mechanisms and packaging of ctDNA, the quantity 
of ctDNA is dependent on the type, location, vascularity, and size of the tumor. For instance, 
hypoxia is a major driver of ctDNA release [32]. Thus, tumor load and ctDNA levels do not 
necessary correlate with each other. Instead of quantitating the levels of ctDNA, many stud-
ies focus on cancer cell-specific, qualitative characteristics of ccfDNA in cancer patients. 
Because ctDNA refers to the cell-free DNA portion in blood that is derived from the tumor 
it harbors the hallmark genomic alterations of the cancer cells from which the DNA is shed.
Circulating Mutant Tumor DNA
Mutations in ctDNA are often studied as qualitative and quantitative biomarkers in cancer 
patients. Advances in PCR-based detection assays have allowed for relatively easy mutant 
ctDNA measurements. When quantitating known mutations, methods such as droplet digi-
tal PCR allow for mutation detection as low as 1 per 10.000 copies of wildtype DNA. Similar 
detection thresholds are met when screening for a broader range of genomic alterations, 
using targeted panels of amplicon deep sequencing. The number of mutations vary by up 
to 1000-fold among specimens from a given cancer type [33]. Although mutant ctDNA 
originates from cancer cells, tumors consist of heterogeneous cancer subpopulations. This 
intratumoral heterogeneity implies that different cancer cells harbor different sets of muta-
tions. Therefore it is prudent to monitor more than one gene mutation when attempting 
to correlate clinical outcomes to mutant ctDNA levels. Moreover, the stroma component 
of cancers is important to consider when quantitating mutant ctDNA. The highly reactive 
stroma in pancreatic cancers for instance, could lead to a shift in the mutant ctDNA fraction 
compared to wildtype ctDNA. In contrast to studies in pancreatic cancer, which have shown 
that fewer myofibroblasts in tumors are associated with poor survival [34], in colorectal 
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cancer it has been shown that a lower cancer cell-to-stroma ratio is associated with worse 
outcomes [35]. Likewise, high levels of cancer-associated fibroblasts in esophageal can-
cer are correlated with a worse clinical outcome [36].The levels of mutant ctDNA in the 
background of wildtype ctDNA could be misleading when correlations are made between 
clinical outcomes and mutant fractions of ctDNA [16]. In early stages of cancer, mutant 
ctDNA may be below the detection limit due to a low tumor load. Also, missed ctDNA can 
be caused by clonal heterogeneity of a tumor, or because a subpopulation carrying the muta-
tion has a low apoptosis rate. In some cases the total ctDNA level is the superior marker of 
cancer load [37], though a particular mutant ctDNA can be informative if an abundant gene 
mutation is assessed [22]. As discussed above, biological factors such as tumor vascularity, 
phagocytosis of dead cells, ctDNA clearance by the kidneys and liver, as well as the sensitiv-
ity of the detection assay will affect the measurements of mutant DNA. Even copy numbers 
of the mutant allele can be different in cancer cells from the same tumor. In colorectal 
cancer patients with detectable mutant KRAS and BRAF ctDNA, mutant allele fractions 
in plasma can range from 0.13% to 68.77%, as determined by Intplex PCR [38]. Therefore, 
most studies separate patients based on the presence or absence of mutant ctDNA for the 
cancer related genes monitored rather than the abundance of the mutant allele fraction.
Circulating micrornAs
MiR biogenesis
Mature microRNAs (miRs) are highly conserved short strands of non-coding RNA, derived 
from hairpin precursor transcripts [39]. After cleavage of primary microRNA (pri-miRNA) 
transcripts by the Drosha/DCGR8 complex, nuclear-to-cytoplasmic transport, and matura-
tion with DICER1[40,41], 21–24 nucleotide long, double stranded mature miRs are formed. 
One of the mature miR strands binds predominantly to the 3’ untranslated region (UTR) 
region of mRNA to regulate protein translation. Additionally, miRs can also bind to the 
open reading frame (ORF) or 5’UTR of target mRNAs to repress or activate translational 
efficiency [42-44]. The discovery of small RNAs that are involved in translation regulation 
via an antisense RNA-RNA interaction was first described in Caenorhabditis elegans [45]. 
To date, more than 2600 human mature miRNAs have been identified and annotated [46], 
with more than half of human protein-coding genes likely regulated by a miR [47].
MiR expression alterations in cancer
MiRs are dysregulated in cancer and play crucial roles in cell proliferation, apoptosis, 
metastasis, angiogenesis and tumor-stroma interactions [48]. Dysregulated miRs can 
function both as oncogenes (e.g. miR-155; miR-21, miR-221; miR-222, miR-106b-93-25 
cluster; the miR-17-92 cluster) and tumor suppressors (e.g. miR-15; miR-16; let-7; miR-34; 
miR-29; miR-122, miR-125a-5p and miR-1343-3p), depending on their downstream targets 
[49,50]. Many human miR genes are located on chromosomal sites that are susceptible to 
14  Introduction
chromosome breakage, amplification and fusion with other chromosomes [51]. Addition-
ally, alterations in RNA binding proteins and cell signaling pathways contribute to cancer 
through miRNA expression changes as well as mutations in core components of the miR 
biogenesis machinery that can promote oncogenesis [40]. It has recently been shown that 
mutant KRAS in colon cancer cell lines leads to decreased Ago2 secretion in exosomes 
and Ago2 knockdown resulted in decreased secretion of let-7a and miR-100 in exosomes 
whilst cellular levels of the respective miRs remained unchanged compared to control 
cells [52]. A systematic expression analysis of 217 mammalian miRs from 334 samples, 
including multiple human cancers revealed extensive diversity in miR expression across 
cancers, and a large amount of diagnostic information encoded in a relatively small number 
of miRs. More than half of the miR (129 out of 217) had lower expression levels in tumors 
compared to normal tissues, irrespective of cell types [53]. miR expression profiles allows 
classification of poorly differentiated cancers and identify tumors of unknown tissue origin 
[53]. In subsequent studies, profiling miR expression improved cancer diagnosis and helped 
identify the tissue of origin in carcinoma with unknown primary site by standard histology 
or immunohistological analyses [54,55].
Cell-free miRs
MiRs are present and stable in the peripheral circulation. The first report on miR expression 
in the circulation in 2008 described detection of four placenta-associated miRs (miR-141, 
miR-149, miR-299-5p, and miR-135b) in maternal plasma during pregnancy, after which 
the level decreased following delivery [56]. In 2008, a study demonstrated increased levels 
of circulating miR-21, miR-155 and miR-210 expression in patients with diffuse large B-
cell lymphoma (DLBCL) compared to healthy controls [57]. Mitchell et al. also showed 
that circulating serum miR-141 could distinguish patients with advanced prostate cancer 
from healthy controls [58]. The vast majority of research on circulating miR signatures in 
oncology is focused on diagnostics [59], in which patients with cancer are compared to 
healthy individuals. Given the profuse inter-individual differences in genetic background 
of individual patients in addition to the heterogeneous nature of cancer, using cf-miR as 
cancer diagnostic biomarkers will remain challenging. Data from a number of laboratories 
suggest that different RNA species can be specifically packaged into microvesicles by ac-
tive sorting mechanisms which have not been fully elucidated [60]. The origin of cf-miR 
is heterogeneous. miR-21 is a good example to illustrate this point. Although the release of 
miR-21 into the circulation is correlated with a multitude of cancer types, it is also highly 
expressed in activated T-cells and associated with inflammation and wound healing [61,62]. 
Elevated circulating miR-21 levels do not merely reflect tumor presence. They can also 
reflect the host response to the tumor, which is important in predicting disease progression. 
Moreover, there are often discordances between cf-miRNA signatures and the paired tumor 
tissue [59]. Assuming that the quality of miRNA measurements is not determined by the 
Chapter 1 15
efficacy of RNA extraction, this suggests that cancer-associated cf-miRNA deregulations 
is more likely to reflect the systemic response to the presence of cancer. Indeed, several 
studies have shown that cf-miRNAs are predominantly derived from blood cells [63] and 
the endothelium [64] in addition to the tumor.
Cell-free miRs as prognostic biomarkers
Cancer progression and systemic drug therapy involve many organ systems and are not 
limited to the primary tumor. This makes cf-miRNA attractive biomarkers for cancer pro-
gression and drug efficacy monitoring. For instance, in serum obtained pre-surgically from 
patients with early stage colorectal cancers, a panel of 6 circulating miRNAs can predict 
cancer recurrence [65]. In pancreatic cancer patients, an expression signature of 6 plasma 
miRs was associated with worse overall survival [66]. Changes in cf-miRNA patterns within 
the same patients can be monitored over time during therapy. The growing evidence of the 
utility of cf-miRNA as cancer therapy response indicators has been accumulating during the 
last few years [67-69]. Cf-miRNAs are likely to surpass the clinical utility of conventional 
protein markers such as CA-125, CA19-9, PSA and radiographical imaging, which have low 
sensitivity and specificity for detection of minimal residual disease and are not designed to 
characterize cancer at the host response level.
ouTlIne of THIs THesIs
Cancer is a heterogeneous disease which is constantly evolving. Cancer cell subpopulations 
have distinct genomic and phenotypic properties and respond differently to treatment.
Chapter 2 assesses clonal subpopulations of pancreatic cancer from a transgenic mouse 
that develops pancreatic cancer induced by mutations in Kras and Trp53. We characterized 
the clonal cells on the genomic, phenotypic and drug-sensitivity level. More importantly, we 
studied the sensitivity of the clonal cells to different types of anti-cancer drugs in the context 
of the mixed heterogeneous tumors in the presence of an intact immune system.
In contrast to tumor biopsies, ‘liquid biopsies’ are new in the field of biomarkers and can 
be obtained repeatedly by blood draws to follow cancer evolution. In order to follow the 
dynamics of cancer over time we studied the mutation patterns in circulating tumor DNA 
over the course of cancer progression in patients with colon and pancreatic cancer in Chap-
ter 3. Plasma DNA mutations in 56 cancer-associated genes before surgical removal were 
compared to the mutations found in the primary tumors. Moreover, at time of metastatic 
disease, the plasma DNA mutations were compared to those at time of the primary disease.
MiRs control genes in cellular processes such as apoptosis, proliferation and inflamma-
tion and miRs are dysregulated in in diseases such as cancer. In contrast to circulating 
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tumor DNA, which can indicate presence of cancer cells, circulating miRs could provide 
information about the host’s response to cancer. In Chapter 4 we analyzed the changes in 
serum miRs in patients with pancreatic cancer after resection, and compared the serum 
miR expression of patients with short versus long progression free survival. The results were 
compared to circulating miRs that are altered in KPC transgenic mice that developed meta-
static pancreatic cancer. We further assessed the expression of two miRs that are associated 
to cancer progression in the patients’ tumor tissues by in situ hybridization.
In Chapter 5 we studied circulating miRs in patients with breast cancer undergoing kinase 
inhibitor treatment. Dovitinib is a multi-kinase inhibitor impacting angiogenesis and the 
tumor-stroma crosstalk. We measured serum miR expression over the course of dovitinib 
therapy to assess whether circulating miRs could indicate drug response or resistance.
The work presented in this thesis is summarized and discussed in Chapter 6.
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AbsTrACT
Cancers consist of heterogeneous cell subpopulations that survived selection during tumor 
evolution. Interactions between these subpopulations and the host impact as well as their 
impact on drug responses are poorly understood. We established a model of tumor hetero-
geneity using clonal cell lines isolated from a KPC (KrasG12D/+; Trp53R172H/+; P48-Cre) mouse 
pancreatic tumor. Deep sequencing of unique mutations characteristic for cancer subpopu-
lations was used to monitor clonal abundance after various anti-cancer therapies in hetero-
geneous tumors that were reconstituted from cell mixtures. We found that the composition 
of heterogeneous tumors is affected by the crosstalk amongst the cancer subpopulations and 
the host environment that includes the immune system as a major player. Some cancer cell 
subpopulations showed sensitivity to anti-PD-1 immune checkpoint inhibitor treatment in 
vivo. This sensitivity was mirrored in vitro by the level of activation of T-cells isolated from 
caecal patches of tumor bearing mice. We provide a platform that comprises the crosstalk 
between cancer cell subpopulations and the host and reveals the impact on drug efficacy.
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InTroDuCTIon
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease for which no curative drug 
therapy currently exists [1]. The approved drug treatment with the antimetabolite gem-
citabine extends disease-free survival after surgery by 6.5 months but does not improve 
overall survival [2]. Mutant KRAS, the major oncogenic driver in PDAC, is present in >90% 
of tumor specimen [3,4], and acts in part via its downstream effector pathway RAF, MEK 
and ERK. MEK kinase inhibitors such as trametinib reduce both RAS-dependent MEK and 
ERK phosphorylation [5]. However, initial studies show that treatment with MEK inhibitors 
does not provide discernible benefit in patients with PDAC [6], indicating that alternative 
pathways downstream of KRAS take over during malignant progression [7,8]
DNA sequence and functional analyses revealed that tumors of diverse histological types 
are composed of clonal cell subpopulations [9-11]. Evolution of these subpopulations is 
driven by an aggregate of mutations and epigenetic changes as well as selective pressure by 
the tumor environment [12-17] that is enhanced by the recruitment of cancer-associated 
stroma and immune cells [18]. Stromal desmoplasia, one of the histologic signatures of 
PDAC, can inhibit the invasion of cancer cells [19,20] but also plays a role in reducing the 
efficacy of chemotherapy [21-24] and in suppressing the activity of the immune system 
[25]. In addition to the stromal / cancer cell interactions, phenotypically different cancer 
cell populations can influence each other’s growth behavior [26-28] as well as treatment 
responses [29,30].
To establish a model that can track cooperation and competition between cancer subpopu-
lations and the host in response to drug treatment, we generated a series of clonal cancer 
cell lines from the well-established LSL-KrasG12D/+; LSL-Trp53R172H/+; P48-Cre driven PDAC 
model [31]. Genomic analysis revealed that each of the clonal cell lines carries a distinct set 
of signature mutations. Rather than exogenously tagging cells, we employed these molecular 
signatures to quantitate the abundance of the clones in reconstituted cell mixtures by deep 
sequencing of DNA extracted from cells in culture or from allograft tumors in compat-
ible, immune-competent mice. Here we show that growth of subpopulations of cancer cells 
in heterogeneous mixtures in culture and in tumors and the effects of treatment with an 
anti-metabolite chemotherapeutic drug (gemcitabine), a MEK kinase inhibitor (trametinib) 
or an immune checkpoint inhibitor (α-PD-1 antibody) revealed distinct sensitivity of the 
clonal subpopulations that was affected by intratumoral, stromal and immune cell interac-
tions.
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MATerIAls AnD MeTHoDs
Mouse experiments
The animal study protocols were approved by the Georgetown University Animal Care and 
Use Committee. The transgenic KPC mouse model was originally described by Hingorani 
et al [31]. Mice were aged 3-6 months at time of the experiments and both sexes were used 
randomly.
KPC derived pancreatic cancer clonal cell line culture
A female KPC mouse 135 days of age was euthanized for tumor harvesting. Fresh mouse 
pancreatic tumor tissue was minced for 5 minutes and shaken at 150 rpm for 1 hour at 37ºC 
in a Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F-12, Gibco Life) 
with 5% fetal bovine serum (FBS), 2 mg/mL collagenase (Sigma), 4 mg/mL trypsin (Sigma), 
50 µg/mL gentamicin (Gibco Life), and 1 IU/mL penicillin/streptomycin (Gibco Life). The 
cell pellet was washed and centrifuged at 600 g in 4ºC in DMEM / F-12, four times. The 
cell pellet was suspended in primary cell culture media (F-12, 10% FBS, 16 µg/mL insulin 
(Gibco Life), 10 ng/mL epidermal growth factor, 1 µg/mL hydrocortisone (Sigma), 4 ng/
mL cholera toxin (Sigma), 50 µg/mL gentamicin, and 0.5 IU/mL penicillin/streptomycin). 
The cells were placed in a 37ºC, 5% CO2, humidified incubator on a Collagen-1 coated 
10 cm culture dish (Corning BioCoat) in primary cell culture media for 40 minutes to let 
fibroblasts attach. Subsequently, the unattached cancer cells were transferred to a regular 
10 cm dish. Primary cell culture media was changed every 48 hours. Pictures were taken 
with the Olympus IX71 inverted microscope. After one week, the primary cancer cells were 
trypsinized, and resuspended in primary cell media in the dilution of a single cell per 200 
µL well plated in a 96-well plate. After 3 weeks incubation, eleven wells contained clonal cell 
populations. The eleven clones were expanded individually to stable clonal cell lines and 
were grown in DMEM/10% FBS from passage 4 onwards.
3D growth in collagen
One thousand clonal cells were embedded in 40 μL of either neutralized rat tail type-1 col-
lagen (Millipore) / DMEM10% FBS mixture. Cells were left in a 37ºC, 5% CO2, humidified 
incubator for 10 days. Images were taken with using an Olympus IX71 inverted microscope.
Western blot analysis
Protein lysates from cells were obtained using a buffer with 50 mM Tris pH 8.0, 150 mM 
NaCl, 40 mM β-glycerophoshpate, 0.25% Na-deoxycholate, 1% NP40, 50 mM NaF, 20 
mM NaPPi, 1 mM EGTA. Before use of the lysis buffer, 1 mM of Na-orthovanadate and 
protease inhibitor cocktail (cOmplete, Roche) was added. Protein lysates were prepared for 
denaturing Bis-Tris gels by adding NuPAGE lithium dodecyl sulfate buffer and Reducing 
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Agent (Novex, Life), followed by 10 minutes incubation at 70 °C. Proteins were separated 
in Bis-Tris gels (Novex, Life) by electrophoresis in NuPAGE MOPS SDS Running buffer 
(Novex, Life). Gels were transferred to polyvinylidene fluoride membranes by the use of the 
iBlot system (Invitrogen). Membranes were blocked with 5% non-fat dry milk in PBS-T for 
1 hour, washed once with PBS-T (0.1% Tween20 in PBS). Primary antibodies (total ERK1/2, 
Cell Signaling #9102 Rabbit pAb) and phospho T202/Y204 ERK1/2, (Cell Signaling #9101 
Rabbit pAb) were diluted to 1:1000 in 5% milk PBS-T. Membranes were incubated at 4 °C 
overnight. Next, membranes were washed 3 times with PBS-T and incubated with second-
ary Horseradish peroxidase-linked anti-rabbit antibody (GE Healthcare, NA934V) in 5% 
milk in PBS-T for 1 hour at room temperature. Membranes were washed 3 times and signals 
were visualized with Immobilon Western Chemoluminescent HRP Substrate (Millipore) on 
HyBlot CL autoradiography film (Denville Scientific). Band intensities were estimated using 
Adobe Photoshop.
rnA sequencing of clonal cell lines
Total RNA was extracted from six clonal cell lines that were grown in DMEM 10% FBS 
using the RNeasy kit (Qiagen) following the manufacturers’ instructions. RNA quality 
was assessed and all samples had a RNA integrity number (RIN) value higher than 7.0, 
verified using the 2100 Bioanalyzer (Agilent Technologies). Truseq Stranded RNA libraries 
were constructed after the depletion of ribosomal RNA using RiboZero. The libraries were 
then sequenced using the Illumina HiSeq 4000 with paired-end 75 nucleotide reads. Gene 
expression data in fragments per kilobase of transcript per million reads (FPKM) for every 
gene in each sample set was analyzed by Gene Set Enrichment Analysis (GSEA), resulting 
in an enrichment score for each gene when each individual clone was compared to the rest. 
The scored genes of the experimental data sets were organized into functionality-specific 
families. The Hallmark family sets represent specific, well-defined biological states or pro-
cesses based on the Molecular Signatures Database (MSigDB) hallmark gene set collection.
exome sequencing of clonal cell lines
Genomic DNA from eight samples was analyzed: Six mouse pancreatic cancer clonal cell 
lines, the corresponding parental KPC mouse tumor tissue and a healthy pancreas from a 
female p48-Cre littermate mouse. Exome sequencing was performed by Otogenetics (Nor-
cross, GA). In short, mouse exons were captured with an Aligent V4 kit and paired-end 
100 nucleotide reads were obtained from the HiSeq2000 (Illumina) with a 30X coverage. 
Whole exome sequencing data were analyzed was mapped to the MM9 assembly using 
BWA (v0.7.16a) [32] and the variant calling analysis was performed with HaplotypeCaller 
as part of the Genome Analysis Toolkit (GATK v3.8-0) [33]. Genetic variants within a 
given pancreatic cancer clone were then detected by comparison to pancreatic tissue from 
a the matched, healthy littermate. We focused on non-synonymous mutations only, known 
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dbSNPs were subtracted. Mutations with less than 5 reads, variant allele frequency less than 
0.2, MQ less than 40.00 and genes with more than one mutation were discarded. Unique, 
clone-specific mutations were validated by Sanger sequencing before using them as clonal 
signature mutations in later allograft tumor experiments.
endpoint PCr
DNA from clonal cells and tissue was isolated using the PrepEase Genomic DNA Isolation 
Kit (Usb), following the manufacturer’s protocol. DNA from mouse tissues from different 
treatment groups was pooled at equimolarity. Per 50 µL of PCR reaction 200 ng of DNA 
from cells or tissues were used. Endpoint PCR was performed using the Platinum Taq DNA 
Polymerase Kit (Invitrogen 10966-034), with PCR buffer containing 1.5 mM MgCl2, 0.2 mM 
dNTP, 0.2 µM primers and 1 U Platinum Taq DNA polymerase, using the Epgradient Mas-
tercycler (Eppendorf). The cycling consisted of 2 min at 95 ⁰C for initial denaturation, 40 
cycles of 95 ⁰C for 30 sec, 61 ⁰C for 30 sec, and 72 ⁰C for 40 sec. PCR amplicon products were 
purified using the QIAquick PCR Purification Kit (Qiagen), removing primers, nucleotides, 
enzymes, mineral oil, salts, and other impurities from the PCR products. Amplicons were 
examined by electrophoresis in 2% agarose gel with 1X TAE buffer, and visualized with 
ethidium bromide and xylene cyanol dye. As a size marker the 1 kb DNA ladder (Invitro-
gen) was used. The gel was examined under UV light for amplicon bands.
Primers used for PCR amplification of Kras and Trp53 for LoxP genotyping clonal cell lines:
gene primer sequence amplicon sizewildtype allele
amplicon size
recombined allele
Kras forwardreverse
5’-GGGTAGGTGTTGGGATAGCTG-3’
5’-TCCGAATTCAGTGACTACAGATGTACA-3’ 270 bp 304 bp
Trp53 forwardreverse
5’- TGACAAGCCTTGCACCTTTCCAAC-3’
5’- CCACAGAGGCTGGATGTGTAA-3’ 239 bp 273 bp
Droplet digital PCr for KrasG12D allele frequency quantification
DNA from six clonal cell lines was used for PrimePCR ddPCR Mutation Detection (Bio-
Rad). Per 20 µL reaction 20 ng DNA were used with ddPCR supermix for probes (no dUTP), 
450 nM primers and 250 nM of both Kras probes. Probes used for KrasG12D allele frequency 
quantification with ddPCR using genomic DNA from clonal cell lines:
Kras
allele primer sequence probe dye / quencher
wildtype forwardreverse
5’-TATCGTCAAGGCGCTC-3’
5’-GCTGAAAATGACTGAGTATAAA-3’ TGGAGCTGGTGGCG
5’– HEX /
3’ – Iowa Black FQ
G12D 
mutant
forward
reverse
5’-TATCGTCAAGGCGCTC-3’
5’-GCTGAAAATGACTGAGTATAAA-3’ TGGAGCTGATGGCGT
5’– 6-FAM /
3’ – Iowa Black FQ
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The PCR mixture was combined with 40 µL Droplet Generation oil for Probes, and placed 
in Cartridges in the Droplet Generator (Bio-Rad). Endpoint PCR was performed with the 
following protocol: Enzyme activation at 95 ⁰C for 10 minutes, 40 cycles of 94 ⁰C for 30 
seconds, 58 ⁰C for 1 minute. Enzyme deactivation was achieved at 98 ⁰C for 10 minutes, 
hold at 4 ⁰C. After PCR, the samples were analyzed in the QX200 Droplet Reader to quantify 
Kras allele frequency.
In vitro growth assays
To monitor clonal growth dynamics in vitro, the xCELLigence Real Time Cell Analysis was 
used as described earlier [34] with 1000 clonal cells/well in DMEM/10% FBS in 16-well 
E-plates (ACEA Biosciences). All cell lines were measured in quadruplicate wells. For dose 
response curves the IncuCyte ZOOM system (Essen Bioscience) was used with 250 clonal 
cells/well plated in 384-well plates in DMEM/10% FBS. After overnight cell attachment, 
trametinib (Selleckchem) or gemcitabine (LC Laboratories), were added in triplicate wells 
at different concentrations as indicated in the respective figures. The IncuCyte Zoom system 
measured Cell Confluence every 12 hours. Growth inhibition was normalized to DMSO 
control and the respective IC50 values were derived by non-linear curve fitting using log 
[inhibitor] vs. normalized response with variable slope (Prism GraphPad 5.0).
Treatment of pooled mixture of clones in vitro for deep sequencing
Twenty thousand cells per clonal line, to make a mixture of 6 cell lines, were plated in 
T175 flasks in DMEM10%FBS and allowed to attach for 6 hours. 25 nM of gemcitabine (LC 
Laboratories) or 100 nM of trametinib (Selleckchem) or DMSO in PBS as a control were 
added respectively. Cells were allowed to grow to confluency (4 days for the DMSO, 7 days 
for the trametinib and 11 days for the gemcitabine treated cells). Floating cells were washed 
away and DNA was isolated from the remaining attached cells after trypsinization.
Growth assay with conditioned media in vitro
Two hundred thousand cells from each of the six clonal cell lines mixed together, or 1.2 
million clonal cells alone, were plated in T175 flasks in DMEM10%FBS. After 48 hours, the 
conditioned media was collected and centrifuged in 0.22 μM membrane vacuum filtration 
columns (Millipore) to sterilize and remove debris. The conditioned media was stored in 4° 
Celsius until use. For the growth assay, clonal cell lines G8 and C8 were plated in 16-well 
xCelligene E-Plates (see above). The cells were plated at a 1:1 ratio of the conditioned media 
(c.m.) from the clone mix, together with fresh DMEM/10%FBS, or in c.m. from the respec-
tive clones (C8 or G8) and fresh DMEM/10%FBS. Different concentrations of trametinib 
(Selleckchem) or DMSO in PBS as a control were added after cells had attached for 6 hours. 
The cell index was monitored every 5 hours and dose response curves were generated in 
Prism Graphpad 5.0.
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Allograft tumors
The mouse PDAC cells were tested for mycoplasma contamination and are negative. 
One million clonal PDAC cells were injected subcutaneously into the flanks of immune 
competent, compatible wildtype mice (relatives of the KPC mouse). Drug treatments were 
initiated when tumors had established after ~1 week: 250 μg of rat monoclonal anti-mouse-
PD-1 (clone BE0146, BioXCell, New Hampshire, USA) in 50 μL PBS via intraperitoneal 
injection twice a week, or isotype mAb in PBS as a control; Gemcitabine (LC Laboratories) 
at 40 mg/kg in sterile water, or water as a control, with 5 doses in week 1 and 2 doses in week 
2 by intraperitoneal injections; trametinib (GSK1120212, Selleckchem) by oral gavage at 0.5 
mg/kg in 3% DMSO dissolved in 0.5% methylcellulose / 0.2% Tween80 (Sigma) daily for 2 
weeks, the carrier mix served as a control.
Histopathology and Immunohistochemistry
Immunohistochemical staining of tumor tissue was performed for α-Smooth Muscle Actin 
(Rabbit α–SMA monoclonal antibody, Abcam ab124964). Five micron sections from for-
malin fixed paraffin embedded tissues were de-paraffinized with xylenes and rehydrated 
through a graded alcohol series. Heat induced epitope retrieval was performed by immers-
ing the tissue sections at 98 °C for 20 minutes in 10 mM citrate buffer (pH 6.0) with 0.05% 
Tween. Staining was performed using the VectaStain Kit from Vector Labs according to 
manufacturer’s instructions. Briefly, slides were treated with 3% hydrogen peroxide and 
10% normal (animal) serum and exposed to 1:1000 Rabbit α–SMA (Abcam ab124964), 
or α–PD-L1 (Cell Signaling Technology #64988) in Normal antibody diluent (MP Bio-
medicals) overnight at 4 °C. Slides were exposed to anti-rabbit biotin-conjugated secondary 
antibody (Vector Labs), Vectastain ABC reagent and DAB chromagen (Dako). Slides were 
counterstained with Hematoxylin (Fisher, Harris Modified Hematoxylin), dehydrated and 
mounted with Acrymount. Images were captured using an Olympus IX71 inverted micro-
scope. Histopathological evaluations were done with advice from pathologist Dr. Bhaskar 
Kallakury.
Amplicon deep sequencing
The six genes with clonal signature mutations were PCR amplified and validated by Sanger 
sequencing (MCLab). Purified PCR amplicons of these clonal signature genes plus mutant 
Kras and mutant Trp53 for all cancer cells were from DNA from allograft tumors that were 
pooled in equimolarity. PCR amplicons were quantified using the Quantifluor ONE dsDNA 
kit on the GloMax-Multi-Plus Microplate Reader (Promega) by following the manufacturer’s 
protocol. Amplicons were used for MiSeq deep sequencing. Primers used for PCR amplifi-
cation of the eight genes containing clonal and ubiquitous cancer cell signature mutations:
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gene primer sequence variant[mm9 position]
amplicon 
size
Trp53
(ubiquitous)
forward
reverse
5’- GAAAGGGAGGAAGAAGGAAAG-3’
5’- CTTCCAGATACTCGGGATACA-3’
chr11:69402014
G>A 492 bp
Kras
(ubiquitous)
forward
reverse
5’-TGGACTTTCTTGCACCTATGG-3’
5’-AGTGTTGATGAGAAAGTTGTAAGTG-3’
chr6:145195291
C>T 481 bp
Olfr1157
(C8)
forward
reverse
5’- TCTTAGATTTGGGAAGACCTTACA-3’
5’- CCCACCTCACAGTCATCATT-3’
chr2:87802181
G>C 494 bp
Nox4
(D10)
forward
reverse
5’- GAGCACTTGGCAATGTAAGAATAG-3’
5’- CCCAGAATAACCCACTCACTAAA-3’
chr7:94462586
C>T 493 bp
Matn4
(F2)
forward
reverse
5’- GCACATACACACCACCATCT-3’
5’- GCTACACTCAGAAGTGACATCC-3’
chr2:164222680
C>T 481 bp
Baiap3
(C5)
forward
reverse
5’- GTAGGAGCCTTACAACAGGAAG-3’
5’- GCTAGTTGACTGGCAACAGTA-3’
chr17:25387359
G>T 500 bp
Arhgap25
(G8)
forward
reverse
5’- GCTCCTTGTTCTCCTGAATCC-3’
5’- CATACACGTGATACCCAGACATAC-3’
chr6:87426299
T>C 497 bp
Pla2g4d
(G9)
forward
reverse
5’- AAGTTCCAGGATAGCGACAAG-3’
5’- GATCCTTGGATTCCCTTGGAG-3’
chr2:120094626
G>T 502 bp
Amplicons were pooled according to their sample type after quantitation as above. Pooled 
amplicons were normalized to a concentration of 10 ng/μL, and then diluted further to 0.2 
ng/μL in nuclease free water. Library construction: Each amplicon pool was constructed 
into a library using the Nextera XT DNA library preparation kit (Illumina). Briefly, 1 
ng of each amplicon pool was enzymatically sheared and simultaneously tagged with an 
adapter. A unique index sequence was added to each library sample through a 12-cycle 
PCR amplification. Each sample was purified and size selected to capture greater than 500 
bp amplicons using AMPure XP beads. Quality of the indexed libraries was assessed using 
the High Sensitivity DNA kit on the 2100 Bioanalyzer system (Agilent Technologies). The 
libraries were normalized and pooled together by following the Nextera XT DNA user guide 
(Illumina).
Miseq sequencing and data analysis
Before sequencing, an aliquot of the library pool was denatured at 96°C for 2 minutes and 
then kept on ice. One percent of 12.5 pM PhiX Control V3 (Illumina) was spiked into the 
denatured library pool. Paired end 2x150 bp sequencing was performed on the MiSeq using 
the MiSeq Reagent Nano kit v2 (300 cycles) according to the manufacturer’s protocol (Illu-
mina). All primary- and run-quality analyses were performed automatically on the MiSeq. 
Alignment to the mus musculus genome 9, NCBI 37 assembly (mm9) and quality trimming 
were executed by the Burrows-Wheeler Aligner tool on the MiSeq. All point mutations 
specific to each sample were reviewed by manual visualization of the reads in the Integrated 
Genomics Viewer (Broad Institute) and variant allele frequencies (VAF) were quantified. 
Clonal abundance in the tumors was normalized to the VAF of Trp53R172H, to account for 
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wildtype stroma in the tumors. The minimum VAF for clone specific genes was set to 0.01%, 
in case the clonal mutations were below detection.
qrT-PCr analysis
RNA from allograft tumors was isolated using the RNeasy Mini Kit (Qiagen) following the 
manufacturer’s protocol. 500 ng of RNA was used for complementary DNA synthesis with 
the iScript cDNA synthesis Kit (BioRad), with 4 μL reaction mix, 1 μL reverse transcriptase 
in a 20 μL reaction. The Epgradient Mastercycler (Eppendorf) cycling consisted of 5 min 
at 25 °C, 30 min at 42 °C, 5 min at 85 °C, hold at 4 °C. Next we performed qRT-PCR in a 
20 μL reaction using the iQ SYBR Green Supermix (BioRad), containing 10 μL of SYBR 
Green mix, 1 μL of cDNA and 200 nM primers for the following mouse genes: (β-Actin 
forward primer GGCGCTTTTGACTCAGGATTTAA, β-Actin reverse primer CCTCAGC-
CACATTTGTAGAACTTT; α-SMA forward primer GTCCCAGACATCAGGGAGTAA; 
α-SMA reverse primer TCGGATACTTCAGCGTCAGGA. The Realplex2 Mastercycler 
Epgradient S (Eppendorf) cycling consisted of 3 min at 95 °C, and 40 repeats of 15 sec at 95 
°C, 30 sec at 60 °C, 20 sec at 68 °C. Data analysis was performed with Prism 5.01.
flow Cytometry analysis of leukocytes in allograft tumors
The mixture of 6 clonal PDAC cell lines (1 million total) or individual clonal cell lines 
were injected subcutaneously into immune competent wildtype mice, and allograft tumors 
were allowed to grow for 10 days before tumor tissue collection. Single cell suspensions 
were generated by mechanic and enzymatic digestion of tumor tissues. Cell suspensions 
were washed and 1-2 million cells were stained as follows. Cells were labeled for Live/
Dead (Invitrogen, Thermofisher, Ref: l-23105) followed by blockade of Fc receptors with 
CD16/CD32 (clone 2.4G2; BD Biosciences, 553141). After 10 minutes incubation, cells 
were stained with a cocktail of mAbs: anti-mouse-CD45 (clone 30-F11; 564590), NK-1.1 
(clone PK136; 562864), B220 (clone RA3-6B2; 563103), CD3e (clone 145-2C11; 564661), 
CD4 (clone RM4-5, 563151), CD8a (clone 53-6.7, 564920), PD-1 (clone J43; 744549), CD25 
(clone PC61; 565134), all from BD Biosciences. Cells were acquired with FACS Symphony, 
BD Biosciences and analyzed with FlowJo and Prism Graphpad 5.01.
Mouse caecal patch T-lymphocyte isolation
The mixture of 6 clonal PDAC cell lines (1 million total) was injected into the peritoneal 
cavities and subcutis of immune competent wildtype mice, and pancreatic tumors were 
allowed to grow for 2 weeks. After euthanasia, ceacal lymphoid patches were harvested 
resected in a sterile hood, then cut and shredded in 4 mL of sterile PBS containing 2% FBS 
and 1 mM EDTA. The cell suspensions were collected in gentle Macs C tube (cat. # 130-
093-237) and further dissociated with the gentleMACS (Miltenyi Biotec) for 15 minutes as 
following: Loop, Spin 150 rpm 2 min, Ramp 400 rpm 30 sec, End loop. In a sterile hood, 
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remaining aggregates were removed by passing cell suspension through a 70 μm mesh nylon 
cell strainer cap (BD Falcon) into a 5 mL Polystyrene round bottom tube. The cells were 
centrifuged for 5 min at 200 x g, supernatant was aspirated and cells resuspended in 1.5 mL 
fresh PBS containing 2% FBS and 1 mM EDTA. T-lymphocytes were isolated using the Ea-
sySep Mouse T Cell Isolation Kit (Stemcell Technologies), according to the manufacturer’s 
protocol. In brief, per 1.5 mL sample, 75 μL Rat Serum was added, in addition to 75 μL 
Isolation Cocktail. The samples were inverted 15 times and left at room temperature for 10 
minutes. RapidSpheres were vortexed and 112 μL was added per sample. The samples were 
inverted 15 times and left at room temperature for 2.5 minutes. The samples were gently 
mixed by pipetting and placed inside the EasySep Violet Magnet (StemCell Technologies) 
for 2.5 minutes at room temperature. The T-lymphocyte suspensions were poured into ster-
ile 15 mL Falcon tubes. Live T-lymphocytes were quantitated using Countess cell counting 
chamber slides (Invitrogen), and Trypan Blue stain (Invitrogen) with the Countess.
T-lymphocyte culture in vitro
The T-lymphocytes were centrifuged at 100 x g for 5 minutes, and after aspiration of the 
supernatant, the T-cells were suspended in RPMI (Gibco Life) with 10% fetal bovine serum, 
100 units/mL penicillin and 100 μg/mL streptomycin, and 30 units/mL mouse recombinant 
Interleukin-2 (StemCell Technologies). The cells were plated in 96-well plates (~20,000 
live T-cells per well) and placed in a humidified 37°C, 5% CO2 incubator. As pilot experi-
ment, 100 cancer cells of the equal mixture of the 6 PDAC clonal cell lines were added and 
incubated for 72 hours. In the following experiment, 1500 clonal cancer cells per well were 
added to the T-cells, together with 20 μg/mL rat monoclonal anti-mouse-PD-1 (clone 
BE0146, BioXCell) or 20 μg/mL isotype igG2a (BioXCell).
As the control condition of activated T-lymphocytes, the wells were incubated with 5 μg/
mL hamster anti-mouse-CD3e (eBioscience) in sterile PBS overnight before T-cell isolation, 
whereafter T-lymphocytes were incubated with 30 units/mL mouse recombinant Interleu-
kin-2 and 2 μg/mL hamster anti-mouse-CD28 (eBioscience). After 72 or 48 hours of T-cell 
incubation in vitro, images were taken with using an Olympus IX71 inverted microscope. 
The conditioned media was collected in 1.5 mL microcentrifuge tubes and spun down for 5 
min at 300 x g. The supernatant was stored at -80 º Celsius in 100 μL aliquots until further 
analysis.
elIsA for mouse Ifn-γ in the supernatant of T-lymphocytes
Supernatant from the T-cells was thawed on ice. IFN-γ was measured in 100 μL supernatant 
per condition using the Mouse IFN-γ ELISA Ready-SET-Go! Kit (Invitrogen), following the 
manufacturers’ protocol. In brief, a Corning Costar 9018 ELISA 96-well plate was coated 
with 100 μL/well of capture antibody in 1X Coating Buffer. The plate was sealed and incu-
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bated overnight at 4° Celsius. Wells were washed with 250 μL 0.05% PBS-T (wash buffer) 3 
times. Wells were blocked with 200 μL 1X ELISA Diluent for 1 hour at room temperature. 
After washing once with wash buffer, 100 μL of the T-cell supernatant was added to the 
wells, or RPMI-10% or 1X Diluent as controls. The mouse IFN-γ standard was serial diluted 
in 1X Diluent from 4,000 to 4 pg/μL. After 2 hours incubation at room temperature, the 
wells were washed with wash buffer 5 times. Detection antibody in 1X Diluent was added 
to the wells in 100 μL incubated at room temperature for 1 hour. After 4 washes, 100 μL/
well of Avidin-HRP* diluted in 1X ELISA/ELISPOT was added to the wells and incubated 
at room temperature for 30 minutes. Wells were washed 7 times before adding 100 μL/well 
of 1X TMB Solution. The plate was incubated at room temperature protected from light for 
15 minutes. The reaction was stopped with 50 μL 1 M H2SO4 per well. Luminescence was 
measured at 450 nm using the Victor2 Wallac reader (Perkin Elmer).
resulTs
Isolation of clonal cell lines from a mouse PDAC model
Genetically engineered mouse models (GEMM) can recapitulate human pancreatic ductal 
adenocarcinoma (PDAC) pathology. In particular, the LSL-KrasG12D/+; LSL-Trp53R172H/+; 
P48-Cre, (KPC) model [31], mimics the genomic instability and disease progression, in-
cluding metastases, of human PDAC. In addition to the heterogeneity of primary pancreatic 
tumors in the KPC model, diaphragmatic and peritoneal metastases are polyclonal [35]. 
However, clonal variants within a single pancreatic tumor derived from this model have not 
been characterized in depth.
To model intratumoral clonal heterogeneity, we established clonal cell lines from a primary 
PDAC lesion of a KPC mouse (Fig. 1a). The primary tumor showed the characteristic ductal 
adenocarcinoma and desmoplastic histopathology (Fig. S1a), and the liver and lungs of the 
KPC mouse contained metastatic lesions (Fig. S1b). After a brief expansion of the primary 
PDAC cells from multiple tumor regions in 2D cell culture, we generated eleven clonal cell 
lines by single cell cloning (Fig. 1a). Genotyping of the clonal PDAC cell lines confirmed 
heterozygosity for the Kras locus (wildtype and recombined Kras) and a loss of the wildtype 
Trp53 allele (Fig. S1c), similar to previous assessments of PDAC cells from KPC mice [31].
The clonal PDAC cell lines are polymorphic and genetically heterogeneous
From the initial cell line panel we selected six cell lines with distinct cell morphology and 
3D growth phenotypes: The clones D10 and F2 are spindle-shaped, whereas C5, G8 and G9 
display cuboidal morphology (Fig. S1d).
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To evaluate signal transduction downstream of mutated KRAS, we assessed ERK1/2 phos-
phorylation in the individual clones by Western Blot analysis. Different levels of phospho 
ERK1/2 in the clonal cell lines grown in vitro (Fig. 1b) indicate distinct stimuli in addition to 
the presence of the KrasG12D oncogenic driver mutation. Differences in the KrasG12D variant 
allele frequency (VAF) of 1:1 to 4:1 (Fig. S1e) did not match with the different levels of ERK 
phosphorylation. This corroborates previous studies showing that KRAS mutation status is 
only poorly related to ERK activation [36-38], and suggests additional, distinct regulators of 
ERK1/2 activity amongst the clones derived from the same KrasG12D driven tumor.
Collagen can reveal invasive behavior of pancreatic epithelial cells [39-41] and we assessed 
whether the clonal PDAC cell lines show different formation of ductal structures during 
3D growth in type 1 collagen. The ability to develop ducts was poor for clones G8 and G9, 
whereas clone C5 formed wide ducts with blunt terminal buds, and C8 and F2 generated 
meshes of thin tubules (Fig. 1c).
Distinct gene expression patterns were found for the clonal cell lines grown in vitro by 
RNA sequencing. When comparing the clonal gene expression values to the average ex-
pression of all six clones, we found that clone G9 had the highest number of differentially 
expressed genes with 90 genes being upregulated more than 2-fold and 179 genes being 
down regulated. The lists of genes can be found in Data file S1. Gene set enrichment analysis 
was performed and the Hallmark Pathway families that were distinct for the clonal cell lines 
are shown in Figure 1d.
Next we assessed the genomic heterogeneity using whole exome sequencing of DNA from 
the parental tumor tissue and from the six individual clonal cell lines. To avoid contamina-
tion by circulating or metastatic cancer cells, genomic DNA from a tumor-free pancreas of 
a healthy female littermate mouse was used as a control. In the parental tumor tissue 174 
non-synonymous that lead to amino acid substitutions were detected. The lists of muta-
tions in the clonal cell lines and the tumor are shown in Data file S2. The clonal cell lines 
contained 146-247 mutations (Fig. 1e). Based on the multicellular oncogenic activation, 
the KPC model gives rise to multifocal cancer [35]. We found 64 ubiquitous mutations that 
are shared among all clonal cells and the parental tumor (Table S1), supporting the notion 
that the clonal cells were derived from a common ancestor that was selected for at an earlier 
stage of tumor progression. Approximately half (45% to 67%) of the mutations found in 
the clonal cell lines were detectable in the tumor tissue at the sequencing depth applied 
to the genomic DNA. The different abundance of the clonal subpopulation in the tumor 
tissue as well as the dilution of the tissue DNA by stromal cell DNA explains that not all of 
the mutations found in the cell lines were also detectable in the original tumor tissue. The 
number of unique mutations range from 18 in C5 and G8 to 89 in clone C8 (Fig. 1f). The list 
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Figure 1. Characterization of clonal cell lines from a KPC mouse pancreatic tumor.
a. Workfl ow for the generation of clonal cell lines. A pancreatic tumor from an LSL-KrasG12D/+; LSL-
Trp53R172H/+; P48Cre/- (KPC) mouse was harvested and cultured for one week. An image of the primary 
cancer cell growth is shown (scale bar = 100 μm). When the culture reached confl uence, cells were 
transferred to a 96-well culture plate for single cell cloning. After 3 weeks of incubation eleven wells 
contained clonal cell lines (grey circles).
b. Western blot for phospho ERK1/2 (Thr202/Tyr204) and total ERK1/2 protein in clonal cell lines.
Chapter 2 35
of unique signature mutations is shown in Table S2. Cluster analysis of the mutations show 
the relationship between the tumor tissue and the clonal cells and Indicates that clone C8 is 
most distinct (Fig. 1g).
In summary, we found that the KPC tumor harbors genetically distinct cancer subpopula-
tions, that matches with previous studies in both murine and human PDAC [11,35,42,43]. In 
the experiments described below we took advantage of the unique mutations in individual 
clones, to track and quantitate their abundance in clonal mixtures in cell culture as well as 
tumor growth in vivo.
In vitro drug responses of the clonal PDAC cell lines are distinct
To uncover potential differences in growth pathway activity of the clonal cell lines we evalu-
ated their sensitivity to different drugs. Monolayer growth of the clonal cell lines shows some 
differences in the growth rates as well as at the maximum level of confluence, as indicated 
by the impedance measurement (Fig. 2a). Clone G8 has the highest growth rate compared 
to the other clones (Fig. 2b). We next assessed the sensitivity of the clonal cell lines to 
gemcitabine that is the approved for the treatment of PDAC, and evaluated the response 
of the clonal cell lines to a series of pathway-targeted drugs. Initially, 196 kinase inhibitors 
that target >34 kinases were tested for their growth inhibitory effect at a fixed concentra-
tion of 500 nM (data not shown). From this screen, we found that drugs targeting MEK, a 
RAS-effector known to be activated in human KRAS mutant PDAC [44] distinguished best 
between the clones. We also included the anti-metabolite gemcitabine in the analysis since it 
is approved for the treatment of PDAC. Dose response curves of treatment with gemcitabine 
and the clinically used MEK inhibitor trametinib (Fig. S2a) showed IC50 values ranging 
from 15 to 205 nM between the clonal cell lines in vitro (Fig. 2c). Gemcitabine was not as 
selective, with IC50 values ranging from 5 to 19 nM (Fig. 2c). These distinct sensitivities to 
anti-cancer drugs with different mechanisms of action amongst cell subpopulations from 
the same tumor indicate the functional heterogeneity of growth pathway activity in the 
clonal cell lines. There was no correlation between gemcitabine or trametinib sensitivity 
and the proliferation rates or the levels of ERK1/2 phosphorylation of the individual clones.
c. 3D tubular structures of clonal cell lines grown in collagen-1 for 10 days. Scale bar = 100 μm. Equal 
numbers of the clonal cells were grown as 2D monolayers in DMEM 10%FBS for 3 days.
d. Heatmap of the Hallmark Pathway Families of the clonal cell lines in vitro, based on Gene Set Enrich-
ment Analysis (GSEA) of RNA-sequencing gene expression data.
e. Number of non-synonymous single nucleotide variations in the clonal cell lines and the parental 
tumor tissue detected by exome sequencing.
f. Number of unique signature mutations in the clonal cells and the parental tumor tissue.
g. Cluster analysis of the gene mutations in the clonal cells and the parental tumor tissue. The dashed 
line indicates significant differences (Euclidian distance).
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Figure 2. Clonal drug sensitivity in the context of the mixed population in vitro.
a. Cell growth of the individual clonal cell lines in vitro. Error bars are SEM of 4 replicate wells.
b. Growth rates of individual clonal cell lines in vitro. Slopes of growth curves were calculated from the 
data in Fig. 2a, with error bars representing the SEM of 4 replicate wells. ** P =0.0024 by t-test relative 
to other clonal cell lines.
c. IC50 values of individual clonal cell lines after a 72 hour treatment in vitro with gemcitabine or trame-
tinib, calculated from the dose response curves shown in Suppl.Fig 2b. Error bars represent SEM of drug 
treated cell growth in triplicate wells. Note: log scale of the Y-axis
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In vitro drug responses of clonal cells are altered when growing in the 
heterogeneous cell mixture
As a step towards the analysis of a heterogeneous cancer cell population, we next assessed 
the drug sensitivity of individual clones in the mixed population (Fig. 2d). We hypoth-
esized that resistant clones in the population would have a selective advantage though the 
crosstalk between different clones via secreted factors or cell-cell contact might impact the 
sensitivity to pathway inhibitors. Deep sequencing for the signature mutation of each clone 
(Table 1) was employed to identify and quantitate the abundance of clones in the mixture. 
The number of reads of mutant and wildtype DNA are shown in Table S3. Variant allele 
frequencies (VAF) measured in the starting mixture of the clones were compared to those 
in the clone mixture that had grown under control conditions (DMSO) or gemcitabine (25 
nM) or trametinib (100 nM) until reaching confluence (Fig. 2d). The VAFs under control 
and drug treatment are shown in Fig. 2e-g and the impact of drug treatment on the clonal 
contribution to the cell population in Fig. 2h-j. It should be noted that each cell line retains 
only one copy of the Trp53 allele, with the R172H mutant, that is reflected in the ~100% 
read of the VAF for Trp53, irrespective of the treatment.
d. Schematic depiction of the growth assay of the clonal cell mixture in vitro in the presence of DMSO, 
25 nM gemcitabine or 100 nM trametinib. When cells reached 90% confluency, genomic DNA was ex-
tracted to measure clone abundance by deep sequencing.
e - g. Variant allele frequencies (VAF) of Kras, Trp53 and 6 genes containing clone-specific signature 
mutations, measured by amplicon deep-sequencing. DNA from the untreated cell mix and the clone 
mixture grown in presence of DMSO (e), the clone mixture grown in presence of DMSO or gemcitabine 
(f) or trametinib (g) until confluent. Note the log scale of the Y-axis. Three and two sequencing runs 
were carried out for the starting clone mixture and DMSO treated cells respectively.
h - j. Change in clone abundance after treatment with DMSO (h), gemcitabine (i) or trametinib (j) based 
on the VAFs of the clonal signature mutations, compared to those in the starting clone mix. Note the log 
scale of the Y-axis. The dashed lines indicate 2-fold increase or decrease in clone abundance.
Table 1. Genes with signature mutations used to identify clones by deep sequencing.
clone gene chrom position (mm9)
heterozygous 
variant AAS transcript
C5 Baiap3 chr17 25387359 G>T L170I NM_001163270
C8 Olfr1157 chr2 87802181 G>C I289M NM_146849
D10 Nox4 chr7 94462586 C>T T89M NM_015760
F2 Matn4 chr2 164222680 C>T R339Q NM_013592
G8 Arhgap25 chr6 87426299 T>C K171R NM_001037727
G9 Pla2g4d chr2 120094626 G>T S710R * NM_001024137
Each clone Trp53 chr11 69402014 G>A R172H ^ NM_001127233
Each clone Kras chr6 145195291 C>T G12D NM_021284
chr = chromosome; mm9 = mus musculus reference genome 9; AAS = amino acid substitution;
* = mutation also present in the parental tumor tissue; ^ = loss of wildtype allele
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When the mixed cancer cell population was grown under control conditions, no significant 
enrichment of clones was found (Fig. 2h). This was surprising since clone G8 grows signifi-
cantly faster than the others when grown individually. Paracrine signaling may harmonize 
the growth rate of clones in the mixture. Gemcitabine treatment, selected for clone G9 by 
~4-fold and led to a ~5-10-fold decreased abundance of clones C8, F2 and G8 (Fig. 2i). The 
latter 3 clones were the most sensitive to gemcitabine (Fig. 2c) and their reduced abundance 
matches with their relative sensitivity to the drug. This indicates that cancer cell crosstalk 
had no major impact on the effect of gemcitabine, in line with the cell-autonomous mecha-
nism of action of this anti-metabolite.
In contrast to gemcitabine, treatment with trametinib led to a ~10-fold reduction of clones 
D10 and G9 in the mixed population (Fig. 2j). Clone C8 made up the largest portion of 
the population (Fig. 2f) and therefore seems unresponsive to trametinib when grown in 
the presence of the other clones. To our surprise, the most MEK inhibitor-resistant clone 
G8 (Fig. 2c) did not dominate when growing in the presence of the other cell lines and 
trametinib (Fig. 2j). To assess whether secreted factors from the other clones played a role 
in sensitizing clone G8 to trametinib, we conducted an experiment with conditioned media. 
As a comparison we used clone C8, which appeared favored by 2-fold when the mixture was 
treated with trametinib. Clonal cell lines G8 and C8 were grown individually and treated 
with different concentrations of trametinib in the presence of conditioned media from the 
matching cell line, or with the conditioned media from the mixed population. We found that 
clone G8 is sensitized to trametinib when conditioned media from the mixed population 
was added (Fig. S2b) but did not observe this effect for clone C8 (Fig. S2c). We conclude 
from this that growth behavior and drug sensitivity of cancer cell subpopulations can be 
altered by the composition of the population due to paracrine crosstalk.
Tumorigenesis of clonal cell lines in immune competent mice
When placed in the intraperitoneal cavity of immune-competent compatible mice, each 
clonal cell line homes to the pancreas, invading and destroying the tissue architecture 
(Fig. S3a). To easily monitor the tumor growth rate, the individual clonal cell lines were 
also injected subcutaneously into the flanks of compatible mice. It is noteworthy that the 
histopathological features of the subcutaneous tumors were indistinguishable from those of 
orthotopic allograft tumors in the pancreas (Fig. S3b vs S3a). In vivo, clone D10 the most 
fibroblast-like clone (Fig. S1d), generates poorly differentiated tumors, whereas the other 
clones developed differentiated adenocarcinomas with glandular structures, either ortho-
topically or subcutaneously. Differentiation of the tumors was not predictable from the 3D 
growth phenotype of the clonal cell lines in collagen type 1, in which D10 forms tube-like 
structures, whereas G9 and G8 do not (see Fig. 1c). Growth rates of the subcutaneous 
clonal tumors from C5 and D10 were relatively low, whereas clone G8 grew at a significantly 
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higher rate than the other clones (Figs. 3a, S3c). Interestingly, gene analysis indicated an 
upregulation of the allograft rejection response pathway for clones C5 and D10 (Fig. 1d) 
and corroborates the tumor growth phenotype. All clones recruited cancer-associated fibro-
blasts and induced desmoplasia that is pathognomonic for PDAC. Staining of the tumors 
for α-smooth muscle actin (α-SMA) revealed equal proportions of myofibroblasts across 
the subcutaneous allograft tumors from the clonal cell lines (Fig. S3d). The homogeneous 
recruitment of myofibroblasts was confirmed by qRT-PCR analysis of the gene expression 
levels of α-SMA in the clonal allograft tumors (Fig. S3e).
response of heterogeneous tumors to different types of drug therapy
Tumor tissue architecture has profound effects on malignant progression and resistance to 
drug therapy and is controlled by cell-cell and extracellular matrix interactions [19,20,43]. 
In addition, cytotoxic drugs and pathway inhibitors can stimulate or inhibit stromal cells 
that participate in the immune response to a malignant lesion [45-47]. To assess treatment 
responses of PDAC subpopulations in the context of tumor stroma and an intact immune 
system, we inoculated compatible, immune-competent syngeneic mice with an equal mix-
ture of the above described six clonal cell lines and treated them with prototypic drugs that 
target different hallmarks of malignancy. We hypothesized that the relative drug sensitivity 
of clonal subpopulations would be distinct for drugs that act via different mechanisms. Also, 
we surmised that clonal responses in vitro might differ from the in vivo sensitivity due to 
host-tumor interactions. The heterogeneous subcutaneous tumors were allowed to establish 
for one week and mice were then treated for two weeks with intraperitoneal injections of the 
control (PBS containing DMSO or control IgG), gemcitabine, an anti-programmed death-1 
(PD-1) antibody, or oral gavage with trametinib (Fig. 3b). The maximal inhibitory effect on 
tumor sizes after gemcitabine and trametinib was reached after 5 days of treatment, whereas 
the α-PD-1 was most effective in reducing tumor size after 10 days of treatment (Fig. S4a). 
At the end of the two-week treatment period tumors were harvested for evaluation.
Distinct impact of different drugs on the allograft tumor stroma
The impact of stroma is crucial in cancer growth and known to modulate drug responses. 
Thus we initially evaluated the impact of drug treatment on the tumor cell/host stroma 
ratio. For this, we took advantage of the fact that the wildtype Trp53 allele is lost from the 
cancer cell lines and used the Trp53R172H variant allele frequency (VAF) as the readout of 
cancer cell abundance in the tumor tissues (Fig. 3c). Given that stromal cells from the host 
carry two copies of the wildtype Trp53 allele and the cancer cells only one copy of mutant 
Trp53R172H, an equal contribution of stromal and cancer cells to the tumor would result in a 
Trp53R172H VAF of 33.3%. We observed a ~50% VAF indicating that 2/3 of the tumor mass 
is contributed by cancer cells. Although histologically the stroma appears dominant, this is 
mostly due to desmoplasia and not the abundant presence of stromal cells. After gemcitabine 
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Figure 3. Clonal drug sensitivity in the context of heterogeneous tumors.
a. Growth rate of individual clonal allograft tumors. One million clonal cells were injected subcutane-
ously into the fl anks of compatible immune competent mice. Error bars are SEM for n≥3 tumors, * P 
=0.0155 by t-test for the growth of G8 versus the median rate of the other clones.
b. Schematic depiction of allograft tumor generation using the pooled clonal mixture. One million 
mixed clonal cells were injected subcutaneously into the fl anks of immune competent syngeneic mice. 
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treatment the contribution to tumors was not changed relative to control tumors, whereas a 
decrease in cancer cell-specific mutant Trp53R172H from ~49% to ~38% was observed in the 
MEK inhibitor treated tumors (Fig. 3c). Although this decrease was not statistically signifi-
cant, this finding suggests that trametinib may have a greater inhibitory effect on the cancer 
cells than on the tumor stroma. Strikingly, the α-PD-1 treatment resulted in a significant 
decrease of mutant Trp53R172H DNA to ~14%, compared to ~49% in control tumors (Fig. 3c) 
due to immune cell recruitment as well as due to cancer cell death. The immune recruitment 
was validated in the tumor sections, in which showed increased leukocyte infiltration in 
the α-PD-1 treated tumors (Fig. S4b), whilst the different treatments did not impact the 
abundance of α-SMA positive fibroblasts (Fig. S4c).
effects of gemcitabine and trametinib on the growth of clonal subpopulations 
in heterogeneous tumors are different from the effects in vitro
To monitor clonal drug responses we used deep sequencing of tumor DNA and quantitated 
the abundance of clonal signature mutations (Table 1). Variant allele frequencies (VAFs) 
of the clone-specific signature mutations and of mutant Kras and Trp53 under the differ-
ent treatment conditions are shown in Fig. 3d-g (for absolute read counts see Table S4). 
Changes in cancer cell subpopulation abundance in the tumors are shown in Fig. 3h-k and 
discussed in the next sections. Tumor growth of individual clonal tumors without drug 
treatment revealed the fastest rate for clone G8 and the slowest for C5 and D10 (Fig. 3a). 
These distinctions were maintained in the heterogeneous tumors (Fig. 3h), indicating that 
the growth conditions provided in the tumor microenvironment determine clone-specific 
growth rates.
When tumors had established, the animals were treated with control vehicle, gemcitabine, trametinib, 
or anti-PD-1 for 2 weeks. Tumors were collected for histology and genomic DNA was isolated.
c. Trp53R172H variant allele frequency (VAF) in DNA from ≥5 treated tumors, indicating cancer cell load 
in the tumors, measured by amplicon deep sequencing of signature mutations. * P =0.0206 t-test VAF in 
α-PD-1 tumors compared to control tumors. Error bars represent SEM from n=3 sequencing runs for the 
clonal cell mix, n=4 sequencing runs for control tumors, n=2 sequencing runs for gemcitabine tumors. 
DNA from ≥5 tumors was pooled per sequencing run.
d – g. VAFs of Kras, Trp53 and 6 genes containing clonal signature mutations, measured by amplicon 
deep-sequencing, from DNA from (d) the untreated cell mixture and control treated tumors; (e) con-
trol and gemcitabine treated tumors; (f) control and trametinib treated tumors; (g) control and α-PD-1 
treated tumors. Graphs have a log scale for the y-axes, error bars represent SEM, n=3 deep sequencing 
runs for the untreated cell mixture, n=5 for the control tumors, n=2 for the gemcitabine and trametinib 
tumors. DNA from ≥5 tumors was pooled per sequencing run.
h - k. Change in clone abundance in tumors treated with (h) control: (i) gemcitabine; (j) trametinib; 
or (k) α-PD-1. The graphs have a log scale for the Y-axis; the dashed lines indicate 2-fold increase or 
decrease in clone abundance. Clone abundance was normalized to total cancer cell load (Trp53R172H VAF) 
in the tumors. Error bars represent SEM, n=5 sequencing repeats for the control tumors, n=2 for the 
gemcitabine and trametinib tumors. DNA from ≥5 tumors was pooled per sequencing run.
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Next, we compared the impact of gemcitabine and MEK inhibitor treatment on the growth 
of clonal subpopulations. Only the clone G8 showed a reduced contribution to the tumors 
after gemcitabine treatment whilst the slow growing clones C5 and D10 gained ~5-fold in 
abundance (Fig. 3i). Clones C8 and F2, which were inhibited by gemcitabine when grown 
in the mixed population in vitro (see Fig. 2h) were not impacted by gemcitabine in the 
heterogeneous tumors in vivo (Fig. 3i). This suggests that the stroma protects clones C8 and 
F2 from the inhibitory effects of gemcitabine.
The MEK inhibitor treatment of the reconstituted, heterogeneous tumors revealed that clones 
C8 and G8 are sensitive to trametinib treatment (Fig. 3j), whereas G9 gained in abundance 
and became the dominant subpopulation in the tumors (Fig. 3f & j). This contrasts with the 
in vitro findings where clone G9 was sensitive and C8 resistant to trametinib (see Fig. 2j), 
suggesting that the stroma provides stimuli that alter clonal sensitivity to the MEK inhibitor.
Distinct response of clonal subpopulations in heterogeneous tumors to PD-1 
blockade
PDAC is notorious for its dense fibrosis, immune suppressive environment and low number 
of intratumoral effector T-lymphocytes [48,49]. It has been suggested that these factors drive 
the low PDAC responsiveness to immune checkpoint inhibition such as anti-programmed 
death-1 (PD-1) therapy. To assess whether cancer heterogeneity may also play a role in the 
resistance, we investigated the response of the different clones to anti-PD-1 monoclonal 
antibody therapy. Similar to the above drug sensitivity assessments, we injected the mixed 
population of PDAC clones subcutaneously in immune competent mice and treated the ani-
mals for 2 weeks. When measuring the clonal contribution to the allograft tumors (Fig. 3g), 
we found strikingly different responses between the clonal subpopulations. In particular, 
clone C8 was eliminated after α-PD-1 treatment and clone G9 by >70% (Fig. 3k). Interest-
ingly, the contribution of clones C5 and D10 to the cancer lesions was increased by ~10-fold 
after the α-PD-1 treatment (Fig. 3k), suggesting that the growth disadvantage of these two 
clones under control conditions (see Fig. 3h) is not regulated by PD-1 dependent allograft 
rejection, but due to other microenvironmental factors. The differential clonal sensitivity to 
leukocyte-mediated killing of clone C8 and G9 initiated by PD-1 blockade suggests cancer 
cell-intrinsic selectivity and we evaluated the potential mechanism further.
Clonal PDAC cancer cell lines have different abilities to attract leukocytes
Based on the differences in allograft tumor formation and sensitivity to α-PD-1 treatment, 
we investigated the type of immune cells that infiltrate into the allograft tumors, using 
flow cytometry (Fig. S5). Analyses of lymphocytes revealed that the highest numbers of 
infiltrating CD4+ T cells are detected in tumors from clones D10 and G8, whereas the 
CD8+ T-lymphocytes in the tumors from clones C8, F2 and G9 are higher than in tumors 
Chapter 2 43
from the other clones (Fig. 4a). To further elucidate the activation of T-cells in the clonal 
tumors, we measured CD25 and PD-1 surface expression by flow cytometry. Programmed 
Cell Death protein-1 (PD-1) is expressed on T-cells upon continuous activation [50]. CD25, 
also known as Interleukin-2 Receptor α is expressed by regulatory T-cells after stimulation, 
resulting in CD8+ CD25+ memory T-cells, and CD4+ CD25+ suppressive T-cells [51]. 
Allograft tumors from clone C8 contain the highest number of CD4+ PD-1+ and CD8+/
PD-1+ that are stimulated via their T-cell receptors (Fig. 4b-c). This might explain the high 
sensitivity of clone C8 to the α-PD-1 treatment. The second most sensitivity clone to α-PD-1 
treatment G9 also has the highest number of tumor infiltration CD8+ PD-1+ T-cells (Fig. 
4c), supporting this hypothesis. The number of suppressive CD25+ CD4+ T-cells (mean 
36.4% ± 9.1) in the clonal tumors is not associated to different growth phenotypes (Fig. 4b).
Gut associated lymphoid tissue in caecal patches contain cancer reactive T-cells
To investigate whether the differential α-PD-1 sensitivity is mediated by direct cell-cell con-
tact between effector T-lymphocytes and cancer cells, we performed an in vitro co-culture 
experiment. First, we injected the mixture of the six PDAC clonal cell lines intraperitoneally 
in immune competent compatible mice to let allograft tumors develop for two weeks. We 
hypothesized that in tumor bearing mice naïve mouse T-lymphocytes get activated in the 
gut-associated lymphoid tissue (GALT) such as the Peyer’s patches and the caecal patch (the 
murine equivalent of the human appendix vermiformis [52,53], via their T cell receptor 
(TCR), mediated by dendritic cells presenting tumor antigens from the cancer cells. Primed 
T-lymphocytes in the GALT differentiate into effector T-cells, which can migrate to the site 
of origin of the tumor antigens, and kill the malignant cells [54]. To test this hypothesis we 
initially studied the histology of the caecal patch lymphoid tissues and found a significant 
increase in the size of germinal centers in the ceacal patches of tumor bearing KPC mice 
(Figs. S6a-b), suggesting an increase in immune activation compared to healthy mice.
For functional studies, we subsequently isolated T-lymphocytes from caecal patches of 
tumor bearing mice for an in vitro activation assay. Figure 4d provides a schematic overview 
of the procedure. After allowing the mixed clonal allograft tumor growth for two weeks, 
we isolated T-lymphocytes from the caecal patches of the tumor bearing mice, yielding 
~60,000-330,000 live T-cells per mouse. As controls, we isolated T-lymphocytes from the 
caecal patches of healthy wildtype mice, yielding 45,000-48,000 live T-cells per mouse. 
Growth media of the T-lymphocytes was supplemented with interleukin-2 (IL-2) and the 
PDAC clonal cells were added to the cell-cultures. Figure 4e provides a representative view 
of the PDAC clonal cell mixture growing together with the isolated T-cells after 48 hours. 
T-cells from healthy mice as well as from tumor bearing mice attach to the PDAC cells 
(Fig. 4e). Noteably, the PDAC cells in co-culture with T-cells from tumor bearing mice 
de-attached from the plate at a higher rate and show signs of distress (Fig 4e).
44  Intratumoral heterogeneity and tumor-host crosstalk alter drug sensitivity
b
*
**
is
o 
ct
rl
C5
C8
D10
F2
G8
G9
 is
o 
ct
rl
 is
o 
ct
rl
 is
o 
ct
rl
 is
o 
ct
rl
 is
o 
ct
rl
 
clone mix 
PDAC tumors
co-culture with IL-2 
+/- α-PD-1
T-lymphocytes
measure secreted IFN-γ
+
PDAC clones
wt mice
caecal patches
healthy 
controls
C5
C8
D10
F2
G8
G9
clone mix
subcut 
tumors
a c
d e
T-
ce
lls
 fr
om
 h
ea
lth
y 
m
ic
e 
+ 
P
D
A
C
 c
lo
ne
 m
ix
T-
ce
lls
 fr
om
 m
ic
e 
w
ith
 a
llo
gr
af
t 
tu
m
or
s 
+ 
P
D
A
C
 c
lo
ne
 m
ix
f
0.0
0.5
1.0
1.5
2.0
re
la
tiv
e 
m
 IF
N
-γ 
0
20
40
60
80
T-cells
pe
rc
en
t o
f C
D
3+
 c
el
ls
CD4 CD8
0
1
2
3
4
20
40
60
80
CD8 T-cells
pe
rc
en
t o
f C
D
8+
 c
el
ls
0
20
40
60
80
CD4 T-cells
pe
rc
en
t o
f  C
D
4+
 c
el
ls
PD-1 +
CD25 -
PD-1 +
CD25 -
PD-1 -
CD25 +
PD-1 -
CD25 +
α
-P
D
-1
α
-P
D
-1
α
-P
D
-1
α
-P
D
-1
α
-P
D
-1
α
-P
D
-1
Figure 4. Diff erential activation of primed T-lymphocytes by clonal pancreatic cancer cells.
a. Flow cytometry results of tumor infi ltrating lymphocytes. One million cells of the individual clones, 
or the clone mixture were injected subcutaneously into the fl anks of immune competent syngeneic 
mice. When tumors had established after 10 days tumors were harvested and processed for fl ow cytome-
try analysis. Percentage of CD4 and CD8 T cells are graphed as frequency of total T cells (CD3+ T cells).
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Clonal cancer cells activate caecal patch T-cells from tumor bearing mice to a 
different extent
One of the effector mechanisms of activated T-cells is production of Interferon-γ (IFN-γ). 
Indeed, T-lymphocytes harvested from caecal patches of healthy mice do not secrete IFN-γ 
when co-cultured with the clonal PDAC cells (Fig. S6b), whereas T-lymphocytes from 
tumor-bearing mice with intraperitoneal, mixed clone tumors initiated elevated IFN-γ 
secretion in co-cultures with the clonal PDAC cells (Fig. S6c). Although efficiency of the T-
lymphocyte isolation varies between mice (see Fig. S6c), co-cultures of T-cells from tumor 
bearing mice with PDAC clone C8 elicited the highest level of IFN-γ secretion, and clone 
G9 the second highest, relative to the other PDAC clones (Fig. 4f). Oncogenic mutation 
burden and the abundance of tumor infiltrating CD8+ T-lymphocytes are potential predic-
tors for response to anti-PD-1 therapy [55]. Both were found for α-PD-1 sensitive clone 
C8, which has the highest number of unique non-synonymous mutations (see Fig. 1e-f) 
and high numbers of tumor infiltration CD8+ T-cells (see Fig. 4a-b). Complementary to 
these observations, the IFN-γ production by T-cells from allograft tumor bearing mice that 
are co-cultured with PDAC clone D10 in the presence of α-PD-1 is significantly lower than 
the levels elicited by the other PDAC clones (Fig. 4d) and this corroborates the resistance 
of clone D10 to α-PD-1 treatment in vivo (see Fig. 3k). In conclusion, clonal PDAC cell 
lines originating from the same parental PDAC tumor have distinct intrinsic capacities to 
activate primed T-lymphocytes in vitro (Fig. 4f), matching with the distinct responses to 
α-PD-1 treatment in vivo.
We conclude from the above analyses that the crosstalk amongst cancer cell subpopulations 
and the host stroma impacts the sensitivity to different therapeutic approaches distinctly, 
allowing the emergence of discrete resistant subpopulations. Moreover, our results suggest 
that cancer cell-intrinsic factors impact the ab initio sensitivity of subpopulations to im-
mune checkpoint inhibitors.
b. Flow cytometry results of PD-1 and CD25 expression on CD4 T cells in allograft tumors.
c. Flow cytometry results of PD-1 and CD25 expression on CD8 T cells in allograft tumors.
d. Schematic of workflow of T-lymphocytes isolation and culture. T-cells were isolated from the caecal 
patches of healthy control and PDAC allograft tumor bearing mice, and co-cultured together with the 
PDAC clonal cell lines supplemented with Internleukin-2. After 48 hours, interferon-γ was measured 
in the supernatants.
e. Images of the PDAC clone mixture and mouse caecal patch T-lymphocytes co-culture in vitro at 48 
hours. Green arrows indicate T-lymphocytes, black arrows indicate PDAC cells. Scale bar = 100 μm.
f. Relative amount of IFN-γ in the supernatant of ceacal patch T-lymphocytes from mice that carried 
clone mix tumors, co-cultured with the individual PDAC clonal cell lines for 48 hours in presence of 
anti-PD-1 or the igG2a isotype control (iso control), measured by ELISA. Error bars are SEM, measure-
ments from lymphocytes from n=3 mice. Levels of IFN-γ are normalized to the median level of IFN-γ 
secretion by lymphocytes per mouse. Clone C8 ** P=0.0017 and clone D10 * P = 0.0226, by t-test compa-
red to average level of the other clones.
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DIsCussIon
Heterogeneity of human cancers emerges during evolutionary selection of cell subpopula-
tions with different genetic and epigenetic alterations that provide a survival advantage 
under pressure from the microenvironment [9,10,13,26] and continues during therapy [17]. 
Crosstalk between tumor subpopulations is one of the modulators that impact cell growth 
and was recognized in a mammary tumor model several decades ago [56]. A recent study 
systematically evaluated and modeled this crosstalk via secreted factors [28]. The authors 
used the established human breast cancer cell line MDA-MB-468 to generate a panel of 
eighteen derivative cell lines by lentiviral expression of single secreted factors and showed 
that paracrine stimuli from small, less fit clonal subpopulations can still drive malignant 
progression of xenograft tumors in immune-compromised mice. Also, the biologic sig-
nificance of a highly dynamic but small subpopulation of cells was uncovered in human 
melanoma. It was shown that epigenetic regulation by an H3K4 demethylase maintains a 
slow growing, minor subpopulation in melanoma that can escape from treatments targeting 
fast growing populations, can repopulate the tumor and contribute to metastatic growth 
[57]. Patient derived xenografts (PDXs) can partially retain tumor heterogeneity [58]. How-
ever, PDXs need to be maintained in immune compromised animals and thus retain only a 
subset of the microenvironmental features. These examples illustrate the complex biology 
and challenges to generate appropriate experimental platforms that capture the dynamics of 
tumor evolution and allow for the assessment of therapeutic interventions.
In this study, we first deconvoluted a PDAC tumor from the classic KPC model into clonal 
cell lines and then reconstituted heterogeneous tumors to follow clonal dynamics during 
drug treatment in syngeneic, immune competent hosts. Based on the signature mutations 
identified for each clone and the shared Trp53 variant allele amongst the clones, the rela-
tive abundance and stromal contribution can be quantitated in our model in the context 
of an intact immune environment. One of our findings was that clonal cell growth of the 
mixed population in vitro correlated only in part with growth in the presence of host stroma 
and immune cells. Under control conditions the growth in vivo of some clones was slower 
despite their indistinguishable growth rates in vitro. This suggests that the crosstalk with 
immune cells and tumor stroma is different for these clonal cancer cells, though they were 
derived from the same original tumor specimen.
Previous studies have shown the impact of stromal signals on cancer cell drug sensitivity 
[59,60] and more recent models have tried to capture some of the features of the environ-
ment in vitro [59-63]. In the current study, the MEK kinase inhibitor showed the most strik-
ing differences between the findings in vitro and in vivo and we attribute some of this to the 
impact of the inhibitor on crosstalk between cancer cells and stromal cells. Paracrine clonal 
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crosstalk amongs cancer cells can explain the sensitization of clone G8 that was resistant to 
trametinib on its own but sensitized in the mixed cancer cell culture in vitro. A comparison 
of clonal effects of trametinib in the mixed culture in vitro and in the tumors however, 
showed a discordant result for clone G9 that moved from sensitive in vitro to resistant in 
the tumors and clone C8 that moved in the opposite direction (see Fig. 2j vs Fig. 3j). Still, 
under the MEK inhibitor treatment stromal cell abundance increased (Fig. 3c) suggesting 
additional crosstalk of tumor cells and stroma that altered the clonal sensitivity in vivo.
The potential contribution of host immune cells to the differential growth we observed in 
vivo versus in vitro is suggested by earlier studies. One classic study showed distinct immu-
nogenicity of clonal subpopulations of a mouse mammary adenocarcinoma [64]. Surpris-
ingly, we found that immune checkpoint blockade, which leads to increased lymphocyte-
mediated cancer cell killing [65,66], did not reduce the growth of slow growing clones any 
further. In contrast, these clones increased in abundance in the residual tumor after α-PD-1 
treatment and thus appear resistant to checkpoint inhibition. Also, the slower clones C5 
and D10 increased in abundance after treatment with the cytotoxic drug gemcitabine. This 
finding is reminiscent of a recent report that showed that minor dormant human colorectal 
cancer clones can become dominant and reinitiate tumor growth after chemotherapy [67].
The striking differences in immunotherapy efficacy towards clones present in heterogeneous 
tumor mix provides some interesting insights that may allow to overcome resistance. One 
of the clonal cell lines, clone C8, is particularly sensitive to α-PD-1 therapy. The co-culture 
experiment with primed mouse T-lymphocytes and the clonal PDAC cell lines corroborated 
the finding. Antigens specific to clone C8 activated primed T-lymphocytes significantly 
better than those of the other clonal lines generated from the same tumor. TILs are often 
exhausted and thus difficult to use in cell culture experiments [68]. We conducted this 
experiment with T-lymphocytes from the caecal patches of allograft tumor bearing mice. 
We are the first to show that caecal patches of in PDAC bearing mice contain cancer-specific 
effector T-cells, providing a new approach to assess immunotherapy efficacy.
In conclusion, the composition of heterogeneous cancers is affected by crosstalk amongst 
the cancer subpopulations as well as the host environment that includes the immune system 
as a major player. We developed an in vivo model that allows for the quantitation of clonal 
cancer subpopulations in heterogeneous tumors, growing in immune competent animals. 
Our model is suited for the assessment of stromal and immune modulators and their im-
pact on growth of heterogeneous cancer cells. Our study shows that prediction of drug 
efficacy from in vitro analysis of heterogeneous cancer cell populations is dependent on the 
mechanism of action of the studies drugs. Immune response and sensitivity to checkpoint 
48  Intratumoral heterogeneity and tumor-host crosstalk alter drug sensitivity
blockade is cancer clone specific and predictable using co-cultures with appropriately 
primed effector T-cells.
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Supplementary Table 1. List of ubiquitous non-synonymous single nucleotide variations in the clonal 
cancer cell lines and the corresponding parental tumor tissue measured by exome sequencing.
AAS = amino acid substitution
Gene AAS
AB124611 D73G
Aloxe3 A667V
Atp13a4 F568L
Car4 A97V
Clec2g N12S
Cntn5 T966A
Cox11 V62A
Cypt4 N152S
Dock6 W145R
Ecsit S75L
Gjd4 V80L
Gm14459 M80I
Gtse1 P399L
Kcnk15 I195V
Klrc2 A188P
Kras G12D
Gene AAS
Kri1 K241E
Lzts2 H327Q
Mbp G27R
Ncoa3 A706V
Nfam1 R220S
Nrip2 P158S
Nup160 L7R
Olfr311 A210T
Olfr314 T238A
Olfr743 N84S
Pdcd11 P1556L
Pitpnm3 R21Q
Ppfibp1 L371P
Ppl G179R
Rangap1 E389D
Rbbp8 K178R
Gene AAS
Rbm12b2 T574P
Rbpjl T368S
Sec16b R31C
Shisa6 L368I
Slc15a5 G452S
Slc30a4 G64R
Slc45a1 S433L
Slfn14 V301I
Smco2 T163N
Smco3 K193R
Spint3 T86I
Srebf2 R621H
Tas2r136 G202D
Tekt1 A237V
Timm9 R89W
Tmem241 A85S
Gene AAS
Tmem52 T91P
Tonsl T1086M
Trp53 R172H
Trp53rkb A208E
Ttll8 R702L
Ugt1a1 K80M
Uimc1 E709D
Vmn1r12 F61L
Vmn1r15 T38I
Vmn1r6 L264V
Wbp11 D360N
Wfdc12 L70P
Xaf1 C135S
Yipf2 L227F
Zc3h7b A681T
Zfp426 S54T
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Supplementary Table 3. Deep sequencing read counts of the clone-specific signature mutations and 
ubiquitous Kras and Trp53 mutations in DNA from the heterogeneous clone mixtures in vitro. chrom = 
chromosome; mm9 = mus musculus reference genome 9; VAF = variant allele frequency
EQUAL MIX OF UNTREATED CLONAL CELLS – DEEP-SEQ RUN 1
clone gene chrom position (mm9) variant
read 
depth
wildtype
reads
variant 
reads VAF
all Trp53 chr11 69402014 G>A NA NA NA NA
all Kras chr6 145195291 C>T 725 264 461 63.59%
C5 Baiap3 chr17 25387359 G>T 1235 1203 32 2.59%
C8 Olfr1157 chr2 87802181 G>C 501 475 26 5.19%
D10 Nox4 chr7 94462586 C>T 651 625 26 3.99%
F2 Matn4 chr2 164222680 C>T 508 475 33 6.50%
G8 Arhgap25 chr6 87426299 T>C 1207 1136 71 5.88%
G9 Pla2g4d chr2 120094626 G>T 656 583 73 11.13%
EQUAL MIX OF UNTREATED CLONAL CELLS – DEEP-SEQ RUN 2
clone gene chrom position (mm9) variant
read 
depth
wildtype
reads
variant 
reads VAF
all Trp53 chr11 69402014 G>A 860 0 855 99.42%
all Kras chr6 145195291 C>T 533 184 349 65.48%
C5 Baiap3 chr17 25387359 G>T 1298 1264 34 2.62%
C8 Olfr1157 chr2 87802181 G>C 825 797 28 3.39%
D10 Nox4 chr7 94462586 C>T 955 883 72 7.54%
F2 Matn4 chr2 164222680 C>T 1050 925 125 11.90%
G8 Arhgap25 chr6 87426299 T>C 1230 1141 87 7.07%
G9 Pla2g4d chr2 120094626 G>T 742 704 38 5.12%
EQUAL MIX OF UNTREATED CLONAL CELLS – DEEP-SEQ RUN 3
clone gene chrom position (mm9) variant
read 
depth
wildtype
reads
variant 
reads VAF
all Trp53 chr11 69402014 G>A 2371 20 2331 98.31%
all Kras chr6 145195291 C>T 2575 1012 1562 60.66%
C5 Baiap3 chr17 25387359 G>T 2651 2531 120 4.53%
C8 Olfr1157 chr2 87802181 G>C 2663 2522 140 5.26%
D10 Nox4 chr7 94462586 C>T 2823 2643 180 6.38%
F2 Matn4 chr2 164222680 C>T 2614 2381 232 8.88%
G8 Arhgap25 chr6 87426299 T>C 3340 3177 157 4.70%
G9 Pla2g4d chr2 120094626 G>T 2370 2027 336 14.18%
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MIX OF CELLS GROWN IN VITRO WITH DMSO – DEEP-SEQ RUN 1
clone gene chrom position (mm9) variant
read 
depth
wildtype
reads
variant 
reads VAF
all Trp53 chr11 69402014 G>A 1415 0 1407 99.43%
all Kras chr6 145195291 C>T 1247 434 813 65.20%
C5 Baiap3 chr17 25387359 G>T 1492 1461 31 2.08%
C8 Olfr1157 chr2 87802181 G>C 0 - - -
D10 Nox4 chr7 94462586 C>T 2011 1930 81 4.03%
F2 Matn4 chr2 164222680 C>T 0 - - -
G8 Arhgap25 chr6 87426299 T>C 2551 2413 137 5.37%
G9 Pla2g4d chr2 120094626 G>T 1658 1499 159 9.59%
MIX OF CELLS GROWN IN VITRO WITH DMSO – DEEP-SEQ RUN 2
clone gene chrom position (mm9) variant
read 
depth
wildtype
reads
variant 
reads VAF
all Trp53 chr11 69402014 G>A 2054 6 2027 98.69%
all Kras chr6 145195291 C>T 2578 1056 1522 59.04%
C5 Baiap3 chr17 25387359 G>T 2439 2385 53 2.17%
C8 Olfr1157 chr2 87802181 G>C 3013 2770 243 8.07%
D10 Nox4 chr7 94462586 C>T 2868 2705 163 5.68%
F2 Matn4 chr2 164222680 C>T 2795 2393 398 14.24%
G8 Arhgap25 chr6 87426299 T>C 3566 3319 246 6.90%
G9 Pla2g4d chr2 120094626 G>T 2448 2199 244 9.97%
MIX OF CELLS GROWN IN VITRO WITH GEMCITABINE – DEEP-SEQ RUN 1
clone gene chrom position (mm9) variant
read 
depth
wildtype
reads
variant 
reads VAF
all Trp53 chr11 69402014 G>A 1227 0 1221 99.51%
all Kras chr6 145195291 C>T 858 294 564 65.73%
C5 Baiap3 chr17 25387359 G>T 1891 1812 79 4.18%
C8 Olfr1157 chr2 87802181 G>C 1405 1392 13 0.93%
D10 Nox4 chr7 94462586 C>T 924 851 73 7.90%
F2 Matn4 chr2 164222680 C>T 1620 1591 29 1.79%
G8 Arhgap25 chr6 87426299 T>C 1663 1634 29 1.74%
G9 Pla2g4d chr2 120094626 G>T 1316 845 469 35.64%
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MIX OF CELLS GROWN IN VITRO WITH TRAMETINIB– DEEP-SEQ RUN 1
clone gene chrom position (mm9) variant
read 
depth
wildtype
reads
variant 
reads VAF
all Trp53 chr11 69402014 G>A 869 1 866 99.65%
all Kras chr6 145195291 C>T 740 256 484 65.41%
C5 Baiap3 chr17 25387359 G>T 948 933 14 1.48%
C8 Olfr1157 chr2 87802181 G>C 805 680 125 15.53%
D10 Nox4 chr7 94462586 C>T 1022 1016 6 0.59%
F2 Matn4 chr2 164222680 C>T 940 853 87 9.26%
G8 Arhgap25 chr6 87426299 T>C 1555 1439 114 7.33%
G9 Pla2g4d chr2 120094626 G>T 843 831 12 1.42%
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Supplementary Table 4. Deep sequencing read counts of the clone-specific mutations and ubiquitous 
Kras and Trp53 mutations in DNA from the heterogeneous allograft tumors after 2 weeks treatment. 
chrom = chromosome; mm9 = mus musculus reference genome 9; VAF = variant allele frequency; * 
= Arbitrary number, set as minimum sequencing detection threshold (in the case of 0 mutant reads).
SUBCUT TUMORS AFTER CONTROL TREATMENT – DEEP-SEQ RUN 1
clone gene chrom position (mm9) variant
read 
depth
wildtype
reads
variant 
reads VAF
all Trp53 chr11 69402014 G>A 0 - - -
all Kras chr6 145195291 C>T 474 387 87 18.35%
C5 Baiap3 chr17 25387359 G>T 1519 1519 0 0.01% *
C8 Olfr1157 chr2 87802181 G>C 430 418 12 2.79%
D10 Nox4 chr7 94462586 C>T 567 567 0 0.01% *
F2 Matn4 chr2 164222680 C>T 1038 1009 29 2.79%
G8 Arhgap25 chr6 87426299 T>C 1120 1073 47 4.19%
G9 Pla2g4d chr2 120094626 G>T 782 755 27 3.45%
SUBCUT TUMORS AFTER CONTROL TREATMENT – DEEP-SEQ RUN 2
clone gene chrom position (mm9) variant
read 
depth
wildtype
reads
variant 
reads VAF
all Trp53 chr11 69402014 G>A 854 471 379 44.38%
all Kras chr6 145195291 C>T 760 502 258 33.95%
C5 Baiap3 chr17 25387359 G>T 948 948 0 0.01% *
C8 Olfr1157 chr2 87802181 G>C 829 806 23 2.77%
D10 Nox4 chr7 94462586 C>T 1060 1057 3 0.28%
F2 Matn4 chr2 164222680 C>T 1981 1782 196 9.89%
G8 Arhgap25 chr6 87426299 T>C 1236 1192 44 3.56%
G9 Pla2g4d chr2 120094626 G>T 943 890 52 5.51%
SUBCUT TUMORS AFTER CONTROL TREATMENT – DEEP-SEQ RUN 3
clone gene chrom position (mm9) variant
read 
depth
wildtype
reads
variant 
reads VAF
all Trp53 chr11 69402014 G>A 588 419 168 28.57%
all Kras chr6 145195291 C>T 953 658 294 30.85%
C5 Baiap3 chr17 25387359 G>T 1303 1300 2 0.15%
C8 Olfr1157 chr2 87802181 G>C 923 921 2 0.22%
D10 Nox4 chr7 94462586 C>T 1138 1135 1 0.09%
F2 Matn4 chr2 164222680 C>T 1120 1106 13 1.16%
G8 Arhgap25 chr6 87426299 T>C 1202 1145 57 4.74%
G9 Pla2g4d chr2 120094626 G>T 1196 1194 2 0.17%
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SUBCUT TUMORS AFTER CONTROL TREATMENT – DEEP-SEQ RUN 4
clone gene chrom position (mm9) variant
read 
depth
wildtype
reads
variant 
reads VAF
all Trp53 chr11 69402014 G>A 4074 1614 2431 59.67%
all Kras chr6 145195291 C>T 5669 4354 1314 23.18%
C5 Baiap3 chr17 25387359 G>T 5280 5256 20 0.38%
C8 Olfr1157 chr2 87802181 G>C 5823 5732 87 1.49%
D10 Nox4 chr7 94462586 C>T 5705 5691 13 0.23%
F2 Matn4 chr2 164222680 C>T 3889 3551 336 8.64%
G8 Arhgap25 chr6 87426299 T>C 6124 5833 284 4.64%
G9 Pla2g4d chr2 120094626 G>T 5286 4538 742 14.04%
SUBCUT TUMORS AFTER CONTROL TREATMENT – DEEP-SEQ RUN 5
clone gene chrom position (mm9) variant
read 
depth
wildtype
reads
variant 
reads VAF
all Trp53 chr11 69402014 G>A 2638 985 1635 61.98%
all Kras chr6 145195291 C>T 4076 2355 1721 42.22%
C5 Baiap3 chr17 25387359 G>T 4422 4411 11 0.25%
C8 Olfr1157 chr2 87802181 G>C 5481 5282 197 3.59%
D10 Nox4 chr7 94462586 C>T 4177 4172 5 0.12%
F2 Matn4 chr2 164222680 C>T 4668 4194 470 10.07%
G8 Arhgap25 chr6 87426299 T>C 5218 4891 326 6.25%
G9 Pla2g4d chr2 120094626 G>T 4372 4193 170 3.89%
SUBCUT TUMORS AFTER GEMCITABINE TREATMENT – DEEP-SEQ RUN 1
clone gene chrom position (mm9) variant
read 
depth
wildtype
reads
variant 
reads VAF
all Trp53 chr11 69402014 G>A 1142 487 645 56.48%
all Kras chr6 145195291 C>T 1329 844 485 36.49%
C5 Baiap3 chr17 25387359 G>T 1625 1613 12 0.74%
C8 Olfr1157 chr2 87802181 G>C 1241 1200 39 3.14%
D10 Nox4 chr7 94462586 C>T 1467 1451 16 1.09%
F2 Matn4 chr2 164222680 C>T 1644 1510 134 8.15%
G8 Arhgap25 chr6 87426299 T>C 1784 1740 44 2.47%
G9 Pla2g4d chr2 120094626 G>T 1453 1380 73 5.02%
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SUBCUT TUMORS AFTER GEMCITABINE TREATMENT – DEEP-SEQ RUN 2
clone gene chrom position (mm9) variant
read 
depth
wildtype
reads
variant 
reads VAF
all Trp53 chr11 69402014 G>A 1923 1159 751 39.05%
all Kras chr6 145195291 C>T 3141 2795 345 10.98%
C5 Baiap3 chr17 25387359 G>T 2539 2525 13 0.51%
C8 Olfr1157 chr2 87802181 G>C 3644 3601 39 1.07%
D10 Nox4 chr7 94462586 C>T 3444 3432 11 0.32%
F2 Matn4 chr2 164222680 C>T 3050 2895 154 5.05%
G8 Arhgap25 chr6 87426299 T>C 3536 3494 40 1.13%
G9 Pla2g4d chr2 120094626 G>T 2951 2796 152 5.15%
SUBCUT TUMORS AFTER TRAMETINIB TREATMENT – DEEP-SEQ RUN 1
clone gene chrom position (mm9) variant
read 
depth
wildtype
reads
variant 
reads VAF
all Trp53 chr11 69402014 G>A - - - -
all Kras chr6 145195291 C>T 1195 955 240 20.08%
C5 Baiap3 chr17 25387359 G>T 1883 1882 1 0.05%
C8 Olfr1157 chr2 87802181 G>C 884 880 4 0.45%
D10 Nox4 chr7 94462586 C>T 1105 1104 1 0.09%
F2 Matn4 chr2 164222680 C>T 1293 1259 34 2.63%
G8 Arhgap25 chr6 87426299 T>C 2013 1982 31 1.54%
G9 Pla2g4d chr2 120094626 G>T 1147 1037 110 9.59%
SUBCUT TUMORS AFTER TRAMETINIB TREATMENT – DEEP-SEQ RUN 2
clone gene chrom position (mm9) variant
read 
depth
wildtype
reads
variant 
reads VAF
all Trp53 chr11 69402014 G>A 2199 1361 833 37.88%
all Kras chr6 145195291 C>T 3242 2397 845 26.06%
C5 Baiap3 chr17 25387359 G>T 2275 2269 6 0.26%
C8 Olfr1157 chr2 87802181 G>C 3813 3795 16 0.42%
D10 Nox4 chr7 94462586 C>T 2563 2559 2 0.08%
F2 Matn4 chr2 164222680 C>T 2634 2494 137 5.20%
G8 Arhgap25 chr6 87426299 T>C 3467 3425 41 1.18%
G9 Pla2g4d chr2 120094626 G>T 3068 2647 417 13.59%
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SUBCUT TUMORS AFTER α-PD-1 TREATMENT – DEEP-SEQ RUN 1
clone gene chrom position (mm9) variant
read 
depth
wildtype
reads
variant 
reads VAF
all Trp53 chr11 69402014 G>A 497 428 69 13.88%
all Kras chr6 145195291 C>T 594 561 33 5.56%
C5 Baiap3 chr17 25387359 G>T 639 636 3 0.47%
C8 Olfr1157 chr2 87802181 G>C 455 455 0 0.01% *
D10 Nox4 chr7 94462586 C>T 682 678 4 0.59%
F2 Matn4 chr2 164222680 C>T 638 632 6 0.94%
G8 Arhgap25 chr6 87426299 T>C 754 740 13 1.72%
G9 Pla2g4d chr2 120094626 G>T 519 517 2 0.39%
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Supplementary Figure 1. Characterization of heterogeneous clonal cell lines from a KPC mouse pan-
creatic tumor (Related to Figure 1)
a, b. Images of H&E stained, formalin fi xed paraffi  n embedded (FFPE) primary KPC mouse pancreatic 
tumor (a) as well as liver and lung metastases (b). Scale bar = 100 μm.
c. Allele specifi c PCR products of Kras and Trp53 DNA from eleven clonal KPC PDAC cell lines that 
underwent Cre recombination. Lower bands indicate wildtype (wt) alleles; upper bands are the recom-
bined alleles containing the 34 basepair LoxP.
d. Images taken from the 2D monolayers of the individual clonal cell lines in vitro. Scale bar = 30 μm.
e. KrasG12D variant allele frequency (VAF) in six clonal cell lines. Droplet Digital PCR was performed 
using a HEX labeled probe for wildtype Kras and a FAM labeled probe for mutant KrasG12D. Data is pre-
sented as ratio of positive KrasG12D droplets over total Kras positive droplets is shown. Error bars are SEM 
of 2 replicate PCR reactions from 2 clonal cell DNA preparations.
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Supplementary Figure 2. Distinct clonal growth rates and drug sensitivity (Related to Figure 2)
a. Dose response curves of gemcitabine or trametinib after 72 hours. Drugs were added to the clonal 
PDAC cell lines one day after plating. Error bars are SEM from triplicate wells.
b, c. Dose-response of trametinib for clone G8 (b) and C8 (c) in the presence of conditioned media 
(c.m.) harvested from the clone mixture or from G8 or C8 only. A 1:1 ratio of c.m. and DMEM/10%FBS 
was used. Error bars are SEM of 2 replicate experiments, * p< 0.05 t-test for c.m. from the clone mix vs 
c.m. from G8.
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Supplementary Figure 3. Growth of clonal allograft tumors
a. Images of H&E stained FFPE pancreatic clonal allograft tumors. One million clonal cells were injected 
intraperitoneally into compatible immune competent mice and allowed to form tumors. Green dashed 
lines indicate the invasive cancer margins into healthy pancreas tissue. Green arrows indicate cancer. 
Scale bar =100 μm.
b. Images of H&E stained FFPE subcutaneous clonal allograft tumors. One million clonal cells were 
injected subcutaneously into the fl anks of compatible immune competent mice. Scale bar =100 μm.
c. Growth curves of the clonal subcutaneous allograft tumors.
d. Immunohistochemical staining for α-Smooth Muscle Actin protein in FFPE subcutaneous clonal al-
lograft tumors. Scale bar =100 μm.
e. Expression of α-Smooth Muscle Actin mRNA in subcutaneous clonal allograft tumors by qRT-PCR. 
The expression is normalized to beta-Actin. Note the log scale for the Y-axis. Error bars are SEM of 2 
replicate measurements in ≥2 tumors per clonal cell line.
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Supplementary Figure 4. Drug effects on growth of heterogeneous tumors.
a. Relative size of the subcutaneous clone mix allograft tumors. One million cells of the PDAC clone 
mixture were injected subcutaneously into the flanks of compatible immune competent mice. When tu-
mors had established, mice were treated for 2 weeks with either vehicle control, 4 injections of 250 μg rat 
anti-mouse-PD-1 mAb, 7 injections of 40 mg/kg gemcitabine, or daily oral gavage with 0.5 mg/kg trame-
tinib. The relative tumor size is shown per treatment group. Maximal growth inhibition was reached at 
day 5 for gemcitabine and trametinib. and at day 10 of α-PD-1. Error bars are SEM, ***p<0.0001; *p=0.032 
**p=0.0054; versus the respective control group.
b, c. Representative , H&E (b), or α-Smooth Muscle Actin stained (c) subcutaneous allograft tumors at 
the end of different treatments indicated. Scale bar =100 μm.
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Supplementary Figure 5. Gating strategy in the fl ow cytometry analysis of tumor infi ltrating lympho-
cytes. Tumor infi ltrating cells were gated on time, FCS-SSC and live cells. Hematopoietic cells were se-
lected by CD45 expression. Lymphocytes subsets were gated based on expression of: NK cells (NK1.1+), 
B cells (B220+), T cells (CD3+). CD4 T cells (CD3+CD4+) and CD8 T cells (CD3+CD8+) were further 
analyzed by surface expression of PD-1 and CD25.
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Supplementary Figure 6. Mouse ceacal patch derived T-lymphocytes
a. Images of mouse ceacal patches (equivalent to human vermiform appendix) stained with H&E. Ce-
acal patches from n=3 healthy immune competent mice and from n=3 KPC mice were either formalin 
fixed or frozen in O.C.T cryo embedding media, and sectioned. Green dashed lines encircle the germinal 
centers of the lymphoid tissues. Scale bar = 500 μm.
b. Areas of the germinal centers in the lymphoid tissue of the caecal patches from n=3 healthy mice and 
n=3 PDAC bearing KPC mice. * p=0.0316 by t-test.
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Supplementary Figure 6. Mouse ceacal patch derived T-lymphocytes
c. IFN-γ levels in the supernatant of T-lymphocytes isolated from ceacal patches of n=2 healthy mice, 
co-cultured with clonal PDAC cell lines, measured after 48 hours by ELISA. Note the log2 –scale for the 
Y-axis. Error bars are SEM of n=2 mice.
d. IFN-γ levels in the supernatant of primed appendix T-lymphocytes isolated from n=3 mice bearing 
mixed allograft PDAC tumors, co-cultured with the clonal PDAC cell lines in vitro, measured after 48 
hours by ELISA. Note the log2 scale for the y-axis.
68  Intratumoral heterogeneity and tumor-host crosstalk alter drug sensitivity
referenCes
 1. Vincent, A., Herman, J., Schulick, R. et al. (2011) Pancreatic cancer. Lancet 378, 607-620
 2. Oettle, H., Post, S., Neuhaus, P. et al. (2007) Adjuvant chemotherapy with gemcitabine vs observation 
in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. 
Jama 297, 267-277
 3. Bailey, P., Chang, D. K., Nones, K. et al. (2016) Genomic analyses identify molecular subtypes of 
pancreatic cancer. Nature 531, 47-52
 4. Witkiewicz, A. K., McMillan, E. A., Balaji, U. et al. (2015) Whole-exome sequencing of pancreatic 
cancer defines genetic diversity and therapeutic targets. Nat Commun 6, 6744
 5. Gilmartin, A. G., Bleam, M. R., Groy, A. et al. (2011) GSK1120212 (JTP-74057) is an inhibitor of 
MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway 
inhibition. Clin Cancer Res 17, 989-1000
 6. Infante, J. R., Somer, B. G., Park, J. O. et al. (2014) A randomised, double-blind, placebo-controlled 
trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with un-
treated metastatic adenocarcinoma of the pancreas. Eur J Cancer 50, 2072-2081
 7. Greten, F. R. (2014) YAP1 takes over when oncogenic K-Ras slumbers. Cell 158, 11-12
 8. Zhang, W., Nandakumar, N., Shi, Y. et al. (2014) Downstream of mutant KRAS, the transcription 
regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci Signal 
7, ra42
 9. Aparicio, S. & Caldas, C. (2013) The implications of clonal genome evolution for cancer medicine. N 
Engl J Med 368, 842-851
 10. Burrell, R. A., McGranahan, N., Bartek, J. et al. (2013) The causes and consequences of genetic 
heterogeneity in cancer evolution. Nature 501, 338-345
 11. Kim, M. S., Zhong, Y., Yachida, S. et al. (2014) Heterogeneity of pancreatic cancer metastases in a 
single patient revealed by quantitative proteomics. Mol Cell Proteomics 13, 2803-2811
 12. Bozic, I., Reiter, J. G., Allen, B. et al. (2013) Evolutionary dynamics of cancer in response to targeted 
combination therapy. Elife 2, e00747
 13. Saunders, N. A., Simpson, F., Thompson, E. W. et al. (2012) Role of intratumoural heterogeneity in 
cancer drug resistance: molecular and clinical perspectives. EMBO Mol Med 4, 675-684
 14. Bhang, H. E., Ruddy, D. A., Krishnamurthy Radhakrishna, V. et al. (2015) Studying clonal dynamics 
in response to cancer therapy using high-complexity barcoding. Nat Med 21, 440-448
 15. Jamal-Hanjani, M., Quezada, S. A., Larkin, J. et al. (2015) Translational implications of tumor hetero-
geneity. Clin Cancer Res 21, 1258-1266
 16. Kleppe, M. & Levine, R. L. (2014) Tumor heterogeneity confounds and illuminates: assessing the 
implications. Nat Med 20, 342-344
 17. Beckman, R. A., Schemmann, G. S. & Yeang, C. H. (2012) Impact of genetic dynamics and single-cell 
heterogeneity on development of nonstandard personalized medicine strategies for cancer. Proc Natl 
Acad Sci U S A 109, 14586-14591
 18. Neesse, A., Algul, H., Tuveson, D. A. et al. (2015) Stromal biology and therapy in pancreatic cancer: 
a changing paradigm. Gut 64, 1476-1484
 19. Ozdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L. et al. (2014) Depletion of carcinoma-associated 
fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced 
survival. Cancer Cell 25, 719-734
 20. Rhim, A. D., Oberstein, P. E., Thomas, D. H. et al. (2014) Stromal elements act to restrain, rather than 
support, pancreatic ductal adenocarcinoma. Cancer Cell 25, 735-747
Chapter 2 69
 21. Muerkoster, S., Wegehenkel, K., Arlt, A. et al. (2004) Tumor stroma interactions induce chemore-
sistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of 
nitric oxide and interleukin-1beta. Cancer Res 64, 1331-1337
 22. Binenbaum, Y., Na’ara, S. & Gil, Z. (2015) Gemcitabine resistance in pancreatic ductal adenocarci-
noma. Drug Resist Updat 23, 55-68
 23. Sainz, B., Jr., Alcala, S., Garcia, E. et al. (2015) Microenvironmental hCAP-18/LL-37 promotes pan-
creatic ductal adenocarcinoma by activating its cancer stem cell compartment. Gut 64, 1921-1935
 24. Nielsen, M. F., Mortensen, M. B. & Detlefsen, S. (2016) Key players in pancreatic cancer-stroma 
interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells. World J Gastroenterol 
22, 2678-2700
 25. Feig, C., Jones, J. O., Kraman, M. et al. (2013) Targeting CXCL12 from FAP-expressing carcinoma-
associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl 
Acad Sci U S A 110, 20212-20217
 26. Heppner, G. H. (1984) Tumor heterogeneity. Cancer Res 44, 2259-2265
 27. Heppner, G. H. (1991) Cell-to-cell interaction in regulating diversity of neoplasms. Semin Cancer 
Biol 2, 97-103
 28. Marusyk, A., Tabassum, D. P., Altrock, P. M. et al. (2014) Non-cell-autonomous driving of tumour 
growth supports sub-clonal heterogeneity. Nature 514, 54-58
 29. Miller, B. E., Miller, F. R. & Heppner, G. H. (1981) Interactions between tumor subpopulations affect-
ing their sensitivity to the antineoplastic agents cyclophosphamide and methotrexate. Cancer Res 41, 
4378-4381
 30. Zhao, B., Hemann, M. T. & Lauffenburger, D. A. (2014) Intratumor heterogeneity alters most effective 
drugs in designed combinations. Proc Natl Acad Sci U S A 111, 10773-10778
 31. Hingorani, S. R., Wang, L., Multani, A. S. et al. (2005) Trp53R172H and KrasG12D cooperate to 
promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. 
Cancer Cell 7, 469-483
 32. Li, H. & Durbin, R. (2009) Fast and accurate short read alignment with Burrows-Wheeler transform. 
Bioinformatics 25, 1754-1760
 33. McKenna, A., Hanna, M., Banks, E. et al. (2010) The Genome Analysis Toolkit: a MapReduce frame-
work for analyzing next-generation DNA sequencing data. Genome Res 20, 1297-1303
 34. Sharif, G. M., Schmidt, M. O., Yi, C. et al. (2015) Cell growth density modulates cancer cell vascular 
invasion via Hippo pathway activity and CXCR2 signaling. Oncogene 34, 5879-5889
 35. Maddipati, R. & Stanger, B. Z. (2015) Pancreatic Cancer Metastases Harbor Evidence of Polyclonality. 
Cancer Discov 5, 1086-1097
 36. Yip-Schneider, M. T., Lin, A., Barnard, D. et al. (1999) Lack of elevated MAP kinase (Erk) activity in 
pancreatic carcinomas despite oncogenic K-ras expression. Int J Oncol 15, 271-279
 37. Yeh, J. J., Routh, E. D., Rubinas, T. et al. (2009) KRAS/BRAF mutation status and ERK1/2 activation 
as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Mol Cancer Ther 8, 834-843
 38. Sakakura, C., Hagiwara, A., Shirahama, T. et al. (1999) Infrequent activation of mitogen-activated 
protein kinase in human colon cancers. Hepatogastroenterology 46, 2831-2834
 39. Drifka, C. R., Loeffler, A. G., Mathewson, K. et al. (2016) Highly aligned stromal collagen is a negative 
prognostic factor following pancreatic ductal adenocarcinoma resection. Oncotarget 7, 76197-76213
 40. Egeblad, M., Rasch, M. G. & Weaver, V. M. (2010) Dynamic interplay between the collagen scaffold 
and tumor evolution. Curr Opin Cell Biol 22, 697-706
 41. Whatcott, C. J., Diep, C. H., Jiang, P. et al. (2015) Desmoplasia in Primary Tumors and Metastatic 
Lesions of Pancreatic Cancer. Clin Cancer Res 21, 3561-3568
70  Intratumoral heterogeneity and tumor-host crosstalk alter drug sensitivity
 42. Campbell, P. J., Yachida, S., Mudie, L. J. et al. (2010) The patterns and dynamics of genomic instability 
in metastatic pancreatic cancer. Nature 467, 1109-1113
 43. Yachida, S., Jones, S., Bozic, I. et al. (2010) Distant metastasis occurs late during the genetic evolution 
of pancreatic cancer. Nature 467, 1114-1117
 44. Collisson, E. A., Trejo, C. L., Silva, J. M. et al. (2012) A central role for RAF-->MEK-->ERK signaling 
in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov 2, 685-693
 45. Galluzzi, L., Senovilla, L., Zitvogel, L. et al. (2012) The secret ally: immunostimulation by anticancer 
drugs. Nat Rev Drug Discov 11, 215-233
 46. Kidd, B. A., Wroblewska, A., Boland, M. R. et al. (2016) Mapping the effects of drugs on the immune 
system. Nat Biotechnol 34, 47-54
 47. Ott, P. A. & Adams, S. (2011) Small-molecule protein kinase inhibitors and their effects on the im-
mune system: implications for cancer treatment. Immunotherapy 3, 213-227
 48. Sideras, K., Braat, H., Kwekkeboom, J. et al. (2014) Role of the immune system in pancreatic cancer 
progression and immune modulating treatment strategies. Cancer Treat Rev 40, 513-522
 49. Clark, C. E., Hingorani, S. R., Mick, R. et al. (2007) Dynamics of the immune reaction to pancreatic 
cancer from inception to invasion. Cancer Res 67, 9518-9527
 50. Chikuma, S., Terawaki, S., Hayashi, T. et al. (2009) PD-1-mediated suppression of IL-2 production 
induces CD8+ T cell anergy in vivo. J Immunol 182, 6682-6689
 51. Shevach, E. M. (2001) Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med 193, 
F41-46
 52. Alkadhi, S., Kunde, D., Cheluvappa, R. et al. (2014) The murine appendiceal microbiome is altered in 
spontaneous colitis and its pathological progression. Gut Pathog 6, 25
 53. Watson Ng, W. S., Hampartzoumian, T., Lloyd, A. R. et al. (2007) A murine model of appendicitis and 
the impact of inflammation on appendiceal lymphocyte constituents. Clin Exp Immunol 150, 169-178
 54. Halle, S., Halle, O. & Forster, R. (2017) Mechanisms and Dynamics of T Cell-Mediated Cytotoxicity 
In Vivo. Trends Immunol 6,432-443
 55. Topalian, S. L., Taube, J. M., Anders, R. A. et al. (2016) Mechanism-driven biomarkers to guide im-
mune checkpoint blockade in cancer therapy. Nat Rev Cancer 16, 275-287
 56. Miller, B. E., Miller, F. R., Leith, J. et al. (1980) Growth interaction in vivo between tumor subpopula-
tions derived from a single mouse mammary tumor. Cancer Res 40, 3977-3981
 57. Roesch, A., Fukunaga-Kalabis, M., Schmidt, E. C. et al. (2010) A temporarily distinct subpopulation 
of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141, 583-594
 58. Cassidy, J. W., Caldas, C. & Bruna, A. (2015) Maintaining Tumor Heterogeneity in Patient-Derived 
Tumor Xenografts. Cancer Res 75, 2963-2968
 59. Nakasone, E. S., Askautrud, H. A., Kees, T. et al. (2012) Imaging tumor-stroma interactions during 
chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 21, 488-503
 60. Straussman, R., Morikawa, T., Shee, K. et al. (2012) Tumour micro-environment elicits innate resis-
tance to RAF inhibitors through HGF secretion. Nature 487, 500-504
 61. Majumder, B., Baraneedharan, U., Thiyagarajan, S. et al. (2015) Predicting clinical response to anti-
cancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun 6, 6169
 62. McMillin, D. W., Delmore, J., Weisberg, E. et al. (2010) Tumor cell-specific bioluminescence platform 
to identify stroma-induced changes to anticancer drug activity. Nat Med 16, 483-489
 63. Bartlett, R., Everett, W., Lim, S. et al. (2014) Personalized in vitro cancer modeling - fantasy or reality? 
Transl Oncol 7, 657-664
 64. Miller, F. R. & Heppner, G. H. (1979) Immunologic heterogeneity of tumor cell subpopulations from 
a single mouse mammary tumor. J Natl Cancer Inst 63, 1457-1463
Chapter 2 71
 65. Topalian, S. L., Hodi, F. S., Brahmer, J. R. et al. (2012) Safety, activity, and immune correlates of 
anti-PD-1 antibody in cancer. N Engl J Med 366, 2443-2454
 66. Borghaei, H., Paz-Ares, L., Horn, L. et al. (2015) Nivolumab versus Docetaxel in Advanced Nonsqua-
mous Non-Small-Cell Lung Cancer. N Engl J Med 373, 1627-1639
 67. Kreso, A., O’Brien, C. A., van Galen, P. et al. (2013) Variable clonal repopulation dynamics influence 
chemotherapy response in colorectal cancer. Science 339, 543-548
 68. Jiang, Y., Li, Y. & Zhu, B. (2015) T-cell exhaustion in the tumor microenvironment. Cell Death Dis 6, 
e1792

Chapter 3
Circulating cell-free DNA mutation 
patterns in early and late stage colon 
and pancreatic cancer
Eveline E. Vietsch1
Garrett T. Graham1
Justine N. McCutcheon1
Aamir Javaid1
Giuseppe Giaccone1
John L. Marshall1,2
Anton Wellstein1,2.
1 Department of Oncology, Georgetown University, Washington, DC, USA.
2 Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Lombardi Comprehensive Cancer 
Center, Georgetown University, Washington, DC, USA.
Cancer Genet. 2017 Dec;218-219:39-50.
74  Circulating DNA mutations in early and late stage colon and pancreatic cancer
AbsTrACT
Cancer is a heterogeneous disease harboring diverse subclonal populations that can be 
discriminated by their DNA mutations. Environmental pressure selects subclones that ul-
timately drive disease progression and tumor relapse. Circulating cell-free DNA (ccfDNA) 
can be used to approximate the mutational makeup of cancer lesions and can serve as a 
marker for monitoring disease progression at the molecular level without the need for 
invasively acquired samples from primary or metastatic lesions. This potential for molecu-
lar analysis makes ccfDNA attractive for the study of clonal evolution and for uncovering 
emerging therapeutic resistance or sensitivity. We assessed ccfDNA from colon and pan-
creatic adenocarcinoma patients using next generation sequencing of 56 cancer-associated 
genes at the time of primary resectable disease and metastatic progression and compared 
this to the mutational patterns of the primary tumor. 28%-47% of non-synonymous muta-
tions in the primary tumors were also detected in the ccfDNA while 71%-78% mutations 
found in ccfDNA were not detected in the primary tumors. ccfDNA collected at the time of 
progression harbored 3-5 new mutations not detected in ccfDNA at the earlier collection 
time points. We conclude that incorporation of ccfDNA analysis provides crucial insights 
into the changing molecular makeup of progressive colon and pancreatic cancer.
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InTroDuCTIon
Genomic mutations are one of the hallmarks of cancer [1]. The molecular characterization 
of a given cancer relies on the analysis of tissue specimen from a primary or metastatic 
lesion typically obtained at a single time point. However, due to intratumoral heterogeneity, 
the selection of cell subpopulations during cancer evolution and metastasis, the analysis of a 
single tissue specimen will provide only a limited characterization of the molecular makeup 
of the disease [2,3]. Monitoring the molecular characteristics of cancer by serial analyses 
of circulating cell-free DNA (ccfDNA) enables capture of emerging heterogeneity of the 
disease and may support treatment decisions [4,5]. CcfDNA analysis has evolved since its 
inception with improvements in the technologies and detection limits [6,7] and represents 
a set of research tools that appear poised to enter routine clinical care [8,9]. The recent FDA 
approval of a ccfDNA assay for the EGFR T790M mutation in lung cancer supports this no-
tion [10]. Whether ccfDNA should complement tissue analyses in all cancer types remains 
to be studied, especially in early stage diseases [9,11]. However, ccfDNA may be superior to 
tumor tissue DNA in the assessment of cancer heterogeneity and evolution during disease 
progression [12,13]. Here we study the mutational landscape of ccfDNA at diagnosis and 
disease recurrence and compare it to that of DNA from the primary tumor tissues in ten 
patients with colon and pancreatic cancer.
MATerIAls AnD MeTHoDs
Patient samples
Patients with newly diagnosed colon adenocarcinoma (colon AC) or pancreatic ductal 
adenocarcinoma (PDAC) were recruited for blood and tissue collection under the IRB pro-
tocol 2007-345 “Establishment of the High Quality Tumor Biobank and Clinical Database” 
and the Non-Therapeutic Subject Registry (NTSR) Shared Resource protocol Pr000000007 
at the Lombardi Comprehensive Cancer Center at Georgetown University after obtaining 
informed consent. Ten patients were retrospectively selected with the following inclusion 
criteria: initial diagnosis of treatment-naïve resectable primary adenocarcinoma (n=5 colon; 
n=5 pancreatic), surgical resection of the primary tumor, and development of progressive 
disease after surgery. None of the patients had a previous malignant disease. Peripheral 
venous blood samples were collected in EDTA plasma tubes before the surgical removal of 
the primary tumors as well as at time of metastatic disease progression (1-70 months after 
surgery). The blood samples were centrifuged at ≤1300 RCF for 10 min within 2 hours of 
blood collection, after which plasma was
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separated and stored at -80 °C until further analysis. Surgical specimens of the primary 
tumors were frozen in O.C.T and cryo-sectioned into 20 μm scrolls and examined by a 
pathologist for the presence of cancer cells.
DnA isolation
The plasma samples were thawed on ice and circulating cell-free circulating DNA (ccfDNA) 
was isolated from 2 x 100 μL plasma per patient, using the DNA extractor SP Kit (Wako 
cat. # 296-60501) following the manufacturer’s protocol. In brief, 200 μL Enzyme Reaction 
Solution and 5 μL Protein Digestion Solution was added to 100 μL plasma and mixed by 
vortexing. The samples were incubated at 56 °C for 10 min. Thereafter 300 μL of Sodium 
Iodide Solution and 600 μL Alcohol Solution were added and mixed by vortexing. After 
10 min incubation at room temperature, the samples were centrifuged at 16,000 x g for 10 
min at room temperature. The supernatant was discarded and ccfDNA pellets were washed 
with 1 mL Washing Solution A by vortexing. After 5 min centrifugation at 16,000 x g the 
supernatant was discarded. The ccfDNA pellets were washed with 1 mL Washing Solution B 
and centrifuged once more for 5 min. The supernatant was discarded again and DNA pellets 
were allowed to dry. The ccfDNA was diluted in 15 μL of ultra pure water and quantitated 
with the NanoDrop 2000c (Thermo Scientific) and the Promega Quantifluor ONE dsDNA 
Fluorescence Assay (Promega).
Two frozen tumor tissue scrolls of 20 μm thickness per patient with an average weight of 75 
μg and surface of 1.15 cm2 were used for genomic DNA isolation. DNA was isolated using 
the PrepEase Genomic DNA Isolation Kit (USB), following the manufacturer’s protocol. 
In brief, the tissue was homogenized in 240 μL Homogenization Buffer in MagNA Lyser 
Green Beads (Roche) in the MagNA Lyser (Roche). A mixture of 200 μL Chloroform/
Isoamyl Alcohol (24:1), as well as 800 μL Protein Precipitation Buffer were added to the 
lysates. Samples were mixed by vortexing and centrifuged at 13,000 x g for 4 min at room 
temperature. 880 μL of the upper aqueous phase of the sample was transferred to a new 
microcentrifuge tube containing 620 μL isopropanol. The samples were mixed by inverting 
the tubes and centrifuged at 13,000 x g for 4 min. The supernatant was discarded and DNA 
pellets were washed with 1 mL of 70% ethanol by vortexing. The samples were centrifuged 
for 2 min and DNA pellets were allowed to dry. The tumor DNA was diluted in 15 μL of 
ultra pure water and quantitated with the NanoDrop 2000c (Thermo Scientific) and the 
Promega Quantifluor ONE dsDNA Fluorescence Assay (Promega).
56G oncology Panel sequencing library preparation
DNA mutation analysis was conducted using a Targeted Next Generation Sequencing 
Library Preparation Kit that is compatible with circulating cell-free DNA and the Illumina 
MiSeq Platform: the 56G Oncology Panel v2 from Swift Biosciences (Cat. # AL-56248). This 
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panel contains 263 amplicons sized 92-184 bp that covers hotspots, exonic SNPs and con-
tiguous regions of 56 human genes. The list of genes and number of amplicons is provided 
in Table 1. The kit contains a DNA standard with a set of 11 defined allelic frequencies for 
major oncology targets to be used as a sequencing control and DNA from HCT116, RKO 
and SW48 colon cancer cell lines. The 56G Oncology library was prepared according to the 
manufacturer’s protocol. In brief, 10 ng DNA per sample was used for the Multiplex PCR 
Step using the Reaction Mix, and the following Thermocycler Program: 30 sec at 98 ºC, 4 
cycles of 10 sec at 98 ºC, 5 min at 63 ºC, 1 min at 65 ºC, followed by 21 cycles of 10 sec at 
98 ºC, 1 min at 64 ºC, followed by 1 min at 65 ºC and hold at 4 ºC. The resulting amplicons 
were purified using SPRIselect beads (Beckman Coulter, Cat. #B23318) and a DynaMag 
magnetic rack (Invitrogen). Next, a unique combination of Index D50X + Index D7XX was 
added to each sample bead pellet, together with the Indexing Reaction Mix (Swift Biosci-
ences). The samples were incubated at 37 ºC for 20 min with the lid heating turned off. The 
libraries were purified once more with SPRIselect beads and quantitated in triplicates by 
qRT-PCR in a 20 μL reaction using the iQ SYBR Green Supermix (BioRad), containing 10 
μL of SYBR Green mix, 10 μL of diluted library (1:1000), and 500 nM of the following prim-
ers: 5’ AATGATACGGCGACCACCGAGAT 3’; and 5’ CAAGCAGAAGACGGCATACGA 
3’. Serial dilutions of the PhiX Sequencing Control v3, (Illumina Cat. # FC- 110-3001) was 
used as standard. After quantitation, the libraries were normalized to a concentration of 2 
nM and pooled together.
Miseq loading
The library pool was sequenced using the MiSeq v2 300 cycle Reagent Kit (Illumina). Five 
μL of the pooled amplicon library was denatured with 5 μL 0.2N NAOH for 5 min at room 
temperature. The library pool was then diluted to 8 pM with chilled HT1 buffer and 10% 
PhiX v3 control (Illumina) was spiked into the diluted library pool. Six hundred μL of the 
diluted pooled library with PhiX spike-in was loaded into the MiSeq reagent cartridge.
sequencing data analysis
Adapter trimming was conducted per Swift Biosciences recommendation, using cut-
adapt[14]. Paired-end FASTQ samples were aligned to GRCh38 with BWA-MEM. Sorting 
and indexing was done using samtools. Base quality score recalibration followed by local re-
alignment was done using the GATK Java package in conjunction with dbSNP annotation 
(b149) [15]. Variant calling was conducted using the LoFreqV2 (LoFreq*) mutation caller 
[16]. Visualizations were created in R using custom scripts (available on request) employing 
Bioconductor package VariantAnnotation [17]. as well as the plotting framework ggplot2 
and further adapted in Excel 2010 and Illustrator CS3 (Adobe). After mutations were called, 
percent representation was established as (number of variant reads)/(number of reference 
reads + number of variant reads). Variants leading to amino acid changes, with a minimum 
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read count of 5 reads and a frequency above 1% in at least one of the DNA samples are 
shown. The variant frequencies of the expected mutations that were detected in the DNA 
standard are shown in the Supplementary Figure 1. Three variants detected in amplicons 
from patient samples and the DNA standard were discarded as false positives (FGFR1 
D166del; MSH6 F1088frameshift and TP53 P72R).
Table 1. Genes included in the analysis. The amplicon panel is from Swift Biosciences ‘Accel-Amplicon 
56G Oncology Panel v2’. The number of amplicons (#) for each gene is shown.
Gene name # amplicons Gene name # amplicons
ABL1 5 IDH2 2
AKT1 2 JAK2 2 
ALK 2 JAK3 3 
APC 9 KDR 9 
ATM 19 KIT 14 
BRAF 2 KRAS 3 
CDH1 3 MAP2K1 5 
CDKN2A 2 MET 6 
CSF1R 2 MLH1 1 
CTNNB1 1 MPL 1 
DDR2 1 MSH6 4 
DNMT3A 1 NOTCH1 3 
EGFR (HER1) 9 NPM1 1 
ERBB2 (HER2) 4 NRAS 3 
ERBB4 (HER4) 8 PDGFRA 4 
EZH2 1 PIK3CA 11 
FBXW7 6 PTEN 14 
FGFR1 2 PTPN11 2 
FGFR2 4 RB1 12 
FGFR3 6 RET 6 
FLT3 4 STK11 5 
FOXL2 1 SMAD4 10 
GNA11 2 SMARCB1 4 
GNAQ 2 SMO 5 
GNAS 2 SRC 1 
HNF1A 4 TP53 (P53) 21 
HRAS 2 TSC1 1 
IDH1 1 VHL 3 
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resulTs
Patient characteristics and analysis approach
Patients with treatment-naïve adenocarcinomas of the colon (n=5) or the pancreas (n=5) 
that were considered resectable at the time of initial diagnosis were included in this study 
(Table 2). Plasma samples were collected before surgical removal of the primary tumors 
and at the time of disease progression. Resected tumor tissues were cryo-sectioned and 
evaluated by a pathologist to assess cancer cell and stroma abundance. After surgery, pa-
tients received different adjuvant therapies that are listed in Table 2. To assess the mutation 
patterns in early and late stage colon and pancreatic cancer we compared plasma DNA at the 
time of initial diagnosis to that of the primary tumor, as well as to the plasma DNA at the 
time of metastatic disease (Figure 1). For DNA mutation analysis, we sequenced 30 DNA 
samples from 10 patients in a single, next generation deep-sequencing run of 263 mutation 
hotspots in a set of 56 cancer-related genes. The same platform was used for the analysis of 
tissue and circulating cell-free DNA (ccfDNA) to avoid discrepancies in mutation findings 
due to variability in sequencing methods or reagents.
DnA mutations detected
Next generation deep-sequencing of amplicons showed a median depth of 754,000 reads 
per sample. In all pre-surgery plasma samples genomic alterations with a 1% frequency 
were detected, despite a relatively low read coverage in one of the ccfDNA samples (patient 
9 pre-surgery). One out of 10 late stage plasma samples (ccfDNA patient 4 at metastasis) did 
not contain genomic alterations above 1% frequency due to hemolysis and wildtype cellular 
DNA contamination that diluted the ccfDNA mutations. We focused on non-synonymous 
DNA alterations with a variant frequency of at least 1% in one of the samples per patient. 
In the 56 genes assessed we found an average of 10 mutations (range 4-15) in 17 genes in 
the ccfDNA of five colon cancer patients before surgery (Figure 2). The ccfDNA of the five 
patients with resectable PDAC contained fewer mutations, i.e. an average of 8 (range 5-12) 
mutations in 14 of the 56 genes assessed.
Surprisingly, the number of mutations detected in the primary tumors was much lower than 
that in the plasma: In the colon cancer tissues an average of 3 mutations (range 1-4) were 
found in 7 genes (APC, BRAF, CDKN2A, KIT, KRAS, PTEN, TP53; Figure 3). In the pancre-
atic cancer tissues 4 mutations (range 3-6) were found in 7 genes (CDNKN2A, JAK3, KDR, 
KIT, KRAS, SMAD4, TP53; Figure 3). Although our analysis detected mutations in only 7 
genes, it is striking that each patient still had a unique combination of genomic alterations.
At the time of disease progression, the ccfDNA of five patients with metastasized colon can-
cer contains an average of 7 mutations (range 2-11) in 16 genes. The plasma of the patients 
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with metastatic PDAC contained an average of 9 mutations (range 3-12) in 20 genes (Figure 
4). Th is number is close to the number of ccfDNA mutations before surgery. However, some 
of the ccfDNA mutations detected at the time of primary disease were lost at the time of 
metastatic disease, i.e. ABL1, ATM, DNMT3A, FLT3, HNF1A, NRAS and SMAD4. Possible 
explanations are that these mutations occurred in cancer cell subpopulations in the primary 
cancers that were resected, or that the clones carrying the mutations were selected against 
during disease progression.
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Figure 1. Overview of the study. Ten patients were included in the analysis of circulating cell-free DNA 
(ccfDNA) at diagnosis of primary cancer and at the time of progressive disease. DNA from frozen pri-
mary tumors that were collected during surgery was for comparison. All 30 DNA samples were subjected 
to next generation sequencing (NGS) of 56 genes with cancer-associated mutations.
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Figure 2. Circulating cell-free DNA mutation frequency before surgery. Non-synonymous mutations at 
≥1% variant frequency in at least one of the ccfDNA samples. * = premature stop codon; fs=frameshift; 
del=deletion; ¯ = low coverage.
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Comparison of mutations in primary tumors and the circulation at early and 
late stage disease
We evaluated the concordance between DNA mutations in the primary tumors and the 
circulation. For each patient, the mutations above a 1% variant frequency threshold in at 
least one of the DNA samples are shown in Fig. 5. First we compared the similarity between 
primary tumor DNA and ccfDNA before surgery (Table 3). In the patients with colon can-
cer about half (47%) of tumor tissue mutations are also detected in the circulation though 
there is a wide variation between patients. In patients with primary PDAC this concordance 
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Figure 3. DNA mutation frequency in primary tumors. Non-synonymous mutations at ≥1% variant 
frequency in at least one of the primary tumors. * = premature stop codon; fs=frameshift; del=deletion.
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is below one third (28%). On the other hand, it is notable that cancer heterogeneity within 
each patient was much more evident in the mutational landscape of the ccfDNA than in 
tumor tissue DNA. The majority of mutations in the ccfDNA were not detected in the pri-
mary tumor tissues: 71% in colon cancer and 78% of the mutations in PDAC (Table 3). This 
finding illustrates that a tissue section of a given tumor can fail to represent the molecular 
makeup of the entire cancer.
For the current study we had selected a set of patients that developed metastatic disease after 
removal of the primary tumors. We evaluated the genomic evolution during this progres-
sion by comparing the ccfDNA at the time of surgery and metastasis. Table 4 summarizes 
the differences in the ccfDNA mutational landscape at the time of primary and metastatic 
cancer. In five patients with metastatic colon cancer, 34% of the ccfDNA mutations were 
not detected in the circulation at the time of primary disease. These emerging mutations 
indicate clonal evolution of the disease during malignant progression. In PDAC, the pro-
portion of these metastasis-associated ccfDNA mutations is higher; 63% of the mutations 
were not detected during primary disease. Interestingly, the fraction of new mutations at the 
time of metastatic disease is not correlated with the length of time to progression, (Table 4) 
or the type of adjuvant therapy (Table 2). Although this is a small number of patients, it is 
noteworthy that approximately half of ccfDNA mutations detected at the time of primary 
disease were not detected after progression to metastatic disease (45% in colon AC, 59% in 
Table 3. Concordance and discordance between the number of mutations detected in plasma and pri-
mary tumor DNA at the time of initial diagnosis.
Primary tumor versus plasma at the time of diagnosis
Patient Disease
Tumor tissue DNA 
mutations detected in 
plasma samples
Plasma DNA mutations not 
detected in tumor tissues
Cancer cells 
in tumor
1 colon AC 60% (3/5) 79% (11/14) 50%
2 colon AC 0% (0/5) 100% (5/5) 70%
3 colon AC 0% (0/1) 100% (13/13) 90%
4 colon AC 75% (3/4) 77% (10/13) 70%
5 colon AC 100% (3/3) 0% (0/3) 90%
average 47% 71.2% 74%
6 PDAC 25% (1/4) 92% (11/12) 30%
7 PDAC 33% (1/3) 89% (8/9) 40%
8 PDAC 33% (1/3) 86% (6/7) 50%
9 ˉ PDAC 0% (0/3) ˉ 100% (8/8) 50%
10 PDAC 50% (3/6) 25% (1/4) 40%
average 28.2% 78.4% 42%
AC= adenocarcinoma; PDAC= pancreatic ductal adenocarcinoma; ˉ = low sequencing coverage in plas-
ma DNA
86  Circulating DNA mutations in early and late stage colon and pancreatic cancer
P
at
ie
nt
 1
P
at
ie
nt
 2
P
at
ie
nt
 3
P
at
ie
nt
 4
P
at
ie
nt
 5
P
at
ie
nt
 6
P
at
ie
nt
 7
P
at
ie
nt
 8
P
at
ie
nt
 9
P
at
ie
nt
 1
0
ABL1 F401Lfs*3 1.54 0.29 2
APC E1309Dfs*4 15.76 1
APC P1458H 3.17 2.55 2
ATM M349K 7.58 1
BRAF T458Qfs*25 1.21 1
BRAF V600E 2.56 1
CDKN2A E119K 1.10 1
CDKN2A E69G 4.42 1
CDKN2A G136Afs*10 1.67 0.63 0.94 0.64 0.54 5
CDKN2A W110* 1.12 1
CTNNB1 L46R 1.85 1
DNMT3A R882H 1.14 1
ERBB4 C326F 3.94 10.37 4.06 3
FLT3 A813P 3.82 1
FLT3 V825M 2.14 1
HNF1A E230K 1.30 1
JAK3 V722I 58.39 1
KDR C482R 52.32 1
KDR Q472H 52.71 1
KDR V297I 48.95 47.06 2
KIT M535I 2.77 1
KIT M541L 30.33 43.09 52.32 3
KIT M724Rfs*19 1.16 1
KRAS G12V 16.60 1
MAP2K1 R47* 6.48 9.09 7.61 12.45 4
MET N375S 5.66 1
MET Q155H 5.85 9.95 2.58 5.87 12.73 5
NOTCH1 V1578del 0.58 1.12 0.43 3
NRAS G12D 1.05 1
NRAS M72I 1.43 1
PIK3CA I391M 3.67 1
PTEN E73K 1.13 1
PTEN R84K 1.04 1
PTEN X85_splice 19.10 24.68 6.32 6.21 1.12 15.09 6
PTEN Y240Tfs*16 1.33 1
SMAD4 P225A 4.57 1
TP53 G293E 1.41 1
TP53 I251M 8.59 1
TP53 M340Cfs*5 18.43 1
TP53 S362Afs*8 1.27 0.12 0.35 3
TP53 T211I 2.48 1
TP53 Y163C 24.07 1
VHL A149P 2.43 11.16 3.25 5.21 5.13 5
VHL R107L 3.26 5.25 2
11 11 5 2 ^ 4 9 6 6 12 10
^ erythrocyte hemolysis: wildtype DNA contamination variant frequency
0 100
Colon carcinoma Pancreatic carcinoma
number of mutations
Plasma ccfDNA                  
at time of metastasis
Figure 4. Circulating cell-free DNA mutation frequency at the time of metastasis. Non-synonymous 
mutations at ≥1% variant frequency in at least one of the ccfDNA samples. * = premature stop codon; 
fs=frameshift; del=deletion; ^ = hemolysis, increase of wildtype DNA.
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PDAC, Table 4). This would indicate that cancer cell subpopulations carrying these muta-
tions were likely dominant in the primary tumor that was removed surgically. Also, these 
subpopulations did not play a significant role in the metastatic lesions.
In conclusion, we found that ccfDNA analysis complements the molecular insight into the 
genetic make-up of colon and pancreatic cancer and can be particularly helpful in monitor-
ing molecular changes over time.
DIsCussIon
The majority of molecular profiling of human tumors has relied on the analysis of aliquots 
of cancer tissues obtained from surgical resection specimen. Biopsies of cancerous lesions at 
disease progression are used rarely due to obvious disadvantages: They are potentially risky 
invasive procedures, time consuming and expensive. Also, cancer cells in tissue biopsies 
may be sparse due to the limited size of tissue recovered and against the background of 
wildtype stromal cells. Most importantly, subpopulations of a heterogeneous tumor may be 
poorly represented in biopsies. In the current study we sought to assess the changes in the 
mutational makeup of colon and pancreatic adenocarcinoma between the time of primary 
tumor surgery and detection of metastatic disease using ccfDNA. In this study we provide 
a direct comparison of mutation detection in primary tumor DNA and plasma ccfDNA 
Table 4. Concordance between the number of mutations detected in plasma at the time of initial
diagnosis and detection of metastasis.
ccfDNA mutations at the time of primary versus metastatic disease
Patient Disease Gain of mutations after metastasis
Loss of mutations after 
metastasis
Time to metastasis 
[months]
1 colon AC 40% (4/10) 38% (5/14) 70
2 colon AC 64% (7/11) 20% (1/5) 20
3 colon AC 40% (2/5) 77% (10/13) 12
4 ^ colon AC 0% (0/1) 92% (12/13) 5
5 colon AC 25% (1/4) 0% (0/3) 1
average 33.8% 45.4% 21.6
6 PDAC 38% (3/8) 58% (7/12) 16
7 PDAC 67% (2/3) 89% (8/9) 9
8 PDAC 80% (4/5) 86% (6/7) 18
9 PDAC 58% (7/12) 38% (3/8) 15
10 PDAC 70% (7/10) 25% (1/4) 7
average 62.6% 59.2% 13
AC, adenocarcinoma; PDAC, pancreatic ductal adenocarcinoma; ^, hemolysis and wildtype cellular 
DNA contamination
88  Circulating DNA mutations in early and late stage colon and pancreatic cancer
pr
e 
su
rg
er
y 
cc
fD
N
A
pr
im
ar
y 
tu
m
or
 D
N
A
m
et
as
ta
si
s 
cc
fD
N
A
APC E1560V 5.74 1
APC K1308* 1.84 1
APC P1458H 3.17 1
APC R1435* 23.68 1
ATM M349K 7.58 1
BRAF V600E 1.91 2.56 2
CDKN2A G136Afs*10 1.27 0.88 2
EGFR V96A 7.38 1
ERBB4 C326F 5.37 3.94 2
ERBB4 M953K 3.22 1
KRAS G12V 48.00 1
MAP2K1 R47* 6.39 6.48 2
MET N375S 5.66 1
MET Q155H 7.38 5.85 2
NOTCH1 V1578del 1.69 0.58 1
PIK3CA I391M 3.67 1
SMO M525V 1.52 1
TP53 Q144del 1.10 46.93 2
VHL A149P 8.72 2.43 2
VHL R107L 3.80 3.26 2
14 5 10
Patient 1                                          
Colon Carcinoma
number of mutations
pr
e 
su
rg
er
y 
cc
fD
N
A
pr
im
ar
y 
tu
m
or
 D
N
A
m
et
as
ta
si
s 
cc
fD
N
A
ABL1 F401Lfs*3 1.54 1
APC Q1291* 25.79 1
BRAF V600E 6.23 2
CDKN2A G136Afs*10 0.73 1.67 2
CDKN2A L65P 34.60 1
CTNNB1 L46R 1.85 1
ERBB4 C326F 3.96 10.37 2
KIT M535I 2.77 1
KRAS G13D 38.38 1
MAP2K1 R47* 9.09 1
MET Q155H 3.25 9.95 2
PTEN X85_splice 3.16 24.68 2
TP53 I251M 8.59 1
TP53 S362Afs*8 1.27 1
TP53 V73Rfs*76 22.52 1
VHL A149P 7.02 11.16 2
5 5 11
Patient 2                                                
Colon Carcinoma
number of mutations
pr
e 
su
rg
er
y 
cc
fD
N
A
pr
im
ar
y 
tu
m
or
 D
N
A
m
et
as
ta
si
s 
cc
fD
N
A
APC P1458H 12.06 1
BRAF S467P 1.20 1
BRAF V600E 3.39 1
ERBB2 C315R 1.50 1
ERBB4 C326F 7.26 1
FLT3 V825M 2.14 1
HNF1A E230K 1.30 1
MAP2K1 R47* 9.62 1
MET Q155H 10.13 2.58 2
PTEN X85_splice 41.14 6.32 2
TP53 I251M 9.63 1
TP53 N268Tfs*77 2.93 1
TP53 S9N 2.29 1
TP53 V216G 45.16 1
TP53 X331_splice 1.97 1
VHL A149P 9.45 3.25 2
13 1 5
Patient 3                                        
Colon Carcinoma
number of mutations
pr
e 
su
rg
er
y 
cc
fD
N
A
pr
im
ar
y 
tu
m
or
 D
N
A
m
et
as
ta
si
s 
cc
fD
N
A
BRAF V600E 8.28 32.61 2
EZH2 X649_splice 1.28 1
KIT Y568C 1.52 1
MET Q155H 1.41 1
PIK3CA L94P 1.64 0.73 0.67 3
PTEN F90Lfs*9 17.70 1
PTEN L112P 1.49 1
PTEN N323Mfs*21 5.81 19.80 2
PTEN X85_splice 1.98 1
TP53 D281G 2.04 1
TP53 P152Rfs*18 4.76 1
TP53 R273C 5.87 1
TP53 X331_splice 1.43 1
TP53 Y234H 1.29 1
13 4 1 ^
^ erythrocyte hemolysis: wildtype DNA contamination
Patient 4                     
Colon Carcinoma
number of mutations
pr
e 
su
rg
er
y 
cc
fD
N
A
pr
im
ar
y 
tu
m
or
 D
N
A
m
et
as
ta
si
s 
cc
fD
N
A
KIT M541L 46.66 16.48 30.33 3
KIT M724Rfs*19 1.163 1
NOTCH1 V1578del 0.611 0.276 1.119 3
TP53 Y163C 3.236 53.24 24.07 3
3 3 4
Patient 5                                                     
Colon Carcinoma
number of mutations
pr
e 
su
rg
er
y 
cc
fD
N
A
pr
im
ar
y 
tu
m
or
 D
N
A
m
et
as
ta
si
s 
cc
fD
N
A
APC E1560V 5.54 1
APC P1458H 15.83 2.55 2
BRAF T458Qfs*25 1.21 1
BRAF V600E 2.55 1
ERBB4 C326F 12.73 1
GNA11 R166H 4.64 1
KRAS G12R 22.30 1
MAP2K1 R47* 20.18 7.61 2
MET Q155H 16.21 5.87 2
PTEN E73K 1.13 1
PTEN R84K 1.04 1
PTEN X85_splice 14.07 6.21 2
SMAD4 Q256* 4.89 1
SMARCB1 P383Rfs*100 1.90 0.18 2
TP53 C135Y 14.63 1
TP53 I251M 14.24 1
VHL A149P 18.97 5.21 2
VHL p.R107L 7.74 1
12 4 8
Patient 6                                        
Pancreatic Carcinoma
number of mutations
pr
e 
su
rg
er
y 
cc
fD
N
A
pr
im
ar
y 
tu
m
or
 D
N
A
m
et
as
ta
si
s 
cc
fD
N
A
APC P1458H 6.35 1
BRAF K473* 1.49 1
BRAF S465P 1.14 1
CDKN2A E69G 4.42 1
KDR V297I 42.00 49.81 48.95 3
KRAS G12D 20.44 0.47 2
MAP2K1 R47* 12.56 1
MET Q155H 7.85 1
PTEN X85_splice 12.20 1
TP53 I251M 7.63 1
TP53 R248W 30.84 1
VHL A149P 6.86 1
9 3 3number of mutations
Patient 7                              
Pancreatic Carcinoma
pr
e 
su
rg
er
y 
cc
fD
N
A
pr
im
ar
y 
tu
m
or
 D
N
A
m
et
as
ta
si
s 
cc
fD
N
A
APC E1309Dfs*4 15.76 1
ERBB4 C326F 8.28 1
KDR Q472H 61.00 48.97 2
KIT M541L 43.09 1
KRAS G12R 23.13 1
MAP2K1 R47* 7.61 1
MET Q155H 5.97 1
PIK3CA E545A 1.02 1
PTEN X85_splice 7.84 1.12 2
TP53 L206Wfs*41 1.13 1
TP53 M340Cfs*5 18.43 1
TP53 S106R 16.22 1
VHL A149P 7.59 1
7 3 5number of mutations
Patient 8                               
Pancreatic Carcinoma
pr
e 
su
rg
er
y 
cc
fD
N
A
pr
im
ar
y 
tu
m
or
 D
N
A
m
et
as
ta
si
s 
cc
fD
N
A
APC P1458H 28.13 1
ERBB4 C326F 22.83 4.06 2
FLT3 A813P 3.82 1
JAK3 V722I 45.70 58.39 2
KDR V297I 48.18 47.06 2
KRAS G12R 8.21 1
MAP2K1 R47* 12.45 1
MET Q155H 93.84 12.73 2
PTEN X85_splice 40.75 12.54 2
PTEN Y240Tfs*16 1.33 1
SMAD4 P225A 4.57 1
TP53 G293E 1.41 1
TP53 I251M 20.29 1
TP53 R175G 100.00 1
VHL A149P 100.00 5.13 2
VHL R107L 82.45 5.25 2
8 ¯ 3 12
¯ =  low coverage
Patient 9                          
Pancreatic Carcinoma
number of mutations
pr
e 
su
rg
er
y 
cc
fD
N
A
pr
im
ar
y 
tu
m
or
 D
N
A
m
et
as
ta
si
s 
cc
fD
N
A
CDKN2A E119K 1.10 1
CDKN2A G101Afs*17 5.25 1
CDKN2A W110* 1.12 1
DNMT3A R882H 1.14 1
KDR C482R 52.25 52.60 52.32 3
KDR Q472H 52.32 52.45 52.71 3
KIT M541L 53.84 51.82 52.32 3
KRAS G12V 20.63 16.60 2
NRAS G12D 1.05 1
NRAS M72I 1.43 1
PIK3CA L94P 1.18 1
TP53 T211I 16.78 2.48 2
4 6 10number of mutations
Patient 10                               
Pancreatic Carcinoma
Figure 5. Mutation frequency in ccfDNA and tumors. The results from individual patients are shown 
(n=10). Non-synonymous mutations with ≥1% variant frequency in at least one of the ccfDNA samples. 
* = premature stop codon; fs=frameshift; del=deletion; ^ = hemolysis; ¯ = low coverage.
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Figure 5. Mutation frequency in ccfDNA and tumors. The results from individual patients are shown 
(n=10). Non-synonymous mutations with ≥1% variant frequency in at least one of the ccfDNA samples. 
* = premature stop codon; fs=frameshift; del=deletion; ^ = hemolysis; ¯ = low coverage.
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at diagnosis and at disease recurrence. For this, amplicons covering 263 mutations in 56 
cancer-associated genes were analyzed by deep-sequencing.
It is thought that ccfDNA can provide a better representation of the molecular makeup 
of a malignant disease than a single section from a surgical tumor specimen or a tissue 
biopsy. Also, blood samples can be drawn at deliberate intervals because they only require 
a minimally invasive procedure. In the present study the notion of a broader molecular 
representation is supported by the fact that the ccfDNA revealed approximately twice as 
many mutations as tumor tissue DNA. Very likely the tissue sections analyzed missed por-
tions of the primary tumor that carried subpopulations with these additional mutations. It 
is also conceivable that patients had already developed occult metastatic disease at the time 
of the initial diagnosis and the additional ccfDNA mutations found represented the cancer 
cell subpopulations in the metastatic lesions. It appears that the ccfDNA provides a more 
complex picture of the disease.
Most studies focus on the presence of ccfDNA mutations in one or two genes to compare 
their presence to clinical outcome [18,19]. In our study, we sought to assess the mutation 
patterns in a broad set of genes to highlight tumor heterogeneity and demonstrate clonal 
evolution over the course of disease progression. In colon cancer, for example, ccfDNA has 
been used to track clonal evolution during treatment with the epidermal growth factor re-
ceptor (EGFR)-specific antibodies. Alterations in KRAS, NRAS, MET, ERBB2, FLT3, EGFR 
and MAP2K1 were detected in ccfDNA of patients with primary or acquired resistance to 
EGFR blockade [20]. Using a broad panel of cancer-associated genes rather than frequently 
altered candidate oncogenes such as KRAS overcame one of the potential pitfalls encoun-
tered. None of the KRAS mutations from the seven patients with KRAS mutant primary 
tumors were detected in the ccfDNA at the time of diagnosis, while mutations in other 
genes were detected. Mutant KRAS ccfDNA was, however, found by others in 10 of 34 pan-
creatic patients (29%) [21] or in 136 of 188 (72.3%) of patients with metastatic PDAC [22]. 
Another study showed that mutant KRAS ccfDNA was detected in 14.8%, 45.5%, 30.8%, and 
57.9% of age-matched controls, localized, locally advanced, and metastatic PDAC patients, 
respectively [19]. In circulating exosomal DNA the percentages of mutant KRAS in these 
groups were even higher, i.e. 7.4%, 66.7%, 80%, and 85% respectively [19].
At the time of surgical removal of the primary tumors between 28% and 47% of tumor 
mutations were also detected in ccfDNA. Others have found that in formalin-fixed paraffin-
embedded cancer tissues and plasma from patients with different types of cancer an overall 
concordance of 60% in mutations of 19 genes analyzed [23]. Thus, the concordance found 
here is relatively low. In contrast, over 70% of mutations detected in ccfDNA were not found 
in the tumor samples. This could be due to metastatic disease at the time of diagnosis or 
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poor representation of the primary tumor composition by the histological section obtained 
for the DNA analysis.
Shed DNA in the circulation is fragmented into relatively short size fragments with tumor-
derived DNA exhibiting even higher fragmentation than normal cellular DNA [24]. This 
was also found for specific examples such as the BRAF V600E mutant allele with a fragment 
size <145 base pairs. Indeed detection of EGFR T790M mutant DNA in the circulation of 
cancer patients was improved by selecting for shorter DNA fragment lengths [25]. Com-
parisons of tumor tissue somatic DNA and ccfDNA mutation rate can be impacted by the 
application of different sequencing technologies and amplicon sizes [26,27] as well as read 
depths and these technical issues may bias the data interpretation [21]. To avoid this pitfall 
we used a platform that is adapted to the detection of short DNA fragments found as circu-
lating cell-free DNA. Thus, we sought to avoid differences in amplicon generation, library 
preparation or sequencing depth and all samples were subjected to the same amplicon and 
library generation protocol and analyzed in parallel.
We also compared the clonal evolution of cancer in the ccfDNA mutations over the course 
of disease progression. After metastasis, new ccfDNA mutations are gained both in colon 
(33.8%) and pancreatic cancer (62.6%) and were not detected at the time of diagnosis of the 
primary cancer. This indicates clonal selection due to treatment, malignant progression or 
metastatic spread to different tissues with different microenvironmental selection pressure. 
Complementary to the gain of mutations after metastasis, we also observed a loss of ap-
proximately half of the ccfDNA mutations. This loss of cancer subpopulations will be due to 
surgical removal of the primary tumor as well as patient treatment.
One final caveat in ccfDNA mutation analysis is the assignment of mutant DNA to cancer 
lesions under study rather than spontaneous mutations that occurred in other tissues and 
have no disease relevance. Recently reported analysis of mutation accumulation in human 
adult stem cells in different tissues showed that on average 40 new mutations arise per year 
during the life time of an individual [28]. In a study focused on the analysis of human skin, 
biopsies of physiologically normal skin showed 2 to 6 mutations per million bases per cell 
and matched to a large extent with cancer-associated mutations [29]. Notably, the frequency 
of mutations seen in normal skin is within the median range of 1 - 10 somatic mutations 
observed for human cancers [1]. We did not find detailed reports on ccfDNA mutation 
frequencies in healthy individuals but the occurrence of spontaneous mutations in healthy 
tissues provide a caveat on interpreting mutant ccfDNA as evidence of the presence of a 
cancerous lesion.
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In conclusion, we found that ccfDNA appears to represent the heterogeneity of colon and 
pancreatic cancer more extensively than tumor tissue DNA. The analysis of a relatively 
broad panel of cancer-related genes is feasible for ccfDNA and would allow monitoring of 
changes in the molecular makeup over time and under therapy. A challenge will be to what 
extent altered mutation patterns in ccfDNA could also prompt a change in treatment.
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Supplementary Figure 1. Non-synonymous mutations in the DNA standard provided as a control.
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AbsTrACT
Objectives: Monitoring responses to therapy using changes in the expression of circulat-
ing microRNAs (miRs) could be useful in prognostication of pancreatic cancer (PDAC) 
patients.
Methods: Changes in circulating miRs due to cancer progression in the transgenic KrasG12D/+; 
Trp53R172H/+; P48-Cre (KPC) animal model of PDAC were analyzed for serum miRs that 
are altered in metastatic disease. An analysis of serum miR expression profiles of human 
patients with resectable PDAC was performed using the novel RT-qPCR based IDEAL As-
say which allows for highly sensitive and miR-specific quantitation. Up to 250 serum miRs 
from 28 patients with PDAC were analyzed for changes indicative of PDAC recurrence after 
resection.
Results: Consistent with the results in the KPC mice, we found that high serum miR-125b-
5p and miR-99a-5p expression could distinguish PDAC patients with short progression free 
survival (PFS) after surgery. In situ hybridization of miR-125b-5p and miR-99a-5p in the 
resected PDAC tissues showed that the miRs are highly expressed in inflammatory cells, 
mostly consisting of CD79A expressing cells of the B-lymphocyte lineage.
Conclusions: Circulating miR-125b-5p and miR-99a-5p are potential prognostic biomarkers 
after surgery in patients with PDAC, that reflect an altered immune landscape in response 
to cancer recurrence.
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InTroDuCTIon
Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second most fre-
quent cause of cancer death by 2030 [1]. Approximately 15% of patients have resectable 
disease (stage I or II), whereas more than half of patients have unresectable PDAC [2] . 
Although PDAC can be removed surgically in early stage disease, the 5-year survival rate 
of patients that undergo surgical resection is still only 10% [3-5] . After surgery, adjuvant 
chemotherapy such as gemcitabine treatment is indicated. However, approximately half of 
the patients are not able to receive adjuvant chemotherapy due to health deterioration [6]. 
Also, rapid development of metastases shortly after removal of the primary tumor occurs in 
a subset of PDAC patients. Clinical follow up uses CT imaging, whereas molecular markers 
of PDAC progression during follow up remain underexplored. Since collection of tissue 
biopsies from the pancreas is risky, minimally invasive biomarkers attainable as ‘liquid 
biopsies’ from blood draws are sorely needed to aid in prognostic stratification of patients 
and possible adjustment of the treatment regimen. Here we describe circulating, cell free 
nucleic acids as potential biomarkers.
Mature microRNAs (miRs) are highly conserved short strands of non-coding RNA that 
regulate gene expression. To date, more than 2600 human mature miRs have been identified 
and annotated [7], with more than half of human protein-coding genes likely regulated 
by at least one miR [8]. MiRs are dysregulated in cancer and play crucial roles in immune 
function, cell proliferation, apoptosis, metastasis, angiogenesis and tumor-stroma interac-
tions [9-11]. It is noteworthy that miRs released from cells can induce miR-mediated gene 
expression alterations in neighboring as well as in distant cells when entering the circulation 
[12,13]. In the circulation, miRs are relatively stable and easy to measure, which has inspired 
a vast amount of biomarker research. The majority of research on circulating miR signatures 
in oncology is focused on diagnostics [14-18], however miRs can provide crucial insights 
into cancer progression and the effects of therapeutic interventions [19-22]. In the present 
study, we profiled serum miRs in patients with PDAC who underwent tumor resection, and 
in a transgenic mouse model of PDAC progression, to identify novel circulating biomarkers 
of pancreatic cancer progression.
MATerIAl AnD MeTHoDs
serum mir analysis in KPC mice
The animal experiment with the genetically engineered LSL-KrasG12D/+; LSL-Trp53R172H/+; 
P48-Cre or KPC mice [23] in this study was approved by the Georgetown University Insti-
tutional Animal Care and Use Committee (IACUC). Twelve KPC mice were euthanized at 
the age of 5 months before ~ 1 mL blood was collected via intracardial puncture in Serum 
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Z-Gel tubes with clotting activator (Sarstedt). The serum tubes were inverted 5 times and 
centrifuged at 10,000 x g for 15 minutes. Afterwards the serum was stored in aliquots at 
-80 ºC until further analyses. In addition, pancreas, liver and lungs were collected and 
processed by formalin fixation and paraffin embedding (FFPE). Tissues were stained with 
hematoxylin and eosin (H&E) and the slides were examined by a pathologist to evaluate 
pancreatic neoplasia and to determine the tumor stages. The animals were then divided 
into two groups based on disease progression: one group with PanIN-3 lesions as the worst 
disease stage, and a second group with mice that had invasive pancreatic cancer as well as 
lymph nodes, liver and lung metastases.
Equal volumes of serum samples from the mice belonging to the same group were pooled 
together, followed by miR isolation using the miRCURY RNA Isolation Kit for Biofluids 
(Exiqon). The murine miRs were reverse transcribed to cDNA using the miRCURY LNA™ 
Universal RT microRNA PCR, Polyadenylation and cDNA synthesis kit II (Exiqon). Ex-
pression of 179 miRs was analyzed with the qPCR-based Serum/Plasma Focus microRNA 
PCR Panel (Exiqon) using the ExiLENT SYBR® Green master mix (Exiqon). MiRs with Ct 
values higher than 30 cycles were excluded, resulting in 154 miRs that were evaluated. The 
median miR expression value in each pooled serum sample was used to normalize for miR 
expression. The fold differential expression for each miR was calculated (2-∆∆Ct) and plotted 
using Prism Graphpad 5.01.
Patient blood collection
All patients provided written informed consent for participation and the protocols asso-
ciated with this research were approved by the Erasmus Medical Center Medical Ethical 
Committee (MEC2017-1203). Peripheral venous blood samples were obtained from pa-
tients with treatment-naïve resectable PDAC 1 day before pancreaticoduodenectomy and 
~4 weeks (range 2-6) after resection. Patients who had prior gastro-intestinal malignancies 
were excluded. For each serum sample, a total of 8.5 mL of venous blood was collected in 
SST II Advance serum tubes (BD) with clot activator of silica particles to induce coagula-
tion. After inverting the tubes 6 times, the samples were spun within 4 hours after blood 
draw at 1258 g for 10 min at 4 °C in a swing-bucket centrifuge (Eppendorf 5810R). The 
serum was divided in 1 mL aliquots and stored at -80°C until further analyses.
Patients serum mir quantitation
Cell-free circulating miRs from the patients were isolated from 200 µL serum using the 
miRNeasy serum/plasma miRNA Isolation Kit (Qiagen). Two proprietary pre-mixed spike-
in ~20 nt control RNAs (MiRXES) with sequences distinct from annotated mature human 
miRNAs (miRbase version21) were added into the lysis buffer prior to sample miR isolation, 
in order to evaluate RNA isolation efficiency. Serum miRs were isolated per manufacturer’s 
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recommendation (Qiagen) and eluted in 15 µL nuclease free water. MiRs were reverse 
transcribed using IDEAL miR-specific oligos in a multiplex reaction per manufacturer’s 
instruction (MiRXES). In brief, up to 2 µL sample RNA was mixed together with 1 µL RT 
Spike-in RNA, RT Buffer, nuclease free water, Reverse Transcriptase and a maximum of 
10 different miR-specific RT oligos into 20 µL reactions and incubated at 42 °C for 30 min 
followed by heat inactivation at 95 °C for 5 min, in a SimpliAmp thermal cycler (Applied 
Biosystems). cDNA was stored at -20 °C (up to 4 weeks) and thawed only once. Before miR 
quantitation, the cDNA was diluted 1:10 in nuclease free water.
For the quantitative PCRs, 5 µL of sample cDNAs were mixed with the individual miRNA 
qPCR Assays (MiRXES), nuclease free water and the IDEAL miRNA qPCR Master Mix 
containing the passive reference dye ROX, into reactions of 20 µL volume. PCR amplifica-
tions in the 7500 Fast Real-Time PCR System (Applied Biosystems) were performed using 
the following protocol: 10 minutes at 95 °C, 5 minutes at 40 °C, followed by 40 cycles of: 10 
seconds at 95 °C and 30 seconds at 60 °C with FAM fluorescence reading at the end of this 
step. The raw threshold cycle (Ct) values were determined using the 7500 Software (Ap-
plied Biosystems) with automatic baseline setting. Technical variations introduced during 
RNA isolation and the process of RT-qPCR were normalized using the measurements of the 
spike-in control RNAs.
In screen 1 two hundred fifty miRs were measured in n=3 patients before and after surgery. 
The Ct value cutoff was 33 cycles to ensure reliability of the measurements. MiR levels in 
screen 1 were normalized using the mean expression value of all measured miRs per sample. 
From miR screen 1, 44 miRs were selected for further analyses based on the following two 
criteria: 1.) differential expression before and after surgical tumor removal; 2.) differential 
regulation after resection in patients with different progression free survival.
Next, the selected 44 miRs plus an additional 12 miRs we identified from the literature were 
measured in a second cohort of n=10 patients. Two stably expressed reference genes from 
miR screens 1 and 2 were selected for normalization: miR-29c-5p and miR-421 expres-
sion was used because they represent the mean miR expression values in all our patient 
serum samples. This approach to miR normalization was described by Mestdagh et al. [24]. 
Potential prognostic miRs were selected according to the two criteria described above. In a 
third patient cohort (n=15) sixteen miRs were measured, including the two reference genes 
miR-29c-5p and miR-421.
Data analysis
Patient data were collected during the standard clinical follow up and included patient age, 
sex, treatment type and timing, resection information, pathological TNM-stage, time to 
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death, new co-morbidities, time to progression and type of progressive disease. The qPCR 
Ct values were processed in Excel and converted to fold expression using 2^ -ΔCt, normal-
ized to the median miR expression (in the KPC mice and patient screen 1 analyses), or 
to the expression of reference miR-29c-5p and miR-421 (in the patient screens 2 and 3). 
The pre- and post-surgery serum miR expression values were presented and analyzed in 
Prism Graphpad 5.01 and compared between three patient groups: patients with short PFS 
(0-8 months); median PFS (8-16 months) and long PFS (>16 months). MiRs that were dif-
ferentially expressed between the patients with short versus long PFS within all three patient 
cohorts were considered as potential prognostic miRs. The pre- and post-surgery expres-
sion values of the selected miRs in patients from all cohorts were analyzed by single factor 
ANOVA comparing the short (red) versus long (green) PFS patient groups. Kaplan-Meier 
graphs of PFS for patients with high versus low post-surgery serum miR-122-5p; 125b-5p or 
99a-5p expression values compared were analyzed by Chi square (Logrank) test. The cutoff 
for high and low expression of each miR is based on the median post-surgery expression of 
the respective miR in all 28 patients.
In situ hybridization (IsH) of ffPe pancreatic cancer tissues
Pancreaticoduodenectomy tissue specimens were collected at the Erasmus Medical Center 
for clinical pathology evaluation. Stored FFPE tissue blocks were analyzed for clinical 
histopathological diagnosis. Residual material was used for biomarker analysis. Four µm 
thick tissue sections on extra adhesive glass slides (Leica, Biosystems) were processed in 
the Discovery Ultra instrument (Ventana, Roche). The following automated Discovery 
Universal protocol was used: tissues were preheated at 70 °C for 4 minutes then deparaf-
finized at 70 °C for 12 min. Pretreatment was performed with CC1 for 16 minutes (Cat. # 
950-224, Ventana). One drop of DISC inhibitor (Cat. # 760-4840, Ventana) was applied 
and incubated for 12 min. The 3’ and 5’ - DIG labeled miRCURY LNA miRNA Detec-
tion probes (Qiagen, hsa-miR-125b-5p cat. # YD00611756-BCG; hsa-miR-99a-5p cat. # 
YD00619276-BCG; positive control hsa-U6 cat. # YD00699002-BCG and negative control 
Scramble-miR cat. # YD00699004-BCG) were diluted in formamide-free MiRCURY LNA 
miRNA ISH Buffer (Qiagen cat. # 339450) to a final 20 nM concentration, applied to the 
slides and incubated for 8 minutes. Denaturation was established at 90 °C for 8 min, fol-
lowed by hybridization for 1 hour (at 55 °C for miR-125b-5p; 53 °C for miR-34a-5p; 52 
°C for miR-99a-5p; 54 °C for U6 and at 57 °C for the Scramble-miR). Slides were washed 
twice with SCC (DISCOVERY Ribowash 1x cat. # 760-105, Ventana) and heated to 55 °C 
for 8 min. Slides were washed and heated again to 55 °C for 8 min. One drop of anti-DIG 
HRP enzyme conjugate (Cat. # 760-4822, Ventana) was applied and incubated for 16 min. 
Discovery amplification was performed using one drop of DISC AMP TSA BF and one 
drop of DISC AMP H2O2 BF (Cat. # 760-226, Ventana) for 32 min of incubation. One 
drop of DISC anti-BF HRP (cat#760-4828, Ventana) was incubated 16 min, followed by 
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one drop of DISC Ag C silver (Cat. # 760-227, Ventana) incubation for 16 min. The tissues 
were counterstained with Hematoxylin II (Cat. # 790-2208, Ventana) for 8 min, followed by 
incubation with Bluing Reagent Post Counterstain (Cat. # 760-2037, Ventana) incubation 
for 4 min. Adjacent tissue sections were stained with Hematoxylin and Eosin (H&E). The 
slides were scanned using the Nanozoomer 2.0-HT slide imager (Hamamatsu).
Immunohistochemistry for CD79A human pancreatic cancer tissues
Immunohistochemistry was performed with an automated immunohistochemistry staining 
system (Ventana BenchMark ULTRA, Ventana Medical Systems) using the 3,3’-diamino-
benzidine method. In brief, following deparaffinization and heat-induced antigen retrieval 
for 64 min, the tissue sections were incubated with a rabbit monoclonal antibody raised 
against human CD79A (clone EP82, ready to use, Cell Marque) for 32 minutes at 36 °C. 
A subsequent amplification step was followed by incubation with hematoxylin II counter 
stain for 8 min and then a blue-colouring reagent for 8 min according to the manufacturer’s 
instructions (Ventana). The slides were scanned using the Nanozoomer 2.0-HT slide imager 
(Hamamatsu).
resulTs
Changes in serum mirs during pancreatic cancer progression in KPC mice
The LSL-KrasG12D/+; LSL-Trp53R172H/+; P48-Cre or KPC transgenic mouse model develops 
metastatic PDAC that recapitulates the human disease [23]. We investigated the serum miR 
expression in mice with PanIN lesions and mice with metastatic PDAC to assess whether 
serum miRs are altered during cancer progression. For this purpose we collected serum 
from KPC mice at 5 months of age and first evaluated the histology of the pancreas (Fig. 
1a), lung and liver tissues (Fig. 1b). Serum from mice (n=3) with PanIN-3 as the highest 
grade component of lesions in the pancreas and from mice with metastatic PDAC (n=3) 
was combined into two pooled samples. The two pooled serum samples were analyzed for 
expression of 179 mature miRs by q-PCR. The 154 miRs that were detected in the serum 
of mice with metastases were then compared to those in mice with preinvasive PanIN-3 
lesions (Supplementary Fig. 1). We found that fourteen serum miRs are downregulated 
more than 3-fold in mice with metastatic disease compared to age-matched mice with only 
preinvasive lesions, whereas thirteen miRs are upregulated >3-fold in the serum of mice 
with PDAC metastases (Table 1). Strikingly, the circulating miR that is upregulated the most 
in progressive cancer, miR-122-5p, is altered more than 22-fold. These findings indicate that 
serum miR expression is impacted during cancer progression which we further evaluate in 
human patients with PDAC.
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b
Figure 1. KPC mice with different stages of pancreatic neoplasia at the age of 5 months. (a) Images of 
formalin fixed, paraffin embedded (FFPE), H&E stained pancreatic tissues obtained from LSL-KrasG12D/+; 
LSL-Trp53R172H/+; P48-Cre (KPC) mice at the age of 5 months. PanIN-3 lesions are indicted by the green 
arrows, invasive pancreatic cancer is indicated by the red arrows. 20X magnification, scale bar = 100 µm. 
(b) Images of FFPE, H&E stained liver and lung tissues from KPC mice at the age of 5 months. Metas-
tatic pancreatic cancer lesions are indicated by the black arrows. 10X magnification, scale bar = 100 µm.
Table 1. Differentially expressed serum miRs in KPC mice with pancreatic cancer metastases compared 
to mice with pre-invasive PanIN-3 lesions. 
Serum miR
Fold 
down-
regulation
Serum miR
Fold
upregula-
tion
miR-15a-5p -7.69 miR-122-5p 22.63
miR-451a -7.69 miR-125b-5p 8.22
miR-15b-5p -6.25 miR-133a 5.94
miR-142-3p -5.88 miR-133b 5.82
miR-186-5p -4.17 miR-10b-5p 5.28
miR-103a-3p -3.85 miR-99b-5p 5.21
Let-7i-5p -3.70 miR-365a-3p 5.17
Serum miR
Fold 
down-
regulation
Serum miR
Fold
upregula-
tion
miR-25-3p -3.45 miR-125a-5p 5.13
miR-93-5p -3.33 miR-99a-5p 5.03
miR-16-5p -3.23 Let-7b-3p 4.26
miR-19a-3p -3.23 miR-145-5p 3.86
miR-148b-3p -3.13 miR-28-3p 3.46
miR-20a-5p -3.03 miR-143-3p 3.41
miR-425-5p -3.03
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Changes in serum mirs after tumor resection in patients with pancreatic cancer
Next, we analyzed pre- and post-pancreaticoduodenectomy serum from patients with re-
sectable PDAC (n=28) who underwent surgery at the Erasmus Medical Center Rotterdam, 
in the Netherlands between 2013 and 2017. Patient characteristics are summarized in Table 
2. Our aim was to assess the change in serum miR expression after surgery in patients with 
different progression free survival (PFS). In order to measure miR levels we used a novel 
technology that allows for exceptionally miR-specific and sensitive quantitative Real Time 
PCR [25]. The IDEAL assay from MiRXES is explained in Fig. 2a and utilizes miR-specific 
reverse transcription, as well as a combination of a miR-specific forward and reverse primer 
to detect and quantitate specific miRs. Details of the approach are shown in Fig. 2b. We ini-
tially profiled 250 miRs before and after primary tumor resection in 3 patients with PFS of 7, 
11 or 18 months. The miRs that were measured in screen 1 are listed in Supplemental Table 1. 
From the 250 miRs, 190 were detected by qPCR and only 44 miRs were differentially altered 
after surgical tumor removal in the patients with different PFS. In a second cohort of PDAC 
patients (n=10), we measured the 44 informative miRs from screen 1, and an additional 12 
miRs that were selected from the literature (Supplemental Table 2). We again compared the 
change in serum miR expression after surgery to the PFS. From this analysis, we found that 
14 miRs can indicate disease progression after surgery. To test this in an indpendent third 
cohort of patients (n=15), we measured the levels of these 14 selected miRs (miR-122-5p, 
miR-125b-5p, miR-34a-5p, miR-99a-5p, miR-146b-5p, miR-154-5p, miR-379-5p, 193b-3p, 
miR-186-5p, miR-450a-5p, miR-301a-3p, miR-99b-5p, miR-181a-2-3p and miR-130a-3p) 
before and after surgery. When taking the miR measurements of all 28 pancreatic cancer 
patients together, we found that only miR-122-5p, miR-125b-5p and miR-99a-5p show a 
differential expression after surgery in patients with different PFS (Fig. 3a). Although the 
differential changes in expression of miR-122-5p, miR125b-5p and miR99a-5p did not 
reach statistical significance, these three miRs increase after tumor resection in patients 
who develop progressive cancer within 8 months, and decrease after tumor resection in 
patients who have a long PFS of more than 16 months (Fig. 3a). The Kaplan-Meier curves 
in Fig. 3b show post-surgery serum miR levels in relation to the progression free survival 
of the 28 patients that were analyzed. Despite the fact that miR-122-5p is upregulated 22-
fold in KPC mice with metastatic disease, miR-122-5p is not differentially expressed in 
patients with short versus long PFS after surgery (Fig. 3b). On the other hand, patients with 
high serum levels of miR-125b-5p or miR-99a-5p after surgery have a significantly worse 
prognosis (Fig. 3b). In summary, we found that miR-125b-5p and miR-99a5p are prognostic 
circulating biomarkers in KPC mice and in patients with pancreatic cancer.
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Mir-125b-5p and mir-99a-5p are highly expressed in infl ammatory cells in 
human resected pancreatic cancers
In order to assess the expression of miR-125b-5p and miR-99a-5p further, we analyzed the 
resected pancreatic cancer tissues by in situ hybridization (ISH) with DIG-labeled locked 
nucleic acid miR probes. Th e positive and negative controls for the ISH assays are shown in 
Supplemental Figure 2. MiR-125b-5p is expressed at low levels in the cytoplasm of normal 
acinar cells, as well as in a fraction of the PanIN cells (Fig. 4a). However, a small fraction of 
cells in the stroma surrounding the invasive cancer cells express high levels of miR-125b-
5p (Fig. 4b). Th ere is no diff erence in the number of miR-125b-5p-high stroma cells in 
tumors from patients with short versus long PFS. Insterestingly, the miR-125b-5p-high 
cells pertain in infl ammatory cell aggregates in the tumor stroma and are located within 
clusters of CD79A positive cells (Fig. 4b), indicating that miR-125b-5p may play a role in 
B-lymphocyte/ plasma cell infi ltration in pancreatic cancer stroma. MiR-99a-5p expressing 
cells are less abundant than miR-125b-5p positive cells in the pancreatic tumors. MiR-99a-
5p positive cells are only present in limited regions of tumor stroma, specifi cally in muscular 
and connective tissue where pancreatic cancer cells invade into. Fig. 5 shows tumor regions 
with cells that express high levels of miR-99a-5p. In the centers of the pancreatic cancers 
Screen # 1 (250 miRs) 
pre + post surgery
n=3 PDAC patients [PFS]
NT003 [18 months]
PP011 [6.5 months]
NT017 [10.9 months]
60 miRs not detected
146 miRs not informative
Screen # 2 (54 miRs)
+ 2 reference miRs
pre + post surgery
n=10 PDAC patients
40 miRs not informative
44 miRs from screen # 1
12 miRs from literature
Screen # 3 (14 miRs)
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pre + post surgery
n=15 PDAC patients
11 miRs not informative
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miR-99a-5p
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forward primer
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nested reverse primer    
sensitive signal
Figure 2. Analysis approach of prognostic miRs in the serum of patients with resectable pancreatic can-
cer. (a) Schematic of the IDEAL real time RT-PCR assay from MiRXES. MiR-specifi c reverse transcripti-
on (RT) and a miR-specifi c pair of forward and reverse primers lead to high specifi city and sensitive PCR 
signals. miR = microRNA; nt = nucleotides; RT= reverse transcription; cDNA = complementary DNA. 
(b) Overview of performed serum miR analysis in patients with resectable pancreatic ductal adenocar-
cinoma (PDAC) to identify indicators of progression free survival (PFS) after surgical tumor removal.
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there are no cells that express miR-99a-5p. When comparing the location of CD79A positive 
cells in the adjacent tissue slides, we observed that the miR-99a-5p expressing inflammatory 
cells are in close proximity to cells of the B-cell lineage (Fig. 5).
In summary, we found that high expression of serum miR-125b-5p and miR-99a-5p is as-
sociated with pancreatic cancer progression in transgenic mice as well as in patients after 
surgical tumor removal. MiR-125b-5p as well as miR-99a-5p is highly expressed in a subset 
of inflammatory cells in the pancreatic tumor stroma, and are associated with cells from 
the B-lymphocyte lineage. The abundance of inflammatory cells expressing high levels of 
miR-125b-5p or miR-99a-5p in the tumor tissues was not different in patients with short 
versus long progression free survival.
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Figure 3. Expression levels of three serum miRs in pancreatic cancer patients with different outco-
mes. (a) Average expression levels of serum miRs 122-5p; 125b-5p or 99a-5p before and after surgery 
in 3 groups of patients with different progression free survival (PFS) duration. Serum miR values were 
normalized to the average expression of reference miR-29c-5p and miR-421 for each sample. Note the 
log scale of the Y-axis. Error bars are SEM, P-values by single factor ANOVA comparing the short (red) 
versus long (green) PFS patient groups. (b) Kaplan-Meier graphs of PFS for patients with increased or 
decreased serum miR-122-5p; 125b-5p or 99a-5p levels after surgical tumor removal. P values by Chi 
square (Logrank) test.
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Figure 4. MiR-125b-5p detection by in situ hybridiation in pancreatic cancer tissues. Images of resected 
pancreas tissues from patients with pancreatic cancer. Consecutive FFPE tissue sections were stained 
with H&E or a DIG labeled miR-125b-5p probe. MiR-125b-5p expression is detected with silver resulting 
in brown/black staining, whereas nuclei are stained with Hematoxylin in blue. (a) Representative ima-
ges of low expression of miR-125b-5p, (green arrows), in untransformed pancreatic acinar cells and cells 
that underwent acinar to ductal metaplasia (ADM) or pancreatic intraepithelial neoplasia (PanIN). (b) 
Representative images of cells in the tumor stroma with high expression of miR-125b-5p (red arrows). 
Corresponding tissue sections are stained with H&E and B-lymphocyte marker CD79A.
112  Circulating miR-125b-5p and miR-99a-5p in pancreatic cancer progression
DIsCussIon
Until now, approved non-invasive circulating biomarkers for the prognostication of patients 
with pancreatic cancer are lacking. Clinical follow up of pancreatic cancer patients in the 
Netherlands is not standardized [26] and currently consists of physical examination and at 
times radiographical imaging by CT scans which have a low performance in detecting early 
metastatic disease. Repeated blood draws followed by miR expression analysis that could 
stratify patients at higher risk for progressive disease and could prompt treatment adjust-
ment would vastly improve patient care. MiRs are suitable candidates for the prediction of 
cancer progression due to their altered expression during tumorigenesis and their stability 
in the circulation[22].
Numerous studies have shown that circulating miRs are altered in early PDAC as well as in 
metastatic PDAC [27]. Zhou et al. showed that patients with early PDAC could be distin-
guished from healthy controls by the plasma upregulation of miR-122-5p; miR-125b-5p; 
miR-192-5p; miR 193b-3p; miR-122-3p and miR-27b-3p before treatment [14]. In contrast, 
they found that pre-treatment decreased miR-125b-5p was associated with worse OS. It 
was recently shown that increased serum expression of the miR-99 family is associated to 
H
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p
C
D
79
A
pancreatic cancer invasion into surrounding stroma
Figure 5. MiR-99a-5p detection by in situ hybridiation in pancreatic cancer tissues. Images of resected 
pancreas tissues from patients with pancreatic cancer. Consecutive FFPE tissue sections were stained 
with H&E or a DIG labeled miR-99a-5p probe, ora B-lymphocyte marker CD79A. Red arrows indicate 
miR-99a-5p expression, detected with silver resulting in brown/black staining, whereas cell nuclei are 
stained with Hematoxylin in blue.
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pancreatic cancer diagnosis [28]. Studies similar to these, which assess circulating miR 
levels for the diagnosis of PDAC are difficult to corroborate. Inconsistent results are due to 
interpatient diversity as well as technical differences in quantitation and data normalization 
[29].
Unfortunately, a subset of patients with PDAC that undergo primary tumor resection 
rapidly succumb to disease recurrence, whereas other patients have long progression free 
survival after surgery. Identifying the patients at risk for early disease recurrence could 
prompt adjustments in adjuvant treatment decisions and improve patient outcome. In the 
current study, we performed a prognostic miR biomarker analysis using serum samples of 
treatment-naïve, resectable PDAC patients. We profiled serum miR expression before and 
after surgery and compared the changes to the progression free survival of the patients. This 
comparison highlights the change in serum miR levels after removal of the primary cancer. 
The prognostic miRs identified in the patients were also indicative of PDAC metastases in 
the KPC mice, supporting their biologic importance for pancreatic cancer progression.
Genetically engineered mouse models of pancreatic cancer have led to major improve-
ments in the understanding of PDAC development. Specifically, the LSL-KrasG12D/+; LSL-
Trp53R172H/+; P48-Cre or KPC mice display progressive PDAC that mimics the features of 
the human disease [23]. KPC mice initially develop preinvasive acinar to ductal metaplasia 
(ADM) and pancreatic intraepithelial neoplasia (PanIN) lesions before widespread PDAC, 
all in the presence of an intact immune system. The median survival of KPC mice is 5 
months and all mice succumb to the disease before the age of one year [23]. We performed 
a cross-species comparison of serum microRNA expression: the prognostic miRs we identi-
fied in the patients were also correlated to PDAC metastases in the KPC mice, confirming 
their importance in pancreatic cancer progression.
Circulating miRs that are associated with cancer presence often do not originate from 
cancer cells themselves. For example, miR-125b expression in colorectal liver and lung 
metastases is ~3 fold and ~7-fold higher in the stroma than in the cancer cells [30]. Indeed, 
the majority of circulating miRs are derived from blood cells and the endothelium [31,32]. 
PDAC progression goes hand in hand with alterations in systemic immune cell profiles 
[33] and this link between altered circulating miRs during cancer progression and immune 
cells was confirmed in our study. We found that miR-125b-5p and miR-99a-5p levels are 
soaring in cells that are closely associated to B-lymphocytes in the tumor stroma. Others 
have shown that miR-125b-5p is upregulated in B-lymphocytes [34] and can cause leukemia 
in mice [35,36]. In pancreatic tumors, high levels of infiltrating plasma cells are signifi-
cantly correlated with worse prognosis in patients after surgery [37]. We found that after 
surgical tumor removal, patients with high levels of serum miR-125b-5p or miR-99a-5p 
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have shorter progression free survival. MiR-125b-5p and miR-99a-5p belong to the 20 most 
abundant miRs in human plasma exosomes [38], indicating that these miRs are actively 
packaged and released into the bloodstream. Circulating miRs are transferred from cell 
to cell and can elicit immune modulation [39]. MicroRNA-containing T-regulatory-cell-
derived exosomes suppress pathogenic T helper 1 cells [40]. Serum miRs interact more 
with immune-related mRNA genes that with non-immune related genes [41]. A recent 
study showed that miR-125b-5p and miR-99a-5p both downregulate the activation of γδ 
T-lymphocytes and their cytotoxicity to lymphoma cells [42]. In humans and rats, treatment 
with methylprednisolone leads to increased plasma miR-99a-5p levels, suggesting miR-99a-
5p is involved in systemic immune suppression [43]. Others have shown that miR-99a-5p 
inhibits the mammalian target of rapamycin (mTOR) signaling in bladder cancer cells [44], 
which was also described in gastric cancer tisues by Zhang et al. [45]. mTOR is not only an 
important cancer-related pathway, mTOR is also crucial for hematopoietic cell fate [46,47]. 
The differentiation of naïve T-cells into distinct effector T cells is promoted by mTOR [46]. 
In the absence of mTORC1 activity myeloid differentiation is impaired due to a block in 
glucose uptake and lipid metabolism [48]. Cell-free miR-99a-5p levels are high in the blood 
of patient with progressive pancreatic cancer, suggesting that the miR is produced at high 
levels by a subset of leukocytes, and can potentially be taken up by other cells, leading to the 
abrogation of mTOR among other pathways.
On the other hand, expression of miR-122-5p is liver specific and absent in most other tis-
sues [49-51]. In the KPC mice with metastatic PDAC, miR-122-5p was upregulated 22-fold 
in comparison to mice with pre-invasive lesions. In the patients who underwent surgical 
tumor resection serum miR-122-5p levels went up after surgery in patients with early 
disease recurrence, however post-surgery serum miR-122-5p levels could not distinguish 
patients based on PFS, or based on the presence of liver metastases. This may suggest that 
liver damage is present at some level in all patients who undergo pancreaticoduodenectomy 
for pancreatic cancer.
There has been very little to no research that compares the levels of miRs after surgical 
removal of primary pancreatic cancers. In our study we compared serum miRs pre and post 
resection in treatment naïve patients that were operated at the Erasmus Medical Center 
between 2013 and 2017. Recently it became clear that patients with (borderline) resectable 
PDAC that undergo preoperative chemo/radiotherapy have a better survival [52,53]. From 
now on all patients with (borderline) resectable PDAC in the Netherlands will be offered 
to receive preoperative chemotherapy, if the performance status of the patient permits and 
the patient is willing to undergo systemic treatment. Chemotherapy has a vast impact on 
the immune landscape [54,55]. Whether serum miR-125b-5p and miR-99a-5p remains 
to be predictive of disease progression after surgery in pre-treated patients remains to be 
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evaluated. Therefore we are currently collecting blood samples to evaluate the changes in 
the serum miRs of patients with (borderline) resectable patients who undergo pre-operative 
FOLFIRINOX chemotherapy or gemcitabine/radiotherapy.
In summary, serum miR-125b-5p and miR-99a-5p levels are potential indicators of early 
disease recurrence after surgery in patients with pancreatic cancer and are likely originat-
ing from immune cells. Further dissection of the dynamics and functions of miR-125b-5p 
and miR-99a-5p in the immune response to pancreatic cancer will provide fundamental 
information to assist in the development of biomarkers and better immune therapies.
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Supplementary Table 1. List of miRs that were detected in screen # 1 in the serum of n=3 patients with 
resectable PDAC before and after surgical tumor resection.
let-7c-5p let-7d-5p miR-16-5p miR-24-3p miR-99a-5p miR-150-5p
miR-196a-5p miR-199a-5p miR-199a-3p miR-208a-3p miR-215-5p miR-223-3p
miR-200b-3p miR-15b-5p miR-27b-3p miR-30b-5p miR-125b-5p miR-128-3p
miR-135a-5p miR-152-3p miR-153-3p miR-191-5p miR-23b-3p miR-126-5p
miR-126-3p miR-154-5p miR-193a-3p miR-194-5p miR-302d-3p miR-382-5p
miR-328-3p miR-323a-3p miR-326 miR-345-5p miR-409-3p miR-146b-5p
miR-495-3p miR-497-5p miR-518b miR-92b-3p miR-181a-2-3p miR-144-5p
miR-29c-5p miR-193b-5p miR-532-3p miR-885-5p miR-301b-3p miR-1246
miR-320d miR-15a-5p miR-19b-3p miR-20a-5p miR-26a-5p miR-27a-3p
miR-28-5p miR-98-5p miR-29b-3p miR-106a-5p miR-192-5p miR-129-5p
miR-30d-5p miR-139-5p miR-10a-5p miR-181a-5p miR-224-5p miR-130a-3p
miR-142-3p miR-9-3p miR-125a-5p miR-17-5p miR-190a-5p miR-195-5p
miR-200c-3p miR-301a-3p miR-99b-5p miR-361-5p miR-378a-5p miR-330-3p
miR-337-3p miR-324-3p miR-338-3p miR-425-3p miR-429 miR-452-5p
miR-485-5p miR-491-5p miR-21-5p miR-421 miR-181c-3p miR-221-5p
miR-223-5p miR-125a-3p miR-219a-2-3p miR-500a-5p miR-374b-5p miR-1271-5p
let-7f-5p miR-19a-3p miR-25-3p miR-92a-3p miR-95-3p miR-96-5p
miR-10b-5p miR-34a-5p miR-103a-3p miR-199b-5p miR-122-5p miR-132-3p
miR-133a-3p miR-143-3p miR-145-5p miR-127-3p miR-146a-5p miR-185-5p
miR-186-5p miR-188-5p miR-29c-3p miR-200a-3p miR-130b-3p miR-30e-5p
miR-30e-3p miR-339-5p miR-335-5p miR-133b miR-196b-5p miR-20b-5p
miR-451a miR-484 miR-486-5p miR-193b-3p miR-493-3p miR-590-5p
miR-769-5p miR-140-3p miR-193a-5p miR-34b-3p miR-337-5p miR-151a-5p
miR-423-5p miR-616-3p miR-628-5p miR-874-3p miR-1290 miR-1304-5p
let-7a-5p let-7b-5p miR-221-3p miR-22-3p miR-29a-3p miR-30a-3p
miR-32-5p miR-93-5p miR-100-5p miR-30c-5p miR-183-5p miR-204-5p
miR-205-5p miR-219a-5p miR-222-3p miR-141-3p miR-134-5p miR-206
miR-320a miR-106b-5p miR-363-3p miR-365a-3p miR-370-3p miR-375
miR-378a-3p miR-379-5p miR-151a-3p miR-148b-3p miR-324-5p miR-450a-5p
miR-432-5p miR-519c-3p miR-503-5p miR-539-5p miR-487b-3p miR-584-5p
miR-425-5p miR-21-3p miR-7-1-3p miR-34a-3p miR-106b-3p miR-99b-3p
miR-362-3p miR-342-5p miR-589-5p miR-1226-3p
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Supplementary Table 2. List of miRs that were measured in screen # 2 in the serum of n=10 patients 
with resectable PDAC before and after surgical tumor resection.
let-7d-5p miR-144-5p miR-28-5p miR-375 miR-616-5p
let-7g-5p             miR-146b-5p miR-29c-5p     miR-379-5p miR-627-5p
let-7i-5p miR-154-5p miR-301a-3p miR-421 miR-651-5p
miR-103a-3p                  miR-154-5p miR-302f miR-450a-5p miR-885-5p
miR-122-5p        miR-155-5p miR-30e-3p miR-454-3p                     miR-9-3p
miR-1226-3p miR-16-5p miR-330-3p miR-486-5p                      miR-98-5p
miR-125b-5p miR-181a-2-3p miR-34a-3p miR-491-5p miR-99a-5p
miR-127-3p miR-186-5p miR-34a-5p miR-493-3p miR-99b-5p
miR-1285-3p   miR-18a-3p miR-34b-3p miR-495-3p
miR-130a-3p miR-191-5p miR-363-3p   miR-584-5
miR-135b-5p   miR-221-3p                   miR-370-3p miR-590-5p 
miR-140-3p miR-22-3p miR-374b-5p miR-616-3p
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miR-145-5p
miR-28-3p
miR-143-3p
miR-1
miR-29c-3p
miR-126-3p
miR-200a-3p
miR-192-5p
miR-139-5p
miR-27b-3p
miR-215
miR-132-3p
miR-194-5p
miR-375
miR-150-5p
miR-574-3p
miR-152
miR-148a-3p
miR-342-3p
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miR-27a-3p
miR-324-5p
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miR-33a-5p
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miR-23b-3p
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miR-223-3p
miR-29a-3p
miR-24-3p
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miR-378a-3p
miR-221-3p
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miR-23a-3p
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miR-424-5p
miR-22-3p
miR-423-3p
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miR-22-5p
miR-30a-5p
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miR-21-5p
miR-146a-5p
miR-210
miR-141-3p
miR-151a-5p
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miR-191-5p
miR-339-5p
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miR-28-5p
miR-331-3p
miR-130a-3p
miR-324-3p
miR-338-3p
miR-363-3p
miR-185-5p
miR-93-3p
miR-339-3p
let-7d-5p
let-7i-3p
miR-484
miR-652-3p
miR-326
miR-30c-5p
miR-320a
miR-205-5p
miR-20b-5p
miR-18a-5p
miR-92a-3p
miR-128
miR-130b-3p
miR-19b-3p
miR-200c-3p
miR-328
miR-142-5p
miR-423-5p
miR-18b-5p
miR-421
miR-26b-5p
miR-301a-3p
miR-106a-5p
miR-140-3p
miR-15b-3p
miR-140-5p
miR-222-3p
miR-486-5p
let-7g-5p
miR-296-5p
miR-30e-5p
miR-20a-5p
miR-425-5p
miR-148b-3p
miR-19a-3p
miR-16-5p
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Supplementary Figure 1. Relative expression levels of serum miRs in KPC mice with pancreatic cancer 
metastasis. Serum miRs from two groups of LSL-KrasG12D/+; LSL-Trp53R172H/+; P48-Cre (KPC) mice with 
different disease stage at the age of 5 months were analyzed. Serum from KPC animals with pancreatic 
cancer metastases (n=3 mice) was pooled and compared to pooled serum from n=3 mice with preinva-
sive PanIN-3 lesions. 155 microRNAs were detected by qPCR and expression levels were normalized to 
the median expression value per sample. MiRs that were differentially expressed > 3-fold are highlighted 
in red and green. Note the log scale for the Y-axis.
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Supplementary Figure 2. MiR in situ hybridization (ISH) controls. Images of FFPE tissues that are 
stained with silver after in situ hybridization of dual-DIG labeled miR probes leading to brown/black 
staining. Nuclei are stained with Hematoxylin in blue. Scale bars = 250 µm. (a) U6 expression in human 
colon and testis tissue, serving as positive controls for the ISH assay. (b) MiR-125b-5p expression in 
120  Circulating miR-125b-5p and miR-99a-5p in pancreatic cancer progression
Her2Neu positive human breast cancer and human testis tissues. Note the distinct staining patterns in 
the breast cancer cells and Sertoli cells that have low miR-125b-5p expression (green arrows) versus the 
single cells in the stroma that have high expression (red arrows). (c) MiR-99a-5p expression in human 
pancreatic cancer and liver. Cells in the stroma with high levels of miR-99a-5p are indicated with the 
red arrows. (d) Scramble miR expression in human colon and testis tissues, which serves as a negative 
control for the ISH assay.
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AbsTrACT
Serial analysis of biomarkers in the circulation of patients undergoing treatment (“liquid 
biopsies”) can provide new insights into drug effects. In particular the analysis of cell-free, 
circulating nucleic acids such as microRNAs (miRs) can reveal altered expression patterns 
indicative of mechanism of drug action, cancer growth, and tumor-stroma interactions. 
Here we analyzed plasma miRs in patients with hormone receptor positive, metastatic 
breast cancer with prior disease progression during aromatase inhibitor therapy (n = 8) in a 
phase I/II trial with the multiple tyrosine kinase inhibitor dovitinib (TKI258). Plasma miR 
levels were measured by quantitative RT-qPCR before and after treatment with dovitinib. 
A candidate miR signature of drug response was established from a 379 miR screen for 
detectable plasma miRs as well as from the published literature. Changes in miR expression 
patterns and tumor sizes were compared. In this analysis we identified miR-21-5p, miR-
100-5p, miR-125b-5p, miR-126-3p, miR-375 and miR-424-5p as potential indicators of a 
response to dovitinib. The altered expression patterns observed for the six circulating miRs 
separated patients with resistant disease from those with drug responsive disease. There was 
no relationship between adverse effects of dovitinib treatment and identifiable changes in 
miR patterns. We conclude that changes in the expression patterns of circulating miRs can 
be indicators of drug responses that merit prospective studies for validation.
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InTroDuCTIon
One of the hallmarks of cancer is the oncogenic activation of receptor tyrosine kinases 
(RTKs) that control cell growth and survival [1-3]. In addition to the autocrine cancer cell-
autonomous effects, RTKs mediate the paracrine crosstalk between tumor cells and host 
stroma that controls fibrosis, tumor angiogenesis and the immune environment [4-8]. Thus, 
small molecule kinase inhibitors or antibodies that target ligands or receptors have become 
a mainstay of RTK targeted cancer therapy.
A recently added kinase inhibitor is dovitinib (TKI258 or CHIR-258), an orally available 
inhibitor of multiple RTKs that include FGFR1, FGFR3, VEGFR, KIT, and PDGFRβ with 
IC50 values < 30 nmol/L [9]. Integrated analysis of clinical and preclinical studies indicates 
that inhibition of FGFR signaling by dovitinib disrupts the paracrine interaction between 
prostate cancer and stromal cells and thus mediates the antitumor effect [10]. In some men 
with metastatic prostate cancer, dovitinib treatment led to improvements in bone scans 
and lymphadenopathy [10]. Furthermore, in pretreated patients with metastatic renal cell 
carcinoma, dovitinib showed significant antitumor activity in a phase-I study [11]. More-
over, in patients with metastatic renal cell carcinoma that were previously treated with a 
VEGFR tyrosine kinase inhibitor and an mTOR inhibitor, dovitinib treatment resulted in 
two partial responses (3.6%) and 29 stable diseases (52.7%) in a phase-II setting [12]. In a 
phase I/II and pharmacodynamic study in patients with advanced melanoma dovitinib was 
found to decrease levels of soluble VEGFR2 in plasma, consistent with FGFR and VEGFR 
inhibition [13]. Additionally, melanoma patients showed dose dependent changes in the 
vascularity of liver metastases after 2 days of dovitinib treatment [13]. Finally, in patients 
with breast cancer dovitinib showed more antitumor activity in tumors with high levels of 
FGFR1 amplification. In the FGFR1-amplified breast cancer group, a 20.2% reduction in 
tumor size was found after dovitinib but no reduction in tumors with less than six copies 
of FGFR1 [14].
Blood based molecular analyses (“liquid biopsies”) are used for serial monitoring of cancer 
progression as well as the response to treatment [15]. Here we focus on the analysis of mi-
croRNAs (miRs) in the circulation, which are transcribed, processed, packaged and released 
from cells in normal and in diseased tissues as part of the local and at-a-distance cellular 
crosstalk [16,17]. Distinct alterations in circulating miRs can reflect dysregulation of cell 
proliferation, immunity and stromal interactions. As shown in numerous studies, circulat-
ing miRs can serve as predictors of cancer outcome [18-22] and may allow for a real-time 
assessment of treatment responses after surgical resection [23], chemotherapy [24-27] or 
pathway targeted therapy [28]. Drug treatment impacts both cancerous lesions and the host 
tissues. Therefore, changing patterns of miRs in the circulation should reflect the impact of 
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the treatment on the cancer lesion as well as the host organism and makes circulating miRs 
suitable biomarkers [15].
Here we analyzed cell-free miRs in the plasma of breast cancer patients in a phase I/II 
trial of dovitinib. We hypothesized that changes in circulating miR patterns can indicate 
dovitinib treatment responses, resistance to treatment, or adverse effects.
MATerIAl AnD MeTHoDs
Patient eligibility
Post-menopausal women with hormone receptor positive, HER2 negative metastatic breast 
cancer 18 years or older were included in this phase I/II open-label single arm trial evalu-
ated dovitinib in combination with an aromatase inhibitor (AI), i.e. anastrozole, exemestane 
or letrozole. Index tumors had to be 10 mm or greater on a CT scan and had previously been 
sensitive to endocrine therapy followed by disease progression after > 2 years of adjuvant 
endocrine therapy. At entry into the study evidence of disease resistance to an AI, defined 
as documented disease progression while receiving an AI, or development of disease recur-
rence < 6 months after completing adjuvant therapy with an AI. Patients had to have a good 
performance status (eastern Cooperative Group 0–1), adequate organ function and had to 
have life expectancy of > 3 months. All patients gave written consent for the clinical trial 
protocol that had been approved by the IRB at Medstar Georgetown University Hospital 
(IRB #2010-535). The trial is registered at clinicaltrials.gov as NCT01484041.
study design and treatment
Dovitinib was given at an oral dose of 500 mg daily 5 days on/2 days off in combination with 
the standard dose of AI (either anastrozole 1 mg daily, exemestane 25 mg daily, or letrozole 
2.5 mg daily). One treatment cycle was defined as 4 weeks. After each cycle, peripheral 
venous blood samples were collected and after removal of personal identifiers plasma was 
separated and stored at – 80 °C until further processing. For the phase I portion of the 
study, if more than 2 dose-limiting-toxicities (DLT) were seen in the first 6 subjects, the 
dose of dovitinib was reduced to 400 mg daily 5 days on/2 days off in combination with 
the fixed dose of AI. Eventually 3 subjects remained on the initial dose of 500 mg and dose 
de-escalation was performed for 9 patients that were treated at 400 mg after the first cycle. 
Tumor responses to treatment with dovitinib were evaluated every 2 cycles (8 weeks) as 
determined by CT scans of patients’ index lesions. The trial was stopped after 12 patients 
had enrolled when the decision was made to discontinue development of dovitinib. Plasma 
samples before and after treatment were collected for only 8 out of 12 patients due to early 
exit from the study by 2 patients, and logistical difficulties.
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Circulating mir analysis
Plasma miR extraction and RT-qPCR analysis was conducted as previously reported [22,29]. 
Briefly, two replicates of 170 µL of plasma were thawed, mixed with 5 volumes of Qiazol lysis 
reagent and vortexed. For one patient, 500 µL plasma pre and post treatment was used to 
extract miRs for a broader analysis of 379 miRs in an array format. The miRs were extracted 
with chloroform and the aqueous phase was further processed using the miRNeasy Mini 
kit (Qiagen, Valencia, CA). MiRs were converted to cDNA using the miScript II RT kit 
(Qiagen Valencia, CA, cat. # 218160). This kit contains a miScript HiSpec buffer MiR to 
enable either mature miRNA profiling (using miScript miRNA PCR Arrays) or mature 
miRNA quantification using individual miScript Primer Assays. In this reverse transcrip-
tion reaction with miScript HiSpec Buffer, mature miRNAs are polyadenylated by poly(A) 
polymerase and converted into cDNA by reverse transcriptase with oligo-dT priming. The 
cDNA is then used for real-time PCR quantification of mature miRNA expression. MiR 
expression was quantified by qRT-PCR, using the SYBR green PCR Master mixture (Qiagen 
cat. # 218073) in an ABI7900HT Real-Time PCR system using (Applied Biosystems, Foster 
City, CA) with 95 °C for 15 min followed by 40 cycles (94 °C for 15 s, 55 °C for 30 s and 
72 °C for 30 s) followed by a melting curve step to evaluate specificity of amplification. A 
broad miR expression array (379 miRs + U6) was performed for global miR profiling using 
one randomly selected patient (# 101) that required 500 µL plasma at baseline and post 
dovitinib treatment (Qiagen Valencia, CA). The miR expression values from the array were 
normalized to the mean expression level of all miRs in the respective sample, to adjust for 
the different quality of RNA preservation and extraction. MiR specific primers were used 
for the panel of six miRs selected for further study (Qiagen Valencia, CA). Expression values 
were calculated using the comparative Ct method. Levels of a panel of six selected signa-
ture of miRs were measured in the plasma of eight patients before and after treatment and 
normalized to U6 levels [30,31]. The data was processed with Prism 5.0 Graphpad software 
for t test analysis and the display of data. Reproducibility of the miRNA assays within and 
across studies supports that these assays are specific for mature miRNAs, as also claimed by 
the manufacturer.
statistical analysis
Principal component analysis (PCA) and the agglomerative hierarchical clustering were 
performed with the miR measurements from all 8 patients and included the levels of the 
selected six miRs before and after treatment. The XLSTAT Version 2014.6.01 from Addin-
soft was used for these analyses. From the PCA and clustering of the miR measurements, 
distinct patterns of patients’ responses to the drug treatment were visualized and patients 
were assigned to distinct response groups. The investigators performing the miR panel 
selection, and the PCA-based assignment of patients to treatment response groups were 
blinded to the clinical outcomes and the measurements of tumor sizes during the trial. 
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Expression level changes of the six selected miRs between groups of patients based on their 
response to dovitinib were compared to baseline levels in Prism Graphpad Version 5.03 by 
using unpaired Student t-test.
resulTs
Patients undergoing dovitinib treatment
Out of the 12 patients enrolled in the trial, 6 patients came off study for disease progression, 
4 patients for toxicity, and 2 patients chose to discontinue treatment. Patient enrollment 
stopped after the 12th patient due to limited clinical benefits and the company’s strate-
gic decision not to develop the drug further. Sufficient amounts and quality of pre- and 
post-treatment plasma samples for miR analysis were available from 8 of 12 patients. The 
comparative miR analysis was done with the pre-treatment and the earliest available plasma 
sample after initiation of dovitinib treatment. For 2 out of 8 patients blood samples were not 
collected after the first cycle of dovitinib (patients 101, 301), therefore miRs were analyzed 
after the second cycle of dovitinib for these patients.
The clinical characteristics of the 8 patients studied as well as their treatments and adverse 
effects are compiled in Table 1. Baseline index tumor size of target lesions before dovitinib 
treatment, obtained from the computerized tomography (CT) measurements are shown in 
Fig. 1a. The change in tumor sizes over the course of dovitinib treatment is shown in Fig. 1b. 
Tumor responses after 8 weeks of treatment were not correlated with tumor sizes at baseline. 
The change in index tumor size based on the CT measurements after 8 weeks of treatment 
were used to separate patients into subgroups, i.e. tumors that had increased in size by more 
than 8% (n = 3; red symbols), decreased in size by more than 8% (n = 3; green symbols), and 
those that were not changed (n = 2; grey symbols) relative to baseline.
selection of circulating micrornAs impacted by dovitinib treatment
We followed the approach and rationale of our recent study on the selection of a panel of 
circulating miRs in patient samples [22]: Six miRs were selected based on the following 
criteria in order of priority: (a) abundance of the miR: Measurable levels in the plasma be-
fore and after treatment; (b) references in the published literature that relate the respective 
miR to breast cancer and/or to FGF, VEGF or PDGF signaling, i.e. the pathways targeted 
by dovitinib; (c) detectable change relative to dovitinib treatment by at least threefold up 
or down. The workflow of the miR analysis is shown in Fig. 1c. To support the selection 
of a small panel of miRs, a screen for 379 miRs and U6 was run on paired plasma samples 
that were obtained before and after treatment of a patient that was randomly selected and 
also contained sufficient amounts of U6 for the assay. In this qRT-PCR based miR expres-
sion array, 135 of 379 miRs were detectable above the threshold expression level in samples 
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collected before and after dovitinib treatment (Additional file 1: Table S1). After data nor-
malization using the mean expression value of all miRs detectable in the respective samples, 
60 miRs showed a down-regulation and 33 miRs an upregulation of at least threefold after 
Table 1. Patients with hormone positive metastatic breast cancer treated with dovitinib.
pt # age
index 
lesion 
tumor size 
at baseline
aromatase 
inhibitor
total #
cycles of
dovitinib
dovitinib
dose AE after first cycle
change in 
tumor size 
after 8 w 
dovitinib
sites of 
metastases
001 61 6.5 cm Exemestane 6 500 mg
fatigue
GI: nausea, dry mouth
Neuromusc: myalgia, 
dizziness
- 9.23%
lymph 
nodes, bone, 
skin/soft 
tissue
002 32 15 cm Anastrozole 1 500 mg
fatigue
GI: nausea, vomiting, 
diarrhea, dehydration, 
poor appetite,
Neuromusc: headaches,
blurred vision, 
lightheadedness,
Liver: ALP↑
+ 6.0%
lymph 
nodes, lung, 
bone
004 65 2.9 cm Letrozole 2 400 mg
fatigue, hypertension, bone 
pain,
GI: anorexia, nausea, 
dyspepsia
+ 24.14% lung, liver
005 58 5.7 cm Exemestane 3 400 mg
fatigue,
GI:, nausea, vomiting, 
anorexia, dysgeusia,
Neuromusc: muscle 
weakness
Liver: ALP↑ , AST↑
+ 24.56%
lymph 
nodes, soft 
tissue, liver
101 64 1 cm Anastrozole 4 500 mg
serum amylase↑, 
creatine↑, magnesium↑
Liver: GGT↑
- 30.0% lymph nodes, bone
102 57 4.8 cm Letrozole 2 400 mg GI: nausea,Liver: GGT↑ 0%
lymph 
nodes, bone
103 52 13.1 cm Anastrozole 7 400 mg
GI: diarrhea,
Neuromusc: backpain,
Liver: GGT↑, ALT↑, ALP↑
- 21.37%
lymph 
nodes, bone, 
pleura, liver
301 51 1 cm Letrozole 3 400 mg
hypokalemia
GI: diarrhea, dyspepsia
Neuromusc: arthralgia,
Liver: triglycerides↑, 
ALT↑, ALP↑, GGT↑ 
Anemia, Cholesterol↑
+ 10% lung
pt, patient; cm, centimeter; mg, milligram; AE, adverse events; GI, gastro-intestinal; Neuromusc, neu-
romuscular; PD, progressive disease;
ALP, alkaline phosphatase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transpeptidase; AST, 
aspartate aminotransferase; w, weeks.
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the treatment. Six circulating miRs i.e. miR-21-5p, miR-100-5p, miR-125b-5p, miR-126-3p, 
miR-375 and miR-424-5p were selected based on the three criteria that were outlined above. 
Th e expression of the 6 miRs was then measured by qRT-PCR before and aft er dovitinib 
in all patients. Th e change in expression aft er treatment relative to baseline is shown in 
Fig. 2. A > 100-fold concentration range of these six miRs was found in the circulation of 
the patients. Th e response to dovitinib was distinct amongst patients indicating diff erential 
drug eff ects between patients.
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Figure 1. Breast cancer lesion sizes, treatment responses and design of the miR analysis.
a. Patient numbers are color coded to indicate changes in tumor sizes after 8 weeks of treatment (red = 
increase, green = decrease, grey = no change). The sizes of the index lesions were measured by CT before 
treatment with dovitinib (baseline).
b. Change in tumor size of the index lesion during the course of dovitinib treatment.
c. Flow chart of plasma miR analysis design. From a genome wide miR expression array with samples 
collected before and after dovitinib treatment in a single patient, 6 signature miRs were selected and 
tested for their indication of a dovitinib response in 8 patients. Further criteria for selection of the miRs 
are provided in the ‘Results’ section.
Chapter 5 133
Plasma mir levels as indicators of response to dovitinib treatment
To evaluate whether the circulating miRs could indicate patient’s responses based on the 
change in expression aft er dovitinib, we used principal component analyses (PCA) and 
clustering analysis. Th e PCA in Fig. 3a indicates the pattern changes per patient changes 
based on the miR levels before and aft er the initial dovitinib treatment (4–8 weeks). Th e 
closed circles in the PCA (Fig. 3a) indicate the expression signature of six miRs at baseline 
per patient. We found three categories of patients based on the change in miR levels aft er the 
initial dovitinib treatment as indicated by the direction of the arrows pointing from baseline 
to post treatment. A cluster analysis of miR patterns (Fig. 3b) separated the patients into 
two major
groups with one group split further into two subgroups (P < 0.05). PCA and cluster analyses 
of miR expression patterns were carried out by investigators that were blinded to the disease 
outcome. Aft er completion of these analyses, the patient treatment responses were matched 
to the miR response data and are shown with a color code indicative of treatment responses 
(see Fig. 1b). Th e three patients with tumors that were resistant to dovitinib treatment 
pl
as
m
a 
m
iR
 e
xp
re
ss
io
n 
[fo
ld
]
(U
6 
an
d 
pr
e-
tre
at
m
en
t n
or
m
al
iz
ed
)
100
10
1
0.01
0.1
plasma miRs after dovitinib treatment
patient number and treatment timing
00
1-
4w
00
1-
16
w
00
1-
20
w
00
2-
4w
00
2-
8w
00
4-
4w
00
5-
4w
10
1-
8w
10
2-
4w
10
3-
4w
10
3-
8w
10
3-
24
w
30
1-
8w
miR-125b-5p
  miR-126-3p
miR-21-5p
miR-375
miR-424-5p
miR-100-5p
Figure 2. Eff ect of dovitinib treatment on plasma miR levels of patients with metastatic breast cancer. 
MiRs were measured in plasma samples of patients collected before and after dovitinib treatment. The 
change in expression levels of six miRs relative to U6 in eight patients at diff erent treatment times (in 
weeks; w) is shown. The dashed lines indicate two fold up- or down-regulation of miR expression levels 
after treatment. The numbers on the x-axis indicate the patients. The color code of patients indicates 
changes in tumor sizes during treatment (red = increase, green = decrease, grey = no change).
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showed distinct changes of plasma miR expression in the PCA and in the cluster analysis 
relative to patients with stable disease or tumor regression in the fi rst 8 weeks. Interestingly, 
the baseline miR signatures did not separate responding from non-responding patients 
(closed circles in Fig. 3a). Moreover, no relationship was found between the adverse eff ects 
of dovitinib listed in Table 1 and the changes in miR patterns aft er dovitinib.
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Figure 3. Expression patterns of circulating miRs separate patients based on the response to dovitinib 
treatment. a. Principal component analysis of the expression of six miRs before treatment (closed cir-
cles) and after treatment (open circles): patients 001, 002, 004, 005, 102, 103: 4 weeks; patients 101, 301: 
8 weeks. The arrows indicate the before-to-after direction of the change. Patients that are separated by 
color code to indicate changes in tumor sizes after 8 weeks treatment (red = increase, green = decrease, 
grey = no change). b. Cluster analysis of the miR expression changes after 4 or 8 weeks treatment with do-
vitinib. The dashed line indicates signifi cant diff erences (Euclidian distance) between 3 patient groups. 
c. Changes in six circulating miRs early after dovitinib treatment (4 weeks, except patient 101 and 103 at 8 
weeks) based on tumor responses. The fold change in expression after treatment relative to U6 is indica-
ted. Error bars = SEM, *P < 0.05; **P = 0.0032; ***P = 0.0006 by unpaired t-test. d. Principal Component 
Analysis of the changes in expression of six miRs after dovitinib at multiple time points. The red circle 
includes patients with dovitinib resistant tumors. Patient 103 at 24 weeks is the exception in this group.
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A comparison of the changes in miR expression after initial treatment in patients with 
tumor progression (n = 3) versus patients with stable disease or tumor regression (n = 5) 
shows that 5 out of 6 miRs were differentially expressed. In patients with treatment-resistant 
tumors relative to patients with stable disease or sensitive tumors miR-125b-5p, -126-3p, 
-375, 424-5p, and -100-5p were significantly down-regulated after the initial dovitinib treat-
ment (Fig. 3c). This suggests that miR patterns after initial treatment can serve as response 
indicators. This could then support a decision to continue or terminate a planned treatment. 
For example, patient 001 showed a 9.23% reduction in tumor size after 2 cycles of dovitinib. 
However, acquired resistance became evident on the CT measurements at 24 weeks (see 
Fig. 1b). The lack of a response based on CT measurements is obvious at 24 weeks but was 
already evident based on the circulating miR patterns at 16 weeks, as seen in the PCA (Fig. 
3d). Additionally, patient 103 had a long-term anti-tumor response to dovitinib (Fig. 1b). 
However, when this anti-tumor response began to diminish at 24 weeks, the circulating 
miR pattern was already similar to that of the resistant group of patients (Fig. 3d). Thus, the 
change in expression levels of six miRs selected here may serve as biomarkers of anti-tumor 
responses during treatment with a TKI in patients with metastatic breast cancer.
DIsCussIon
Here we report that distinctly altered patterns of circulating miR expression are observed 
in patients after treatment with dovitinib. Plasma miRs have a major potential as cancer 
biomarkers [30,32-34]. MiRs are deregulated as a result of the uncontrolled cell prolifera-
tion, stromal remodeling and immune regulation that define cancer and are stably exported 
into the circulation. Distinct alteration in circulating miRs reflects dysregulation of cell 
growth and stroma recruitment and the impact of therapy. Generally speaking, the six miRs 
selected as potentially informative miRs for a dovitinib effect will reflect the effects of the 
drug on the host as well as on the tumor and serial blood sampling relative to treatments 
may capture the dynamics of these events.
The function of the five miRs that show a significant change in dovitinib-responsive tu-
mors (Fig. 3c) and a possible relation with drug efficacy is discussed next. Recent work 
indicates that elevated miR-125b expression predicts poor prognosis in breast cancer and 
is a candidate therapeutic target in AI-resistant breast cancers [35]. Interestingly, miR-125b 
expression is transiently induced in endothelial cells upon stimulation with VEGF or by 
ischemia [36]. Also, miR-125b inhibits translation of vascular endothelial (VE)-cadherin 
mRNA, in vitro tube formation by endothelial cells, and induced nonfunctional blood ves-
sel formation in vivo resulting in inhibition of xenograft tumor growth [36]. This matches 
with an antiangiogenic effect of dovitinib treatment expected from an inhibitor that targets 
FGF and VEGF pathways.
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MiR-126 is considered the prototype of an endothelial-specific miRNA. VEGF-A is a target 
for miR-126 and studies suggested that miR-126 could suppress tumor growth and tumor 
angiogenesis through VEGF-A signaling [37,38]. Others described miR-126 as an inde-
pendent suppressor of the sequential recruitment of mesenchymal stem cells and inflam-
matory monocytes into breast cancer stroma to inhibit lung metastasis [39]. This study 
also demonstrated a correlation between miR-126 downregulation and poor metastasis-free 
survival of breast cancer patients [39]. The expression of miR-126 has been shown to be 
downregulated in breast metastases [40], as well as different cancers acting as a tumor sup-
pressor by inhibiting tumor growth [41,42]. The treatment related upregulation in patients 
with dovitinib-responsive tumors fits with this role of miR-126.
Circulating miR-375 is negatively correlated with disease relapse and resistance to neoad-
juvant chemotherapy in stage II–III breast cancer patients [43]. Wu et al. also identified 
miR-375 as the most significantly different miRNA, whose prevalence in the circulation 
appeared to reflect better clinical outcome of breast cancer [43]. miR-424 was reported to 
directly control the expression of FGFR1 and MAP2K1 in the human trophoblast through a 
discrete 3’UTR site [44]. Thus, the increase observed in patients with dovitinib-responsive 
tumors suggests a relationship between the altered circulating miR-424 levels and the ef-
ficacy of dovitinib towards one of its known targets, the FGF receptor pathway.
MiR-100 was the most differentially upregulated miR in patients with dovitinib-responsive 
tumors (Fig. 3c). It has been shown that miR-100 inhibits the maintenance and expansion 
of breast cancer stem cells in basal-like cancer and plays a role in cancer free-survival, as 
confirmed by a cohort analysis of patient tumors implicating low expression of miR-100 as 
a negative prognostic factor [45]. Thus, the upregulation in patients with treatment respon-
sive tumors matches with the role ascribed to this miR.
Given the complex interplay of cancer and stroma that includes distinct drivers in different 
cancers as well as genetic and environmental differences in the patient, analysis of patterns 
of miRs can provide a more reliable read-out than individual miRs and will compensate for 
this heterogeneity. Also, rather than evaluating absolute levels of single miRs in patients 
with different genetic backgrounds, co-morbidities and lifestyle, our study suggests that 
it is more informative to evaluate changes in the expression patterns of a set of miRs due 
to therapy and during the course of the disease. Here, we assessed miR expression pattern 
changes in response to therapy, and evaluated whether this differs amongst patients with 
different courses of their disease.
As a caveat, the small size of the current study limits the potential for general conclusions. 
However, we have attempted to follow the guidelines of McShane et al. [46] and were sur-
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prised by the robustness of the relationship between the change in tumor size and circulating 
miR pattern changes. Rather than trying to find a correlation between miR pattern changes 
and cancer lesion treatment responses we opted to use the miR pattern changes to assign 
patients to different response groups in an analysis of miRs that was blinded to the patient 
outcome. This blinded assignment of patients to distinct response groups also strengthens 
the conclusions one can draw from the findings.
In conclusion, altered patterns of serially analyzed circulating miR expression patterns can 
indicate the impact of treatment on the whole organism as well as cancer lesion. Changes in 
the pattern changes after treatment will be informative on the potential long-term benefit 
of the therapy and thus can provide an early decision point for continuation of a given 
treatment [15]. The current study suggests that the use of circulating miRs for treatment 
monitoring could be useful in treatment decisions though a prospective trial will be neces-
sary to unanimously confirm the utility of the approach described here.
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Supplemental Table 1. Genome wide miR expression screen before and after dovitinib treatment. An 
RT-qPCR assay was performed on a paired set of one patient’s (#101) plasma samples. Abundant miRs 
with cycle numbers (Ct) below 32 are listed.
Ct before treatment Ct after treatment
mean Ct value 26.08 28.76
miR
hsa-let-7a-5p 21.18 28.84
hsa-let-7b-5p 21.13 29.23
hsa-let-7c 24 27.32
hsa-let-7d-3p 24.98 30.29
hsa-let-7d-5p 23.88 28.66
hsa-let-7e-5p 23.34 30.57
hsa-let-7f-5p 22.39 28.14
hsa-let-7g-5p 23.18 28
hsa-let-7i-5p 24.69 30.52
hsa-miR-1 26.26 29.68
hsa-miR-100-5p 25.84 25.96
hsa-miR-101-3p 28.89 31.75
hsa-miR-105-5p 23.97 28.92
hsa-miR-106b-5p 25.34 29.53
hsa-miR-107 28.24 31.2
hsa-miR-1180 28.44 30.7
hsa-miR-122-5p 24.41 29.22
hsa-miR-124-3p 30.76 29.45
hsa-miR-125a-5p 24.19 30.75
hsa-miR-126-3p 22.06 28.27
hsa-miR-126-5p 21.01 25.53
hsa-miR-127-3p 26.79 24.73
hsa-miR-128 27.53 30.96
hsa-miR-1290 27.65 30.44
hsa-miR-130a-3p 26.20 29.52
hsa-miR-130b-3p 30.16 28.34
hsa-miR-132-3p 28.72 30.42
hsa-miR-132-5p 18.40 22.68
hsa-miR-134 28.10 25.74
hsa-miR-135a-5p 26.52 28.35
hsa-miR-142-3p 26.69 26.95
hsa-miR-142-5p 29.40 30.56
hsa-miR-144-3p 23.24 28.89
hsa-miR-144-5p 28.05 30.54
hsa-miR-146a-5p 23.17 28.52
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Supplemental Table 1. Genome wide miR expression screen before and after dovitinib treatment. An 
RT-qPCR assay was performed on a paired set of one patient’s (#101) plasma samples. Abundant miRs 
with cycle numbers (Ct) below 32 are listed. (continued)
Ct before treatment Ct after treatment
hsa-miR-146b-5p 25.78 30.07
hsa-miR-148a-3p 25.57 28.82
hsa-miR-148b-3p 25.73 30.86
hsa-miR-150-5p 23.16 24.2
hsa-miR-151a-3p 24.99 30.77
hsa-miR-151a-5p 26.59 30.68
hsa-miR-152 27.94 31.8
hsa-miR-155-5p 27.62 30.84
hsa-miR-15b-3p 26.59 30.58
hsa-miR-15b-5p 30 28.89
hsa-miR-16-5p 20.35 25.82
hsa-miR-17-5p 25.37 30.13
hsa-miR-181a-5p 30.10 28.25
hsa-miR-181c-3p 27.52 26.2
hsa-miR-183-3p 29.46 24.87
hsa-miR-185-5p 24.96 29.12
hsa-miR-186-5p 23.05 26.68
hsa-miR-187-5p 29.66 28.44
hsa-miR-18a-3p 27.53 30.61
hsa-miR-18a-5p 25.86 29.3
hsa-miR-18b-5p 26.56 30
hsa-miR-191-5p 22.90 26.49
hsa-miR-192-5p 28.10 30.63
hsa-miR-193a-5p 28.23 31.38
hsa-miR-194-5p 28.82 31.82
hsa-miR-195-5p 20.69 25.43
hsa-miR-197-3p 24.89 30.34
hsa-miR-199a-3p 23.43 29.72
hsa-miR-19a-3p 24.67 30.01
hsa-miR-19b-3p 24.57 28.62
hsa-miR-200b-3p 29.35 28.78
hsa-miR-200c-3p 29.95 29.95
hsa-miR-200c-5p 28.11 28.87
hsa-miR-205-3p 31.50 28.2
hsa-miR-20a-5p 24.31 30.28
hsa-miR-20b-5p 25.46 31.56
hsa-miR-21-5p 20.53 22.91
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Supplemental Table 1. Genome wide miR expression screen before and after dovitinib treatment. An 
RT-qPCR assay was performed on a paired set of one patient’s (#101) plasma samples. Abundant miRs 
with cycle numbers (Ct) below 32 are listed. (continued)
Ct before treatment Ct after treatment
hsa-miR-210 31.13 30.21
hsa-miR-22-3p 23.56 18
hsa-miR-22-5p 28.9 30.72
hsa-miR-221-3p 20.89 25.28
hsa-miR-221-5p 31.13 31.18
hsa-miR-222-3p 26.92 30.08
hsa-miR-223-3p 20.93 25.44
hsa-miR-223-5p 27.47 30.39
hsa-miR-23b-3p 24.68 30.7
hsa-miR-24-3p 22.73 28.22
hsa-miR-25-3p 22.19 25.1
hsa-miR-25-5p 28.73 30.21
hsa-miR-26a-5p 22.54 28.48
hsa-miR-26b-5p 23.99 30.02
hsa-miR-27a-3p 24.28 30.39
hsa-miR-27b-3p 23.96 31.57
hsa-miR-28-3p 28.58 28.57
hsa-miR-29a-3p 27.09 28.32
hsa-miR-30a-5p 25.49 30.78
hsa-miR-30c-5p 24.43 30.2
hsa-miR-30d-5p 24.70 29.46
hsa-miR-30e-3p 26.54 31.72
hsa-miR-30e-5p 25.31 28.94
hsa-miR-31-5p 31.75 30.52
hsa-miR-320a 22.70 27.08
hsa-miR-320b 26.99 28.49
hsa-miR-324-5p 28.80 30.8
hsa-miR-328 27.10 25.24
hsa-miR-330-3p 30.11 28.12
hsa-miR-342-3p 24.57 26
hsa-miR-34c-3p 30.18 31.46
hsa-miR-34c-5p 30.76 32
hsa-miR-361-5p 26.24 31.96
hsa-miR-370 28.46 27.48
hsa-miR-373-5p 28.32 31.92
hsa-miR-374b-5p 24.95 30.92
hsa-miR-375 28.81 28.46
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Supplemental Table 1. Genome wide miR expression screen before and after dovitinib treatment. An 
RT-qPCR assay was performed on a paired set of one patient’s (#101) plasma samples. Abundant miRs 
with cycle numbers (Ct) below 32 are listed. (continued)
Ct before treatment Ct after treatment
hsa-miR-382-5p 26.41 31.61
hsa-miR-411-5p 30.34 24.96
hsa-miR-421 28.64 26.86
hsa-miR-423-3p 27.85 31.73
hsa-miR-424-5p 27.03 27
hsa-miR-431-5p 28.45 25.94
hsa-miR-433 27.18 23.85
hsa-miR-451a 20.63 25.1
hsa-miR-484 24.07 28.61
hsa-miR-486-5p 19.30 24.83
hsa-miR-489 25.67 20.59
hsa-miR-495-3p 26.41 24.73
hsa-miR-497-5p 30.11 30.95
hsa-miR-539-5p 29.31 21.08
hsa-miR-551b-3p 31.74 30.66
hsa-miR-652-3p 24.95 31.68
hsa-miR-661 28.82 27.68
hsa-miR-7-5p 25.79 30
hsa-miR-720 23.97 31.37
hsa-miR-744-5p 24.12 30.61
hsa-miR-92a-3p 21.04 27.99
hsa-miR-92b-3p 27.24 30.67
hsa-miR-93-5p 25.75 28.65
hsa-miR-99b-5p 28.62 31.29
RNU6-2 27.26 30.76
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suMMAry AnD DIsCussIon
As early as 1976 scientists noted that genomic instability of a proliferating cancer popula-
tion is followed by additional genetic diversity under the selection pressures in the tumor 
environment, resulting in multiple heterogeneous subpopulations [1]. Cancer heterogeneity 
is the main cause of drug therapy resistance. Therefore, we conducted a study that could 
provide insights for the improvement of effective cancer therapies, described in chapter 
2. We generated a model of cancer heterogeneity by isolating and characterizing clonal 
cancer cell lines from a transgenic LSL-KrasG12D/+; LSL-Trp53R172H/+; P48-Cre (KPC) mouse 
pancreatic cancer (PDAC). We found that the clonal cell lines from the same tumor harbor 
common ancestor mutations and more importantly, each have a set of unique signature 
mutations. Not only do these clonal cell lines grow at different rates in vitro, their sensitivity 
to anti-cancer drugs of various mechanisms of action was distinct.
The novelty of our study lies in the fact that we can mix the clones back together and 
study their drug sensitivity in the context of a heterogeneous population where paracrine 
crosstalk is possible. The unique clonal mutations are used for the measurement of clone 
abundance in the mixed tumors by next generation sequencing (NGS). Although each clone 
is driven by the RAS-RAF-MEK-ERK signaling pathway due to the Kras G12D mutation, 
the clones are differentially sensitive to the MEK inhibitor trametinib on their own. What 
was even more striking is that the clonal sensitivity to trametinib in vitro was altered when 
clones were mixed back together and thus subjected to paracrine signaling. This finding 
was confirmed when using the conditioned media from the clone mixture, and shows that 
pharmacological screenings in vitro using cell lines such as the NCI-60 panel should rather 
be performed in heterogeneous mixtures of cell lines to improve the predictive validity.
We studied the clone mixture as allograft tumors in immune competent syngeneic mice, 
and noticed a difference in growth rate amongst the clones. Moreover, gemcitabine treat-
ment had a stimulating effect on the slow growing clones C5 and D10 that were underrep-
resented in control tumors. Gemcitabine treatment allowed these clones to gain a 4-5 fold 
increase in growth as compared to the control conditions. Others reported similar findings 
in minor dormant human colorectal cancer clones that can become dominant and reinitiate 
tumor growth after chemotherapy [2]. Strikingly, two other clones that were sensitive to 
gemcitabine in vitro, were not responding to gemcitabine in the mixed tumors in presence 
of tumor stroma. This suggests that the crosstalk with the tumor stroma offers paracrine 
factors that protect these clones from the chemotherapy.
A comparison of clonal effects of MEK inhibitor in the mixed culture in vitro and in the tu-
mors showed a discordant result for clone G9 that moved from sensitive in vitro to resistant 
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in the tumors and clone C8 that moved in the opposite direction. Others have also described 
that the tumor environment alters the drug sensitivity of cancer cells [3,4]. Yet, until now, 
most cancer drug screens are performed in vitro, or in xenograft tumors with homogeneous 
cancer cell lines in immune compromised animals.
The beauty of our clonal allograft model lies in the fact that it allows for analyses of het-
erogeneous tumors in the context of an intact immune system. The striking differences in 
α-PD-1 efficacy towards clones present in the heterogeneous tumor mix which we observed 
in our study provides some interesting insights that may allow to overcome resistance to 
checkpoint blockade. One of the clones, C8 is highly sensitive to α-PD-1 treatment and on 
its own attracts the highest number of CD8+ PD-1+ T-lymphocytes towards the tumors. 
We conducted a co-culture experiment in vitro with primed mouse T-lymphocytes and 
the clonal PDAC cell lines to corroborate this finding. In order to generate enough vital 
T-cells we used the caecal patches of tumor bearing mice as source of tumor-reactive T-cells, 
instead of the commonly used tumor infiltrating lymphocytes which are often exhausted 
[5]. We observed that the pancreatic cancer clones elicit different levels of T-cell activation, 
measured by Interferon-γ secretion. Strikingly, growth of one clone, D10 was stimulated 
in vivo by anti-PD-1 treatment and we are currently exploring this further. Moreover, we 
found that that the caecal patch, the equivalent of the human vermiform appendix [6,7], 
contains pancreatic cancer reactive T-cells. We are the first to have shown this and we are 
currently exploring the reactivity of T-cells from the vermiform appendix of patients with 
locally advanced pancreatic cancer.
To conclude chapter 2, we found that the composition of heterogeneous cancers is affected by 
crosstalk amongst the cancer subpopulations as well as the host environment that includes 
the immune system as a major player. We developed an in vivo model that allows for the 
quantitation of clonal cancer subpopulations in heterogeneous tumors, growing in immune 
competent. Our model is suited for the assessment of stromal and immune modulators and 
their impact on growth of heterogeneous cancer cells.
Cancer is a heterogeneous and dynamic disease. Yet, until today, molecular analyses of 
cancer are still performed using small tissue biopsies. In chapter 3 we sought to assess the 
changes in the mutational makeup of colon and pancreatic adenocarcinoma between the 
time of primary tumor surgery and detection of metastatic disease using circulating cell free 
DNA. In this study we also provide a direct comparison of mutation detection in primary 
tumor DNA and plasma DNA at diagnosis. For this, amplicons covering 263 mutations in 
56 cancer-associated genes were analyzed by next generation sequencing. We found that 
on average less than half of colon tumor mutations were detected in the plasma at time of 
diagnosis. For pancreatic cancer this percentage was even lower: less than 30% of pancreatic 
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tumor mutations were detected in the circulating DNA. Whether ctDNA can fully replace 
or complement tissue analyses in all cancer types remains controversial, especially in early 
stage diseases.
Disadvantages of circulating tumor DNA (ctDNA) include the fact that high background 
levels of wildtype DNA can lead to missed ctDNA detection. Also, the genetic make-up of 
dying cells is dominant in ctDNA, and that of vital tumor cells may be underrepresented. 
Others have shown that in formalin fixed-paraffin-embedded cancer tissues and plasma 
from patients with different types of cancer an overall concordance of 60% in mutations 
of 19 genes analyzed was found [8]. Another prospective study with matched plasma and 
tissue samples of 75 cancer patients with different tumor types (61 metastatic and 14 clinical 
stage II patients) looked at 54 genes with digital deep sequencing technology. In the tumor 
tissues, at least one somatic mutation in 44 of 61 samples (72.1%) was found. From those 44 
tissue samples with mutations, ~66 % of the matched patients had detectable mutations in 
the plasma DNA [9]. The sensitivity of ctDNA mutation detection improves as the tumor 
load increases. An extensive study including different cancer types showed that the fraction 
of patients with mutant ctDNA increases with cancer stages: 47% of patients with stage I 
cancers of any type had detectable ctDNA, whereas the fraction of patients with detectable 
ctDNA was 55%, 69%, and 82% for patients with stage II, III, and IV cancers, respectively 
[10].
On the other hand, we detected 71-78% of mutations in the plasma DNA of patients at time 
of diagnosis that were not detected in the tumor tissue. One reason for the discordance is 
the small size of the tumor biopsy. The tumor biopsies are merely a tiny fraction of the entire 
heterogeneous tumor. Moreover, the patients may already have micrometastases that are 
not detected on the CT scans, but already release mutant DNA in the circulation. Overall 
the presence of ctDNA in patients with progressive cancer provides a median lead-time of 
detection of 8-9 months over computed tomography (CT) scans [11,12]. A recent study 
in patients with non-small cell lung cancer patients revealed that 18 patients had detect-
able EGFR T790M ctDNA in their plasma, while the tumor DNA was negative for EGFR 
T790M genotyping [13]. This demonstrates that tissue biopsies may not represent the entire 
cancer cell population, or result in false negative mutation results due to low abundance of 
cancer cells in the specimen. One of the caveats is that circulating DNA mutations may not 
originate from cancer cells. It is worth noting that somatic mutations found in skin biopsies 
from healthy individuals can approach the mutation levels seen in cancers [14], however, 
mutant DNA from healthy tissues is typically below detection in the circulation. This is 
likely due to the induction of senescence in normal cells with mutant DNA rather than 
cell death and shedding of their DNA, and the low frequency of mutations at a variety of 
random sites in the genome. Cancer cells on the other hand are highly abundant, and often 
152  Summary and Discussion
have non-synonymous mutations. More importantly, cancer cells have a high turnover rate 
and thus a high death rate.
We assessed the change in mutations from the time of primary resectable cancer diagnosis 
to the recurrence of cancer after surgical tumor removal and adjuvant therapy in patients 
with colon and pancreatic cancer. This analysis reflects the evolution of primary to recur-
rent cancer. After metastasis, new ctDNA mutations are gained both in colon (33.8%) and 
pancreatic cancer (62.6%) and were not detected at the time of diagnosis of the primary 
cancer. Complementary to the gain of mutations after metastasis, we also observed a loss 
of approximately half of the ctDNA mutations. The analysis of a relatively broad panel of 
cancer-related genes is feasible for ctDNA and would allow monitoring of changes in the 
molecular makeup over time and under therapy.
Summarizing chapter 3, we found that circulating tumor DNA appears to represent the 
heterogeneity of colon and pancreatic cancer more extensively than tumor tissue DNA. By 
comparing the evolution of mutant ctDNA over the course of treatment, emergence of mu-
tations that are associated with therapy-resistant cancer can be studied easily by collecting 
repeated patient blood samples. It is highly likely that liquid biopsies will become essential 
in cancer patient diagnostics and follow-up in the very near future.
Until now, the clinical follow up of patients with pancreatic cancer after surgery is not 
standardized in the Netherlands and consists mainly of clinical physical examination and 
at times radiographical imaging by CT-scans [15]. Simple repeated blood draws followed 
by biomarker analyses could vastly improve patient monitoring and prediction of outcome. 
Circulating microRNAs (miRs) are suitable candidates due to their high stability in the 
circulation and their importance in pathophysiology. In chapter 4 we measured serum 
miRs in patients with treatment-naïve resectable PDAC before and after surgical tumor 
removal and compared the changes of miR levels to the progression free survival of the 
patients. Importantly, we performed a cross-species comparison of serum miR expression: 
we analyzed the serum miR levels in KPC mice that develop metastatic pancreatic cancer. 
The prognostic miRs we identified in the patients were also correlated to PDAC metastases 
in the KPC mice, confirming their importance in pancreatic cancer progression. From the 
250 miRs we profiled, the expression levels of only miR-125b-5p and miR-99a-5p could 
significantly separate patients based on progression free survival after surgery.
Next, we assessed whether miR-125b and miR-99a-5p are expressed in the resected pancre-
atic cancer tissues by using in situ hybridization. To our surprise, the cells that express the 
miRs are very low abundant, and are only present in the pancreatic stroma. It is becoming 
increasingly clear that circulating miRs represent a rich source of information about the 
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status of the immune system. MiRs in the serum originate mainly from endothelium and 
blood cells [17,18]. The circulating miRs are transferred from cell to cell and can elicit im-
mune modulation [19,20]. Serum miRs interact more with immune-related mRNA genes 
that with non-immune related genes [21]. We found that the high miR-125b-5p and miR-
99a-5p expressing cells are limited to inflammatory infiltrates in the connective tissue of 
the pancreatic tumors. After staining the consecutive tumor sections for CD79A we found 
that the high miR-125b-5p and miR-99a-5p expressing cells are in very close proximity 
to CD79A positive cells which are part of the B-lymphocyte lineage. This underlines the 
importance of circulating microRNAs in the host response to cancer. Our future aim is 
to conduct a histopathological validation to study the co-localization of miR-125b-5p and 
miR-99a-5p in various subtypes of immune cells to gain understanding in the immune cell 
function alterations in patients with cancer.
Although there are a multitude of studies comparing circulating miR levels in pancreatic 
cancer patients to healthy controls [22,23], there has been very little to no research that 
compares the levels of miRs after surgical removal of primary pancreatic cancers. In our 
study we compared serum miRs pre and post-surgery from treatment-naïve patients that 
were operated at the Erasmus Medical Center between 2013 and 2017. Recently it became 
clear that patients with (borderline) resectable PDAC that undergo preoperative chemo/
radiotherapy have a better survival [24,25]. From now on all patients with (borderline) 
resectable PDAC in the Netherlands will be offered to receive preoperative chemotherapy, 
if the performance status of the patient permits the therapy, and the patient is willing to 
undergo systemic treatment. Chemotherapy has a vast impact on the immune landscape 
[26,27]. Whether serum miR-125b-5p and miR-99a-5p are also predictive of disease pro-
gression after surgery in pre-treated patients remains to be evaluated. Therefore we are cur-
rently collecting blood samples to evaluate the changes in the serum miRs of patients with 
(borderline) resectable patients who undergo pre-operative FOLFIRINOX chemotherapy 
or gemcitabine/radiotherapy.
In Chapter 5 we analyzed plasma miRs in patients with hormone receptor positive, meta-
static breast cancer with prior disease progression during aromatase inhibitor therapy in a 
phase I/II trial with the multiple tyrosine kinase inhibitor dovitinib. The dual inhibition of 
FGF and VEGF signaling by dovitinib enhances the antitumor effects through the targeting 
of immune evasion and angiogenesis in the tumor microenvironment [28]. We hypoth-
esized that expression of circulating miRs can provide an accurate read-out of these effects 
of dovitinib. Changes in plasma miR levels were measured by quantitative RT-qPCR before 
and after treatment with dovitinib and compared to changes in tumor sizes. The altered 
expression patterns observed for the six circulating miRs (miR-21-5p, miR-100-5p, miR-
125b-5p, miR-126-3p, miR-375 and miR-424-5p) separated patients with resistant disease 
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from those with drug responsive disease. What was striking is that in a patient with long 
term response to dovitinib we observed a change in the circulating miR signature before 
the CT scan showed a reduced effect of the treatment at 24 weeks. Although this study 
consisted of a low number of patients, we conclude that changes in the expression patterns 
of circulating miRs can be indicators of dovitinib response, and this research merits the 
understanding of the host response to metastatic cancer.
ConClusIons
The research in this thesis provides rationale for the implementation of circulating nucleic 
acid analyses into the standard of care of patients with cancer. Until now, cancer tissue 
specimens are used for molecular analyses of cancer, and clinical follow-up consists mainly 
of radiographical imaging. Cancer is a heterogeneous, dynamic disease that constantly 
changes over time and across different locations in the body. To improve our understanding 
in the molecular features of this disease as well as the response to cancer therapy, blood 
samples need to be taken repeatedly and analyzed for changes in circulating nucleic acids. 
Changes in circulating DNA mutations indicate clonal evolution of cancer populations 
and altered abundance of mutant circulating DNA suggests a change in disease burden. 
Moreover, changes in circulating DNA mutations reflect the emergence of resistant clones 
and prompt changes in treatment. In contrast to mutant DNA, circulating microRNAs take 
part in the extracellular crosstalk between cells and provide a readout of the organism’s 
physiologic or disease state. Furthermore, changes in circulating miR patterns can reflect 
the immune landscape, treatment efficacy or resistance as well as adverse effects associated 
with the respective intervention. Thus, the combined serial analysis of mutant DNA and 
microRNAs in the circulation has the potential to provide a molecular footprint of cancer 
and can be used to monitor cancer progression as well as treatment responses in real time 
with a minimally invasive procedure.
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Kanker bestaat uit een groot aantal cellen met een verschillende genetische en fenotypische 
eigenschappen. De cellen vermenigvuldigen zich snel en er komen steeds nieuwe DNA mu-
taties bij doordat de tumor omgeving cellen selecteert met een gunstigere set eigenschappen 
voor overleving. Als kanker cellen zich verspreiden over het lichaam zijn er nieuwe omge-
vingsfactoren waardoor er weer andere kanker cellen overleven. De diversiteit aan kanker 
cellen binnen een patient heet tumor heterogeniteit.
Tumor heterogeniteit is de grootste oorzaak van kanker therapie falen. In hoofdstuk 2 
hebben we een muismodel van tumor heterogeniteit ontwikkeld om de invloed van tumo 
heterogeniteit op therapie resistentie te bestuderen. Hiervoor hebben we klonale kanker 
cellijnen uit een alvleesklier tumor gegenereerd van een transgene LSL-KrasG12D/+; LSL-
Trp53R172H/+; P48-Cre (KPC) muis die alvleesklier kanker ontwikkeld heeft. We hebben 
ontdekt dat deze klonale cellijnen in cel kweek elk een unieke set aan DNA mutaties hebben, 
verschillende groeisnelheden vertonen en verschillend reageren op kanker medicijnen.
De innovatie in onze studie ligt in het feit dat we de klonale cellen weer bij elkaar kunnen 
mengen en in de heterogene groep kunnen volgen door hun unieke DNA mutaties te meten 
met next generation sequencing. De klonale cellijnen reageren verschillend op een medicijn 
dat de belangrijke kanker-geassocieerde MEK pathway remt. Maar als de klonale cellijnen 
samen bij elkaar groeien, verandert de gevoeligheid van de klonale cellen voor de MEK 
remmer. Dit betekent dat de kanker cellen signalen met elkaar uitwisselen waardoor ze 
anders reageren op medicijnen. Daarom is het belangrijk dat medicijn screenings uitge-
voerd worden op mengsels van verschillende kanker cellen, zodat een tumor beter word 
nagebootst.
Als we de klonale cellijnen gemengde tumoren laten vormen in de omgeving van fibrotisch 
bindweefsel en een intact immuun systeem in syngenetische muizen, vinden we dat de 
klonale cellijnen niet even snel groeien. Bovendien reageren de klonale cellijnen heel anders 
op de kanker medicijnen in vergelijking met de resultaten in celkweek. Dit betekent dat 
de tumoromgeving de gevoeligheid van kankercellen op medicijnen beinvloedt en we de 
resultaten van medicijn respons in celkweek niet goed kunnen vertalen naar de resultaten 
in een levend organisme.
Op immuun therapie reageren de klonale cellijnen heel verschillend, ondanks dat ze al-
lemaal uit dezelfde ene tumor afkomstig zijn. We ontdekten dat er een klonale cellijn is 
die heel gevoelig is voor een anti-PD-1 medicijn en deze cellijn is ook beter in staat om 
T-lymphocyten te activeren in vergelijking met de andere klonale cellen. Hiervoor hebben 
we T-lymphocyten geisoleerd uit de blinde darmen van muizen met kanker. Wij zijn de 
eerste onderzoekers die hebben waargenomen dat de blinde darm van muizen met kanker 
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tumor-reactieve T-cellen bevat. Dit gaan wij ook onderzoeken in patienten met inopera-
bele alvleesklier kanker om zo betere immuun therapie opties te ontwikkelen. Samengevat 
kunnen we door ons muismodel belangrijke inzichten vergaren op het gebied van kanker 
medicijn resistentie en de effectiviteit van immuun therapie.
In hoofdstuk 3 bestuderen wij de mutaties in circulerend DNA van patienten met alvlees-
klier en dikke darm kanker. Door middel van next generation sequencing van plasma 
DNA vergelijken we de mutaties ten tijde van de diagnose met de mutaties ten tijde van 
uitgezaaide ziekte. Zo kunnen we de evolutie van de kankercellen bestuderen. Bovendien 
hebben we de mutaties in het circulerende DNA ten tijde van de diagnose vergeleken met 
de mutaties in de tumor weefsels zelf. We hebben ontdekt dat slechts een deel van de tumor 
mutaties in het bloed gemeten konden worden. Dit kan zijn doordat in een vroeg kanker 
stadium de kanker mutaties in het bloed te sterk verdund zijn en dat met de huidige se-
quencing technieken deze nog niet meetbaar zijn. Daarnaast werden er in het bloed ook een 
groot percentage mutaties gemeten die in de tumor niet meetbaar waren. Dit betekent dat 
het kleine tumor weefsel niet voldoende de gehele kanker populatie kan representeren. Ook 
kan het zijn dat er al kleine uitzaaiingen elders in het lichaam aanwezig waren. Vervolgens 
hebben we de circulerende DNA mutaties vergeleken ten tijde van de diagnose met die 
van de uitgezaaide ziekte. Hieruit bleek dat er een flink percentage nieuwe mutaties zijn 
ontstaan en er ook sommige mutaties zijn verloren. We kunnen hieruit concluderen dat 
kanker constant veranderd en dat het bepalen van een behandelings strategie gebaseerd 
op een enkele tumor biopsie niet goed van toepassing is op uitgezaaide kanker. Bovendien 
weerspiegelt circulerend DNA de tumor heterogeniteit beter dan een het DNA van een 
weefsel biopsie.
MicroRNAs (miRs) zijn korte strengen genetisch materiaal die door cellen kunnen worden 
uitgescheiden om vervolgens gen expressie te beinvloeden in andere cellen. MiRs in het 
bloed zijn met name afkomstig van endotheel, bloed en immuun cellen. Veranderingen 
in hoeveelheiden van circulerende miRs kunnen verstoringen in het lichaam weergeven 
en daarom zijn circulerende miRs goede kanker biomarker kandidaten. In hoofdstuk 4 
hebben we de circulerende miRs bestudeerd in het bloed van patienten met alvleesklier 
kanker voor en na operatie. Het doel van de studie was om te onderzoeken of specifieke 
circulerende miRs geassocieerd zijn met progressieve ziekte. Daarnaast hebben we in het 
KPC muismodel van alvleesklier kanker serum miRs vergeleken in muizen met voorsta-
dium van kanker en in muizen met uitgezaaide ziekte. Het bleek dat serum miR-125b-5p 
en miR-99a-5p geassocieerd zijn met progressie van alvleesklier kanker in zowel muizen 
als patienten. Vervolgens hebben we onderzocht in welke cellen deze miRs tot expressie 
komen in de patienten tumoren door middel van in situ hybridizatie. We vonden dat er 
enkele ontstekings cellen in het bindweefsel van de tumoren zijn die deze miR-125b-5p en 
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miR-99a-5p tot expressie brengen. In het specifiek, zijn de miR-positieve cellen in nauw 
verband met B-lymfocyten zichtbaar. Uit ons onderzoek blijkt dat er specifieke circulerende 
miRs geassocieerd zijn met progressieve alvleesklierkanker en dat deze afkomstig zijn van 
immuun cellen. Nader onderzoek moet uitwijzen welke immuun cellen dit zijn en in welk 
stadium van activering de miR-positieve zich bevinden.
In hoofdstuk 5 onderzochten wij of circulerende miRs de effectiviteit van een multi-kinase 
remmer kunnen aantonen in patienten met uitgezaaide borstkanker. Dovitinib remt zowel 
FGFR als VEGR, belangrijke eiwitten in de vorming van bloedvaten en tumor bindweefsel. 
Wij onderzochten of veraderingen in plasma miRs konden aantonen of dovitinib een ef-
fectieve remming geeft op de groei van borstkanker tumoren. Hiervoor onderzochten wij 
de expressie van miRs in het bloed van patienten voor en na gebruik van dovitinib. We 
vonden dat expressie van 6 miRs patienten konden scheiden op basis van hun respons op de 
therapie. Hieruit concluderen we dat circulerende miRs potentiele biomarkers zijn voor de 
effectiviteit van kanker medicijnen.
Deze dissertatie bevat wetenschappelijke onderbouwingen voor de implementatie van cir-
culerende biomarker analyses in de klinische zorg van patienten met kanker. Tot op heden 
worden tumor weefsels gebruikt om de moleculaire eigenschappen van kanker te onder-
zoeken. Kanker is een dynamische, heterogene ziekte die continue verandert onder de druk 
van omgevingsfactoren in het tumor weefsel en anti-kanker behandelingen. Kanker cellen 
in uitzaaiingen bevatten andere genetische en fenotypische kenmerken dan de cellen in de 
primaire tumor. Om deze ziekte beter te bestuderen is het nodig om genetisch materiaal in 
herhaalde bloed monsters te analyzeren. Circulerend DNA kan het genetische landschap 
van de kankercellen in het hele lichaam bloot geven en circulerende miRs lenen zich voor 
het onderzoeken van de staat van het lichaam in reactie op de kanker cellen. Door middel 
van de bovengenoemde circulerende biomarkers kunnen we betere inzichten verkrijgen in 
het ontstaan van kanker progressie en in het verbeteren van therapie.
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